Degradable Microchannel Nerve Guidance Scaffolds for Central and Peripheral Nerve Repair - From Soft to Rigid. by Shahriari, Dena
Degradable Microchannel Nerve Guidance
Sca↵olds for Central and Peripheral Nerve Repair-
From Soft to Rigid
by
Dena Shahriari
A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
(Macromolecular Science and Engineering)
in The University of Michigan
2016
Doctoral Committee:
Associate Professor Je↵ S. Sakamoto, Chair
Assistant Professor Geeta Mehta
Professor Mark H. Tuszynski
Professor Alan S. Wineman
One of the first drawings of a neuron by Santiago Ramo´n y Cajal who once said: “In
adult centers the nerve paths are something fixed, ended, immutable. Everything
may die, nothing may be regenerated. It is for the science of the future to change, if
possible, this harsh decree.” 1928.
© Dena Shahriari 2016
All Rights Reserved
To those with paralysis. And to my family and my love who so beautifully support
me to reach higher for my dreams and turn them into reality.
ii
ACKNOWLEDGEMENTS
I, for most, thank my mother, Roya, who is the symbol of care, warmth and hard
work for me. My siblings, Mahzad, Shabnam, Shirzad and Shabahang have been my
pillars through the years. My family’s continuous support and love have fostered my
ambitions and spirit for hard work. It is also the encouragement and support of my
love, Philipp, who believes in me and patiently comforts me.
I appreciate the support of my amazing friends through the years. Oishi and
Shoeleh who have always supported me and having long conversations on topics from
science to women’s rights never get old. It was also together with Asma, Regina and
Yunsung that we could form a pyramid of encouragement for each other and make
great memories. Dan and Kayla are other dear friends who made working on this
project both joyful and valuable.
My PhD advisor, Prof. Je↵ Sakamoto is greatly appreciated. This work would
have not been possible without him. His intelligence and stimulating ideas shaped
me as a scientist, which I am very much thankful for.
I appreciate Prof. Mark Tuszynski for his vast expertise, intelligence and kind
support through the years. It has been an invaluable opportunity learning from him.
Prof. Wendy Campana is sincerely appreciated for her great knowledge, intelli-
gence and warm spirit. She is a successful female figure I admire.
I am grateful for our invaluable collaboration with Prof. Mark Tuszynski, Prof.
Wendy Campana and their lab members. Their stimulating thoughts, advice and
contributions were pivotal to this work. In addition, all the animal studies presented
iii
in this dissertation including but not limited to surgical procedures and in vivo char-
acterizations were obtained by Prof. Mark Tuszynski as the main PI for the spinal
cord projects and Prof. Wendy Campana as the main PI for the peripheral nerve
work. Dr. Kobi Ko✏er form Prof. Mark Tuszynski’s lab is specially acknowledged
for performing all the spinal cord surgeries and characterizations. Drs. Kenichi Mu-
rakami, Masataka Shibayama and Go Kubota from Prof. Wendy Campana’s lab are
appreciated for performing all the peripheral nerve surgeries and evaluations.
Dr. Dan Lynam is acknowledged for his important and invaluable contribution
to Chapters III, V and VI and the Appendix. Kayla Wolf is appreciated for her
original ideas and hard work on Chapters IV and VI and the Appendix. I also thank
Christopher Scott for his hard work on Chapter V.
I thank all my committee members, Profs. Je↵ Sakamoto, Geeta Mehta, Mark
Tuszysnki and Alan Wineman for their support and great insight.
Lastly, this work would have not been possible without the generous funding
sources. The work was funded by the NIH (R01 EB014986), the Veterans Adminis-
tration and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.
I also greatly acknowledge the National Science Foundation for their Graduate Re-
search Fellowship as well as the Macromolecular Science and Engineering department
at the University of Michigan for a fellowship.
iv
TABLE OF CONTENTS
DEDICATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ii
ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . iii
LIST OF FIGURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x
LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xx
LIST OF ABBREVIATIONS . . . . . . . . . . . . . . . . . . . . . . . . . xxi
ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xxiii
CHAPTER
I. Rationale and Aims . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1 Alginate hydrogel sca↵olds . . . . . . . . . . . . . . . . . . . 1
1.2 Dense alginate sca↵olds . . . . . . . . . . . . . . . . . . . . . 2
1.3 Poly(ethylene glycol) diacrylate (PEGDA) hydrogel sca↵olds 2
1.4 Agarose hydrogel microdrilled sca↵olds with poly caprolactone
(PCL) supporting conduits . . . . . . . . . . . . . . . . . . . 3
1.5 Poly caprolactone (PCL) sca↵olds with high open volume . . 4
1.6 Impact and summary . . . . . . . . . . . . . . . . . . . . . . 4
II. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.1 Spinal cord injury Overview . . . . . . . . . . . . . . . . . . . 6
2.1.1 Spinal cord injury . . . . . . . . . . . . . . . . . . . 6
2.1.2 Acute phase after an injury . . . . . . . . . . . . . . 7
2.1.3 Rehabilitation phase after an injury . . . . . . . . . 8
2.2 Axons and axon regeneration . . . . . . . . . . . . . . . . . . 8
2.2.1 SCI at the anatomical level . . . . . . . . . . . . . . 8
2.2.2 Axon regeneration mechanism . . . . . . . . . . . . 9
2.2.3 Inhibitory environment of SCI for axon growth . . . 11
2.3 Peripheral nerve injury overview . . . . . . . . . . . . . . . . 11
v
2.3.1 PNI impact . . . . . . . . . . . . . . . . . . . . . . 11
2.3.2 Axon regeneration in the peripheral vs. central ner-
vous system . . . . . . . . . . . . . . . . . . . . . . 12
2.3.3 Approaches to peripheral nerve repair . . . . . . . . 13
2.4 Biomaterials used for nerve guidance sca↵olds . . . . . . . . . 14
2.4.1 Biomaterials selection criteria . . . . . . . . . . . . 14
2.4.2 Biological polymers . . . . . . . . . . . . . . . . . . 14
2.4.3 Polysaccharide hydrogels . . . . . . . . . . . . . . . 15
2.4.4 Synthetic polymers . . . . . . . . . . . . . . . . . . 16
2.5 Nerve grafts for axon guidance . . . . . . . . . . . . . . . . . 17
2.5.1 The significance of linear axon guidance . . . . . . . 17
2.5.2 Nerve grafts designs . . . . . . . . . . . . . . . . . . 17
2.5.3 Criteria for nerve guidance sca↵olds . . . . . . . . . 19
2.6 Growth factor delivery . . . . . . . . . . . . . . . . . . . . . . 20
III. Characterizing the Degradation of Alginate Hydrogel for Use
in Microchannel Sca↵olds for Spinal Cord Repair . . . . . . . 23
3.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
3.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
3.3 Experimental . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3.3.1 Fabrication of alginate hydrogel . . . . . . . . . . . 26
3.3.2 Shear modulus measurements . . . . . . . . . . . . 27
3.3.3 Assessing the in vitro degradation rate of alginate disks 28
3.3.4 Pore characterization . . . . . . . . . . . . . . . . . 28
3.3.5 Sca↵old fabrication . . . . . . . . . . . . . . . . . . 29
3.3.6 Surgical procedures and in vivo characterization . . 30
3.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.4.1 In vitro degradation testing . . . . . . . . . . . . . . 31
3.4.2 Pore characterization . . . . . . . . . . . . . . . . . 34
3.4.3 Sca↵old characterization and in vivo testing . . . . 36
3.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
IV. Dense Alginate Films Fabricated into Microchannel Sca↵olds
and Functionalized for a Gradient Protein Release . . . . . . 42
4.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
4.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
4.3 Experimental . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
4.3.1 Alginate film fabrication . . . . . . . . . . . . . . . 44
4.3.2 Material characterization . . . . . . . . . . . . . . . 44
4.3.3 Protein incorporation and bioactivity measurements 45
4.3.4 Dense alginate disk and sca↵old fabrication . . . . . 47
4.3.5 Surgical procedure and in vivo characterization . . . 47
vi
4.4 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . 48
4.4.1 Material properties . . . . . . . . . . . . . . . . . . 48
4.4.2 Protein release measurements and bioactivity char-
acterization . . . . . . . . . . . . . . . . . . . . . . 49
4.4.3 Sca↵old characterization . . . . . . . . . . . . . . . 53
4.4.4 In vivo results . . . . . . . . . . . . . . . . . . . . . 54
4.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
V. Poly(ethylene glycol) diacrylate (PEGDA)Microchannel Scaf-
folds for Spinal Cord Repair Functionalized with Layer-by-
Layer Controlled Protein Release . . . . . . . . . . . . . . . . . 58
5.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
5.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
5.3 Experimental . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
5.3.1 Mechanical testing . . . . . . . . . . . . . . . . . . . 60
5.3.2 Sca↵old fabrication . . . . . . . . . . . . . . . . . . 61
5.3.3 Surgical procedure, sectioning and immunolabeling . 62
5.3.4 LbL deposition and release . . . . . . . . . . . . . . 62
5.4 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . 64
5.4.1 Mechanical properties of PEGDA . . . . . . . . . . 64
5.4.2 Sca↵old fabrication . . . . . . . . . . . . . . . . . . 64
5.4.3 In vivo performance . . . . . . . . . . . . . . . . . . 66
5.4.4 LbL BDNF release . . . . . . . . . . . . . . . . . . 69
5.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
VI. Hydrogel Peripheral Nerve Microchannel Sca↵olds Mechani-
cally Supported by poly caprolactone (PCL) Conduits . . . . 72
6.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
6.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
6.3 Experimental . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
6.3.1 Agarose sca↵old fabrication . . . . . . . . . . . . . . 75
6.3.2 Nerve guidance conduit fabrication and sca↵old as-
sembly . . . . . . . . . . . . . . . . . . . . . . . . . 77
6.3.3 Characterizing the mechanical properties and poros-
ity of PCL . . . . . . . . . . . . . . . . . . . . . . . 78
6.3.4 In vivo testing . . . . . . . . . . . . . . . . . . . . . 79
6.4 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . 80
6.4.1 Agarose sca↵old and PCL conduit characterization . 80
6.4.2 Correlating PCL mechanical properties with porosity 81
6.4.3 PCL conduit flexibility . . . . . . . . . . . . . . . . 82
6.4.4 Sca↵old nerve stump integration . . . . . . . . . . . 82
6.4.5 In vivo characterization . . . . . . . . . . . . . . . . 84
6.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
vii
VII. A Novel Technique to Synthesize and Fabricate High Lumen
Volume poly caprolactone (PCL) Microchannel Sca↵olds for
Spinal Cord Repair . . . . . . . . . . . . . . . . . . . . . . . . . . 88
7.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
7.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
7.3 Experimental . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
7.3.1 Porogen size reduction . . . . . . . . . . . . . . . . 92
7.3.2 PCL/NaCl mixture preparation . . . . . . . . . . . 92
7.3.3 PCL film fabrication and characterization . . . . . . 93
7.3.4 Cell attachment characterization . . . . . . . . . . . 94
7.3.5 Sca↵old fabrication . . . . . . . . . . . . . . . . . . 95
7.3.6 Surgical procedures and in vivo characterization . . 95
7.4 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . 97
7.4.1 NaCl porogen size reduction via planetary ball-milling 97
7.4.2 Salt-leached PCL microstructural analysis . . . . . . 98
7.4.3 Correlating porosity with mechanical properties . . 100
7.4.4 Cell attachment . . . . . . . . . . . . . . . . . . . . 102
7.4.5 Sca↵old characterization . . . . . . . . . . . . . . . 103
7.4.6 In vivo characterization . . . . . . . . . . . . . . . . 107
7.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
VIII. Further Research and Outlook . . . . . . . . . . . . . . . . . . . 110
8.1 Advancing the sca↵old fabrication technology . . . . . . . . . 110
8.1.1 Translating PCL synthesis and sca↵old fabrication
technology to other polymers . . . . . . . . . . . . . 110
8.1.2 Microchannel sca↵old technology for clinical transla-
tion . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
8.2 Criteria for a microchannel sca↵old . . . . . . . . . . . . . . . 115
8.2.1 Material selection and synthesis . . . . . . . . . . . 116
8.2.2 Sca↵old design and fabrication . . . . . . . . . . . . 116
8.2.3 In vivo evaluation . . . . . . . . . . . . . . . . . . . 117
8.3 The dogma of “softer is better” . . . . . . . . . . . . . . . . . 117
8.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
8.5 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
A.1 Dense chitosan microchannel sca↵olds teste in the rat spinal
cords . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
A.1.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . 125
A.1.2 Experimental and results . . . . . . . . . . . . . . . 126
A.2 Microdrilled agarose sca↵olds with chitosan supporting con-
duits implanted in a pig sciatic nerve . . . . . . . . . . . . . . 127
viii
A.2.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . 127
A.2.2 Experimental and results . . . . . . . . . . . . . . . 128
BIBLIOGRAPHY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
ix
LIST OF FIGURES
Figure
2.1 Causes of SCI. Chart is reproduced from [123] . . . . . . . . . . . . 7
2.2 Image of an axon. The arrows show the direction of information flow
through a neuron: from dendrites to cell body to axons. Image is
from [51] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.3 The image illustrates the growth cone of an axon with some of its
main components: actin, lamellipodium and filopodium. Image is
from [89] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.4 The clutch hypothesis for growth cone translocation and axon growth.
The actin-based motor, myosin, anchored to ends of microtubules,
pulls actin filaments toward the central domain. Image is from [146] 10
2.5 The temporal (a) anatomical and functional results and (b) inflam-
matory responses in SCI rodents [38] . . . . . . . . . . . . . . . . . 12
2.6 Cascade of cellular events after an injury to a peripheral nerve dur-
ing Wallerian degeneration. (a) Upon injury, the axon cytoskeleton
and myelin degenerates. (b) Within 1-3 days, Schwann cells and
macrophages start removing the axon and myelin debris. (c) 10-20
days later, Schwann cells form Bu¨nger bands for axons to regenerate
along. Images are from [5]. . . . . . . . . . . . . . . . . . . . . . . . 13
2.7 Examples of di↵erent nerve grafts. (a) Chitosan conduit [3], (b) al-
ginate hydrogel [69], (c) electrospun poly-L-lactic acid (PLLA) fibers
[74], and microchannel sca↵olds from (d) agarose [158], (e) pHEMA
[50] and (f) PLGA [169]. The scale bar in (c) is 50 µm. All the other
scale bars are 500 µm . . . . . . . . . . . . . . . . . . . . . . . . . . 19
x
2.8 (a) Assembly and (b) release of poly (acrylic acid) (PAA) and poly
(ethylene glycol) (PEG) alternating layers on a substrate. One layer
acts as the hydrogen donor and another as the hydrogen acceptor.
Hydrogen bonds are formed at a pH below the pKa of the polymers.
The layers are gradually dissociated when the pH rises above the
pKa. Proteins (red dots) can be taken up in between the polymeric
layers and therefore slowly released upon pH rise . . . . . . . . . . . 21
3.1 (a) Conventional radial and (b) 1-D cross-linking of alginate. Unlike
radial cross-linking, 1-D cross-linking produces uniform disks for up
to 15 mm tall samples . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.2 Visual changes of 11.4 mm-diameter (a) radially cross-linked low-
purity alginate and 1D cross-linked (b) low-purity and (c) high-purity
alginate during in vitro degradation. Unlike radially cross-linked hy-
drogels, 1D cross-linked alginate does not fragment and exhibits uni-
form degradation. Scale bars are 5 mm . . . . . . . . . . . . . . . . 32
3.3 The change in the volume of HP alginate disks during degradation.
The data are normalized to the volume of the samples from day 0.
The disks swell to about 40% by day 6 . . . . . . . . . . . . . . . . 33
3.4 Rheology measurements for low-purity (⇤) and high-purity (4) al-
ginate, including optical images of the high-purity samples (with a
diameter of 11.4 mm) on days 0 and 7. While the shear modulus
drops by 97% within 3 days, the superficial geometry is maintained 34
3.5 SEM image of supercritically dried 3 wt.% alginate showing intercon-
nected pores, which are in the tens of nanometer range. Scale bar is
200 nm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
3.6 Nitrogen desorption data of supercritically dried alginate showing
that the majority of nanopores are 25-35 nm in diameter . . . . . . 35
3.7 (a) Cross-section and (b) longitudinal view of a multicomponent fiber
bundle template consisting of a PMMA matrix and PS fibers. The PS
components (b) maintain PS fiber linearity after the PMMA matrix
is etched. Templated alginate sca↵old cross-section and side view (c)
and (d), respectively. Scale bars in (a) and (c) are 400 µm and in (b)
and (d) are 500 µm . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
xi
3.8 Representative images of neurofilament (green) labeling of a com-
pletely transected rat spinal cord 2 weeks post-implantation: (a)
agarose sca↵old and (b) alginate sca↵old. The agarose hydrogel
sca↵old remained intact while the alginate sca↵old mainly degraded.
Some axonal growth into the agarose sca↵old is observed. A higher
magnification image (c) shows some axonal growth at the rostral end
of the alginate sca↵old. The Scale bars in (a) and (b) are 200 µm
and the scale bar in (c) is 50 µm . . . . . . . . . . . . . . . . . . . . 38
4.1 Fabricating dense alginate films. (a) The top picture on the left shows
alginate hydrogel and (b) the bottom left shows alginate collapsed
film after dehydration. The gray schematics on the right correspond
to predicted macroscopic structure of alginate in either form. The
black dots represent the optional addition of protein molecules tem-
porarily immobilized by the alginate . . . . . . . . . . . . . . . . . . 45
4.2 Fabricating dense alginate films with gradient protein release. (a)
Using a barrier, two reservoirs were created in a rectangular-shape
container and filled with alginate solution- one with and one without
protein. (b) The barrier was removed and the solution was air-dried.
Three pieces of the film as shown with the dashed circles in (b) were
extracted for protein release measurements . . . . . . . . . . . . . . 46
4.3 SEM images of (a) highly porous supercritically dried alginate hy-
drogel versus (b) collapsed alginate film. Scale bar in (a) is 0.15 µm
and in (b) is 1 µm . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
4.4 The elastic modulus of dense alginate films increased by raising the
concentration of the cross-linking solution (CaCl2) . . . . . . . . . . 50
4.5 NIH 3T3 fibroblasts do not attach on (a) hydrogel form of alginate
but attach on (b) dense alginate films. Scale bars are 30µm . . . . . 50
4.6 The graph shows a 50-day sustained release from a lysozyme-loaded
dense alginate film. The schematics represent a dense alginate film
(gray) with protein molecules (black) incorporated. The schematic
on the left demonstrate that, due to the dense alginate structure, the
protein is initially primarily released from the outer layers of alginate.
As the film degrades (schematic on the right), protein can be released
from inner layers . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
xii
4.7 The graph shows the cumulative release profile of a lysozyme-gradient
alginate film described in Fig. 4.2. (⇤) is the release profile of the
section with lysozyme while (x) is from the section without lysozyme.
( ) is the release profile from the center of the film. The comparison
between the profiles shows a gradient release profile can be achieved 52
4.8 The cell proliferation images after 5 days of culturing with cells
treated with (a) 50 ng/ml fresh BDNF as positive control, (b) no
BDNF as negative control, and (c) solution released from dense algi-
nate/BDNF film on day 1. Positive control confirms the proliferation
of cells while only few cells were present on the negative control. Cells
had proliferated when treated with solution released from dense al-
ginate/BDNF film confirming the bioactivity of released BDNF. The
scale bars are 50 µm . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.9 The graph shows the bioactivity results of a BDNF-incorporated al-
ginate film using cellular assay on transfected TrkB 3T3 cells. Prolif-
eration results are normalized to the cell count from 50 ng/ml fresh
BDNF-treated cells. Data show that the released BDNF is at least
partially active . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
4.10 Dense alginate sca↵olds fabricated via two di↵erent techniques. 1)
(a) Alginate films were rolled, (b) cross-linked with CaCl2 into a disk
and (c) microdrilled to obtain microchannel sca↵olds. 2) Subsequent
amounts of alginate solution was dehydrated on top of alginate films
until the disk reached a targeted hight. (d) The alginate disks were
then microdrilled into sca↵olds with channel diameters of 300 µm.
The scale bars are 300 µm . . . . . . . . . . . . . . . . . . . . . . . 55
4.11 Dense alginate sca↵old implanted in a transected T3 rat spinal cord
and immunostained for neurofilaments (green) after 4 weeks. The box
with dashed lines shows the transected spinal cord. The box with
solid lines demonstrate a 250 µm-thick layer of scar tissue formed
at the rostral end. Scar tissue is also formed at the distal end of
the sca↵old. Necrosis of the host spinal cord was also observed (an
example is shown by the solid arrow on the left). In addition, the
dashed arrows point to the sca↵old debris indicating that the sca↵old
fragmented in less than 4 weeks. The scale bar is 250 µm . . . . . . 56
xiii
5.1 The change in the elastic modulus of PEGDA based on its wt.%
and uv crosslinking time. (a) shows the modulus of 5 wt.% ( ),
10 wt.% (⇧) and 15 wt.% (-) did not significantly change when the
uv crosslinking time was increased, while the modulus of 20 wt.%
(x) PEGDA increases when crosslinked for 50 min. Increasing wt.%
increased the elastic modulus as more closely shown in (b) in which a
35 min uv-crosslinking time was used while varying the wt.% of the
PEGDA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
5.2 The longitudinal view of the template (a) and PEGDA sca↵old (b)
shows the sca↵old matches the structure of the template with mi-
crochannels. The scale bars are 0.5 mm . . . . . . . . . . . . . . . . 66
5.3 Linear axon growth is observed through some of the PEGDA sca↵old
channels. Neurofilaments are stained in green. Figure (a) shows a
representative image of a PEGDA sca↵old 4 weeks post-implantation
in the T3 transected rat spinal cord. The boxed region in (a) is
the nerve gap where the sca↵old was inserted. Figures (b), (c), (d)
and (e) are the most axon-dense channels of 4 di↵erent implants and
highlight the reproducibility and e cacy of PEGDA microchannel
sca↵olds in linearly guiding axons along the nerve gap. The scale bar
in (a) is 0.25 mm and the scale bars in (b), (c) and (d) are 0.04 mm 67
5.4 Serotonergic axon presence and regeneration in the nerve gap. The
boxed region shows the transected T3 spinal cord in a rat with the
sca↵old implanted for 4 weeks. 5HT serotonergic axons grew linearly
along some of sca↵old channels. The scale bar is 0.25 mm . . . . . . 68
5.5 PEGDA continues swelling in the spinal cord after initial in vitro
swelling. A cross-sectional image of PEGDA sca↵old 4 weeks post-
implantation in the T3 spinal cord of a rat stained with toluidine blue
is shown. The lumen volume of the sca↵old is 13.8%. Solids arrows
point to the open channels and dashed arrow point to the sca↵old
wall. The scale bar is 0.3 mm . . . . . . . . . . . . . . . . . . . . . 68
5.6 BDNF LbL release profile from PEGDA sca↵olds. The concentra-
tion of BDNF released from a BDNF/LbL-coated PEGDA sca↵old
shows BDNF release for 8 days. The dashed line indicated the mini-
mum BDNF required for nerve regeneration (50 ng/ml). Relatively
high dosages of BDNF is released on days 1 and 2, while the release
plateaus thereafter . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
xiv
6.1 Steps in microdrilling agarose sca↵olds. (a) A sacrificial agarose disk
is placed at the bottom of the well of a well-plate. An agarose disk
with a height equivalent to the desired height of the sca↵old (10 mm
in the present study) was placed over the sacrificial layer with a PS
piece anchoring the disk in place. (b) A CNC-controlled microdrill
patterned linear channels in the agarose disk. (c) A titanium tube
was sharpened to a knife-edge and was used to cut sca↵olds. (d) The
sca↵olds are extracted from the sharpened punch . . . . . . . . . . 76
6.2 Agarose microchannel sca↵old with PCL nerve guidance conduit. (a)
Cross-section showing an array of 0.3 mm inner diameter channels
and 0.085 mm thick walls, (b) longitudinal view shows 10 mm long
linear channels, and agarose sca↵old is inserted in (c) a PCL conduit
with an overhang of 1 mm from each end. The solid arrow points to
the PCL conduit around the agarose sca↵old and the dashed arrow
highlights the additional channels created by the conduit around the
sca↵old. The scale bar in (a) is 0.3 mm and the scale bars in (b) and
(c) are 10 mm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
6.3 Stress-strain curves of non-porous and porous PCL. (a) Dashed line
demonstrates 100% non-porous PCL and solid line indicates 70 vol%
porosity PCL. The elastic modulus of PCL reduces from 182 MPa
to 2.1 MPa while the strain to failure increases from 17% to 100%
when 70 vol% porosity is introduced. (b) is the stress-strain curve of
70 vol% porosity PCL and highlights the elastic behavior to about
17% strain and plastic behavior thereafter . . . . . . . . . . . . . . 82
6.4 An SEM image of a PCL conduit after a simulated suturing test. The
scale bar is 0.1 mm . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
6.5 Interconnected pores are observed in the salt-leached PCL nerve guid-
ance conduit. (b) is a higher magnification of the box in (a). The
scale bars in (a) and (b) are 50 µm and 20 µm, respectively . . . . . 83
6.6 PCL conduit is kink-resistant up to 58 . No kink is present when the
conduit is bent around fingertips. (b) is a magnified image of the box
in (a) and demonstrates no kink is present for at least 58  of bending.
The scale bar in (a) is 10 mm and in (b) is 0.5 mm . . . . . . . . . 84
xv
6.7 The PCL nerve guidance conduit stabilized the agarose sca↵old in
the nerve gap. The agarose sca↵old with PCL conduit 8 weeks post-
implantation (a) in the nerve tissue in vivo and (b) dissected from the
nerve tissue shows the sca↵old remains intact and integrated with the
nerve. The conduit was sutured to the host nerve using two sutures
at each end as shown with solid arrows. Some capillary formation
was observed at the distal end as indicated by the dashed arrow.
The scale bars are 10 mm . . . . . . . . . . . . . . . . . . . . . . . 85
6.8 Axon and Schwann cell penetration into sca↵old channels. (a) The
proximal side of an agarose sca↵old in a PCL conduit in a 10 mm
long rat sciatic nerve gap 8 weeks post-implantation. Neurofilament
(red) immunoreactivity highlights axon penetration into the agarose
sca↵old channels. The boxed region in (a) is magnified in (b), (c), and
(d). (b) Axon immunoreactivity with NF200 (red) and (b) Schwann
cells (SC) immunoreactivity with S100 (green) inside sca↵old chan-
nels. The axon (red) and SC (green) labeling is superimposed in (c),
which indicates their integration. The scale bar in (a) is 400 µm; all
the other scale bars are 100 µm . . . . . . . . . . . . . . . . . . . . 86
6.9 Axons and Schwann cells are located inside some channels and around
the periphery of the sca↵old. Cross-section of an agarose sca↵old
inside a PCL conduit stained with (a) NF200 for axons (red) and
(b) S100 for Schwann cells (green). Axons and Schwann cells grew
through some of the channels and in the interstitial space between
the sca↵old periphery and the inner wall of the PCL conduit. Scale
bars are 400 µm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
7.1 Porogen preparation and film fabrication. (1) Synthesizing a uniform
solution of PCL and NaCl and (2) fabricating porous PCL films. (1):
(a) NaCl is ball-milled to the desired diameter and (b) the NaCl
from (1a) is ball-milled with a PCL:chloroform solution to uniformly
disperse the NaCl. The slurry from (1b) is used on an automated
tape casting apparatus as shown in (2) to produce porous films for
tensile testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
7.2 Steps in fabricating (1) PCL tubes and (2) PCL sca↵olds . . . . . . 96
7.3 Increasing the planetary ball-milling time reduces the particle size
and size distribution. SEM images of NaCl (a) as-received, and NaCl
ball-milled at 400 rpm for: (b) 1 min, (c) 5 min, (d) 30 min, (e) 60
min and (f) 90 min. The inset scale bars are 0.025 mm; all other
scale bars are 0.20 mm . . . . . . . . . . . . . . . . . . . . . . . . . 98
7.4 SEM analysis of 100% PCL (no porosity). The scale bar is 3 µm . . 100
xvi
7.5 SEM analysis before and after salt leaching. A 70 vol% porosity PCL
film fabricated using 17 µm (avg. diameter) NaCl particles (a) prior
to and (b) after salt-leaching. (c) and (d) are higher magnification
images of the dashed-boxes shown in (a) and (b), respectively. The
solid arrow in (c) points to a NaCl particle and the dashed arrows
point to PCL. Scale bars in (a) and (b) are 10 µm and in (c) and (d)
are 5 µm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
7.6 SEM analysis of PCL salt leached with 0.191 mm NaCl. Cross-
sectional SEM image of a 70 vol% porosity PCL film fabricated using
0.191 mm (avg. diameter) NaCl particles. The black arrow points to
a salt-leached pore. The scale bar is 0.1 mm. . . . . . . . . . . . . . 102
7.7 The elastic modulus PCL vs. porosity% created by 0.017 mm NaCl
particles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
7.8 Cell attachment and proliferation on PCL is improved by introducing
porosity and by fibronectin-coating. NIH 3T3 fibroblasts were cul-
tured on (a) uncoated and (b) coated tissue-culture treated flask as
controls, (d) uncoated non-porous PCL film, (e) fibronectin coated
non-porous PCL film, (g) uncoated 30 vol% porous PCL film, and (h)
fibronectin-coated 70 vol% porosity PCL film. Cells were fixed after
72 hr and stained for actin (green) and nuclei (blue). Unlike non-
porous PCL, 70 vol% porosity PCL films provided cell attachment
and proliferation comparable to the positive control. Both groups
exhibited cell attachment and proliferation after fibronectin coating.
SEM images of the top surface of (c) non-porous PCL film and (f)
70 vol% porosity PCL with corresponding magnified images demon-
strate an increased surface roughness in porous PCL. Scale bars in
the magnified boxes in (c) and (f) are 0.01 mm. All other scale bars
are 0.1 mm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
7.9 Optical image of a PCL sca↵old. Microtube inner diameter is 0.260
mm, salt-leached (0.017mm NaCl), 70 vol% porosity PCL walls were
0.060 mm thick. Scale bar is 0.2 mm . . . . . . . . . . . . . . . . . 105
7.10 Interconnected porosity is maintained through the wall of the tubes.
(a) shows the inner surface (b) the cross-section and (c) the outer
surface of a PCL tube. Images in (d), (e) and (f) are the x2 magni-
fications of (a), (b) and (c), respectively. Scale bars in (a), (b), (c)
are 5 µm and in (d), (e) and (f) are 2.5 µm . . . . . . . . . . . . . . 106
xvii
7.11 Axons grow into PCL sca↵olds after implantation in T3 complete
transection. PCL sca↵old is shown 4 weeks post-implantation by
immunolabeling neurofilaments (green). (a) Sca↵old interfaces with
host are indicated by dashed lines. (b) Higher magnification of boxed
region in (a) demonstrate axonal growth into sca↵old and linear
growth pattern. Solid arrows in (b) demonstrate the axons grow
linearly inside the microtubes while the dashed arrow indicate some
axons grow linearly in between the microtubes. The scale bar in (a)
is 0.3 mm and in (b) is 0.1 mm . . . . . . . . . . . . . . . . . . . . 107
8.1 SEM images of PLGA fracture surface with porosity% of 0%, 10%,
20% to 90% are shown in (a), (b), (c) through (j), respectively. By
reducing the PLGA vol% (thus increasing porosity vol%), the mor-
phology changes from a non-porous structure (0% porosity shown in
(a)) to porous structures. Scale bars are 5 µm . . . . . . . . . . . . 112
8.2 The elastic modulus of PLGA decreases by increasing porosity . . . 113
8.3 Cell attachment and proliferation on PLGA is improved when 1)
porous and 2) fibronectin-coated. Primary rat Schwann cells were
cultured on (a) uncoated, (b) laminin-coated and (c) fibronectin-
coated PDL-coated surfaces as controls. Cells were also cultured on
(d) uncoated, (e) laminin-coated and (f) fibronectin-coated 70 vol%
porous PLGA, and also on non-porous PLGA (data not shown). Cells
were fixed after 48 hr and stained for actin (green) and nuclei (blue).
Porous PLGA film provided cell attachment and proliferation com-
parable to the positive control when coated with fibronectin while
non-porous PLGA exhibited no cell survival or attachment regard-
less of the coating substance. Scale bars 50 µm . . . . . . . . . . . . 114
8.4 A cross-sectional image of a PLGA sca↵old with PLGA inner tubes
inserted inside a PCL outer tube. The scale bar is 300 µm . . . . . 114
8.5 PCL microchannel sca↵old. The boxed region in (a) is magnified
in (b), and shows the sca↵old microchannel architecture. (b) is the
longitudinal view of the sca↵old. The scale bar in (a) is 2 mm and
in (b) is 0.5 mm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
xviii
8.6 In vivo evidence averse to the dogma of “softer is better” for spinal
cord repair. Microchannel sca↵olds fabricated from (a) agarose, (b)
alginate, (c) chitosan, (d) PEGDA, (e) PCL and (f) PLGA implanted
in transected spinal cords of rats and stained for neurofilaments after
2 weeks for alginate and 4 weeks for all the other sca↵olds. Axons
are shown in green from (a)-(e) and red in (f) pointed to by solid
arrows. The dashed lines indicate the boundary of the sca↵old walls.
Since alginate sca↵old had degraded when sectioning was performed,
it was di cult to point to its original location; thus, a dashed line is
not shown. As images (a)-(d) demonstrate, the axons do not grow
in close proximity to the foreign substrate and a reactive cell layer
(pointed to by dashed arrows) often forms between the axons and the
hydrogel sca↵olds walls. However, axons grew toward and in close
proximity to PCL and PLGA. The scale bars in (a) and (b) are 100
µm, in (c) 120 µm, in (d) and (e) are 80 µm and in (f) is 100 µm . 120
A.1 Image of a dense chitosan microchannel sca↵old. The scale bar is 0.5
mm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
A.2 The longitudinal view of a dense chitosan microchannel sca↵old im-
planted in a T3 transected rat spinal cord stained for neurofilaments
(green) 4 weeks post-implantation. The dashed box demonstrates the
transected section of the spinal cord. Debris from the sca↵old were
observed (shown with dashed white arrows). In addition, reactive
cell layer is formed around the lesion cavity as pointed by solid white
arrows. The necrosis of host spinal cord shown by a solid black arrow
was also observed. The scale bar is 0.25 mm . . . . . . . . . . . . . 127
A.3 (a) Cross-section and (b) longitudinal image of a microdrilled agarose
sca↵old is demonstrated. In (b) the sca↵old (pointed to by the dashed
arrow) is inserted into a chitosan tube (indicated by a solid arrow).
The scale bars are 150 µm in (a) and 200 µm in (b). . . . . . . . . . 128
A.4 The elastic modulus of dense chitosan film increases as itsmass/surface area
increases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
A.5 (a) Optical image and (b) electron microscopy image of the longi-
tudinal view of an agarose sca↵old inside a chitosan tube in a 10
mm-long sciatic nerve gap in a minipig. The sca↵old (pointed to by
the dashed arrows) is surrounded by a scar tissue as indicated by the
solid arrows. The scale bars are 0.3 mm . . . . . . . . . . . . . . . 130
xix
LIST OF TABLES
Table
2.1 The table shows the percentage of individuals with SCI that are em-
ployed or are students based on the number of years after the injury.
Graph is reproduced from [123] . . . . . . . . . . . . . . . . . . . . 7
8.1 The table summarizes the elastic modulus of the sca↵old materials
used through the dissertation. The elastic modulus of alginate is
calculated from its shear modulus of 155.3 kPa obtained in Chapter
III assuming a poisson’s value of 0.25. ⇤Alginate and chitosan degrade
within weeks in the spinal cord, which e↵ectively results in lower
sti↵ness than what is shown. . . . . . . . . . . . . . . . . . . . . . . 119
xx
LIST OF ABBREVIATIONS
BJH Barrett-Joyner-Halenda
BET Brunauer, Emmett, Teller
BSA bovine serum albumin
SEM scanning electron microscopy
BDNF brain-derived neurotrophic factor
CaCl2 calcium chloride
CNC computer numerical control
HP high-purity
LbL layer-by-layer
LP low-purity
MCFB multicomponent fiber bundles
NaCl sodium chloride
NaOH sodium chloride
NGS nerve guidance sca↵old
PAA poly(acrylic acid)
PBM planetary ball-milling
PCL poly caprolactone
PDL poly-D-lysine
PEG poly(ethylene glycol)
PEGDA poly(ethylene glycol) diacrylate
xxi
PEO polyethylene oxide
PFA paraformaldehyde
PGA poly(glycolic acid)
pHEMA poly 2-hydroxyethyl methacrylate
PLA poly(lactic acid)
PMMA poly(methyl methacrylate)
PNI peripheral nerve injury
PNS peripheral nervous system
PS polystyrene
rcf relative centrifugal force
RCL reactive cell layer
RO reverse osmosis
rpm revolutions per minute
SCI spinal cord injuries
TBS Tris-bu↵ered saline
TrKB tropomyosin receptor kinase B
xxii
ABSTRACT
Degradable Microchannel Nerve Guidance Sca↵olds for Central and Peripheral
Nerve Repair- From Soft to Rigid
by
Dena Shahriari
Traumatic nerve injury is generally permanent and debilitating. There is no avail-
able therapy primarily owing to the lack of spontaneous axon growth in the adult
human central nervous system. In this doctoral work, an interventional technology
was investigated to promote and guide axons through nerve gaps to provide nerve
repair.
Previously, agarose hydrogel microchannel sca↵olds linearly guided axons through
lesion gaps of spinal cords in rats. However, these sca↵olds were non-degradable.
In this work, first the e cacy of degradable hydrogels such as alginate, chitosan
and poly(ethylene glycol) (PEGDA) as nerve guidance sca↵olds was studied. All
the hydrogels, however, were concluded unstable in vivo and provided limited axon
growth.
To fabricate sca↵olds e↵ective for nerve repair poly caprolactone (PCL) with slow
degradation rate (reported over 8 months) was selected and investigated. In addition,
to increase the open volume of sca↵olds, a novel sca↵old architecture and fabrication
process were introduced in which, both the channels open space and the interstitial
xxiii
space between the channels could be utilized for axon growth. A salt-leaching process
was developed to optimize PCL properties such as porosity, sti↵ness and cell adhesion.
The sca↵old design entailed the fabrication of PCL tubes and their assembly inside a
PCL outer tube resulting sca↵olds with >60% open volume (a 3-fold improvement to
state-of-the-art microchannel sca↵olds). When implanted in transected spinal cords
in rats, linear axon growth inside and between the channels was observed.
The PCL sca↵olds, with 3 orders of magnitude higher sti↵ness than the nerve
tissue, provided the highest axon integration and growth in close proximity to the
sca↵old walls when compared to soft hydrogels. This observation is contradictory
to the general belief that an implant with sti↵ness more closely matching the tis-
sue is more e↵ective. Indeed, this doctoral work is the first study that suggests
axon/implant integration is enhanced in vivo when the substrate sti↵ness is orders of
magnitude higher than the host tissue.
This technology was translated to poly lactic-co-glycolic acid (PLGA), for a higher
degradation rate, and was fabricated to clinically-relevant dimensions. Overall, this
dissertation introduces a promising microchannel sca↵old for its translation to human
nerve repair.
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CHAPTER I
Rationale and Aims
Paralysis caused by traumatic nerve damage is generally permanent and debilitat-
ing. A cure does not exist mainly since spontaneous nerve regeneration particularly
in the adult mammalian spinal cord is disorganized and limited. To guide growing ax-
ons and stimulate axon growth toward their distal targets, interventional techniques
are under investigation. Microchannel sca↵olds combined with drug delivery have
previously proven advantageous in promoting a high density of axonal growth in the
spinal cords lesion cavities of rats. However, there is still a need for biocompatible
and month-long degradable microchannel sca↵olds that are functionalized with an
acellular drug delivery technique. In this dissertation, materials synthesis and char-
acterization as well as sca↵old architectures and fabrication techniques for generating
an e↵ective microchannel sca↵old are investigated. The development of acellular drug
delivery systems are also studied. The specific aims of the dissertation are briefly de-
scribed below.
1.1 Alginate hydrogel sca↵olds
In Chapter III, alginate hydrogel was investigated as the sca↵old material. In
vitro degradation of alginate was quantified using rheology, which showed the hydro-
gel sti↵ness decreases by more than 96% in 2 days. Alginate sca↵olds with linear
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channels were engineered by expanding a fiber-optic templating technology and were
implanted in the transected spinal cords of rats. Although some linear axon growth
was observed, the implanted sca↵olds degraded within 14 days before complete axon
growth could occur. Therefore, the studied alginate hydrogel degraded at a higher
rate than required for nerve repair.
1.2 Dense alginate sca↵olds
It was next hypothesized that dense alginate with significantly reduced porosity
has a slower degradation rate than porous alginate hydrogel investigated in Chapter
III. To test this hypothesis, in Chapter IV, alginate films with minimal porosity were
generated. To functionalize the films with a drug delivery technique, proteins were
incorporated with the films and a sustained protein release for 50 days was obtained.
The films could also provide a gradient release of proteins. In addition, the bioactivity
of the released protein was confirmed. Lastly, a sca↵old fabrication technique was
introduced to produce microchannel sca↵olds. However, when implanted in transected
spinal cords of rats, sca↵olds degraded within 28 days, which was not su cient time
for axons to grow through the entire length of the nerve gap (2 mm). Reactive cell
layers (RCL) were also formed at the ends of the sca↵old and the necrosis (unnatural
cell death) of the host spinal cord occurred, indicating the inflammatory response of
the material.
1.3 Poly(ethylene glycol) diacrylate (PEGDA) hydrogel scaf-
folds
In Chapter V, a slower degrading hydrogel, PEGDA, was investigated as the
sca↵old material. The change in the sti↵ness of the material was studied based on its
weight% (wt.%) and uv cross-linking time. Upon selecting a PEGDA composition
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with optimum sti↵ness (30.6 kPa), the hydrogel was modified with RGD peptides
to reduce inflammatory response and improve cell adhesion properties. In addition,
the PEGDA sca↵olds were functionalized with a layer-by-layer (LbL) drug delivery
technique to release brain-derived neurotrophic factor (BDNF), which occurred for 8
days. PEGDA sca↵olds were fabricated using the fiber-optic templating technology.
The sca↵olds were implanted in the transected spinal cords of rats and remained intact
for at least 28 days. However, PEGDA hydrogel sca↵olds swelled in vivo to the degree
that less than 14% open volume was available for nerve growth. Therefore, to obtain
a sca↵old with higher open lumen volume, an alternative approach was needed.
1.4 Agarose hydrogel microdrilled sca↵olds with poly capro-
lactone (PCL) supporting conduits
Chapter VI focuses on a unique sca↵old architecture specifically designed for the
peripheral nervous system (PNS). Unlike the spinal cord which is protected by the
vertebra, peripheral nerves are surrounded by soft tissue and subjected to relatively
large dimensional displacement when limbs move. Therefore, when a guidance scaf-
fold is implanted in the PNS, it is necessary to secure the sca↵old to the nerve stumps
to minimize its movement and to provide mechanical reinforcement. Therefore, the
goal of Chapter VI was to fabricate a supporting conduit that can be placed around
a microchannel sca↵old and be sutured to the nerve stump. PCL was investigated
as the conduit material owing to its high strength. To tailor its mechanical proper-
ties, porosity was introduced to enhance flexibility and suture-ability. Agarose was
investigated as the sca↵old material since its e cacy for axon growth was perviously
confirmed. Microchannel agarose sca↵olds were produced using a microdrill and were
inserted into the PCL conduits. The sca↵olds were implanted in 1 cm-long nerve gaps
in rats sciatic nerves and the PCL conduit was sutured to the nerve stumps. Sca↵olds
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remained stable in the nerve tissue for at least 56 days. In addition, axon penetration
and Schwann cells were observed inside the channels. Overall, PCL conduits were
concluded biocompatible and e↵ective in securing a microchannel sca↵old in cm-long
peripheral nerve gaps.
1.5 Poly caprolactone (PCL) sca↵olds with high open vol-
ume
The work introduced in Chapter VII is aimed to develop the next generation
of biocompatible and degradable sca↵olds exhibiting a significant increase in open
volume. State-of-the-art microchannel sca↵olds have a lumen volume less than 45%
with the rest of the space occupied by the matrix between the channels. To maximize
the sca↵old open volume, a new sca↵old design was introduced in which, microtubes
were assembled inside an outer tube creating interstitial space in between the tubes.
To produce the sca↵olds, PCL tubes introduced in Chapter VI were modified and
used for sca↵old fabrication. A salt-leaching technique was developed to optimize
pore size, sti↵ness and cell attachment properties of PCL. Sca↵olds with over 60%
open volume were implanted in rats transected spinal cords for 28 days. Axonal
penetration and linear growth were observed both inside the innertubes and in the
interstitial space between the innertubes. In addition, the inflammatory response was
the lowest observed compared to agarose, alginate, chitosan and PEGDA sca↵olds
and is therefore considered the most promising microchannel sca↵old compared to
the investigated sca↵olds.
1.6 Impact and summary
The focus of Chapter VIII was to first confirm the clinical translation of the mi-
crochannel sca↵olds. Attempts are taken to confirm the PCL technology described in
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Chapter VII can be translated to other FDA-approved materials. PLGA was investi-
gated since it is one of the most commonly used biomaterials in tissue engineering and
also becasue it degrades faster than PCL (4-8 months as opposed to 1-3 years). PLGA
inner tubes with optimized pore size and sti↵ness were synthesized and inserted inside
a PCL conduit. Preliminary data indicates the potential of these sca↵olds for nerve
repair. Next, the viability of producing microchannel sca↵olds with clinically-relevant
dimensions were shown and their performance was tested in the sciatic nerve gap of
a large animal model (minpig). 10 mm-long PCL microchannel sca↵olds with 8 mm
diameter were produced without limitation to increase the dimensions. Although fur-
ther characterization is necessary, preliminary work showed some motor and sensory
functional recovery. Overall, the viability of translating the technology introduced in
Chapter VII to human clinical applications is suggested.
Next, the criteria for an ideal nerve guidance sca↵old are discussed. In addition,
some of the discoveries of the dissertation are summarized and compared to analyze
the e↵ect of sti↵ness on nerve growth in spinal cord injury. It is suggested that, unlike
the common dogma of “softer is better”, a higher rate and density of axon growth
occurs on rigid polymers compared to soft hydrogels in vivo. Finally, future directions
are discussed.
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CHAPTER II
Introduction
2.1 Spinal cord injury Overview
2.1.1 Spinal cord injury
Individuals with spinal cord injuries (SCI) generally lose sensation and function
at and below the point of injury. Every year about 12,500 new cases of SCI occur
in the USA alone [26, 123]. In 2014, approximately, 276,000 individuals with an
average age of 42 years lived with SCI [123]. SCI are generally caused by vehicu-
lar accidents (39.08%), falls (29.54%), violence (14.4%), and sports and recreational
activities (8.39%) (Fig. 2.1) [123]. The condition is debilitating and is considered
permanent since less than 1% of the individuals fully recover [35, 45, 123]. In addi-
tion, the health complications of SCI progresses over time and about one third of the
individuals need re-hospitalization at least once a year [45, 123]. The life expectancy
of individuals with SCI after the injury is on average 14 years and has remained con-
stant since the 1980s [26, 123]. In addition, the employment and educational status of
individuals is often a↵ected with SCI as shown in Table 2.1 [35, 123]. Overall, there
is a compelling need to develop a treatment for SCI.
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Figure 2.1: Causes of SCI. Chart is reproduced from [123].
Status (%) At injury Year 1 Year 10 Year 20 Year 30 Year 40
Empolyed 58.1 12.2 27.9 34.4 32.9 18.5
Student 15.3 16.1 7.2 2.7 0.7 0.0
Table 2.1: The table shows the percentage of individuals with SCI that are employed
or are students based on the number of years after the injury. Graph is
reproduced from [123].
2.1.2 Acute phase after an injury
The penetration of a damaged vertebrate or an object into the spinal cord can
bruise, crush or transect the spinal cord axons and causes SCI. The first few hours
(about 3 hours) after an injury are crucial to reduce the severity of the injury due to
the immediate swelling of the tissue, which causes secondary damage to the spinal
cord. Depending on the level of the injury, surgeries are generally necessary and
performed as quickly as possible to remove foreign debris and vertebra fragments
[47]. In addition, steroids such as methylprednisolone may reduce inflammation [154].
Orthopedic devices are also often used to stabilize the spine to prevent further damage.
On average, the individual is hospitalized for 11 days [123]. The patient may regain
slight functional motor and/or sensory recovery within 6 months after the injury
owing to some degree of spontaneous spinal cord repair.
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2.1.3 Rehabilitation phase after an injury
After the e↵ects of the acute stage, when trauma has subsided and the patient’s
health is stabilized, rehabilitation may begin. The main purpose of rehabilitation is
to help the individual (and the family members) adjust and learn about healthcare
options, re-establish independence, and prepare for vocational opportunities as/if the
level of injury allows. A variety of health aspects need to be addressed during rehabil-
itation. When 3187 individuals with SCI were surveyed in 11 di↵erent studies, data
indicated that the functions most important to the individuals were bowel/bladder
control, sexual function, upper limb mobility/sensation, and pain [156]. Other studies
have aimed to understand the quality of life aspects most important to the individu-
als; factors such as friend/family relationships, general health/function, employment,
and leisure/recreation were among the aspects individuals preferred more rehabilita-
tion on [156]. In 2014, the rehabilitation stage took an average of 36 days in the USA
[123].
2.2 Axons and axon regeneration
2.2.1 SCI at the anatomical level
The information-processing components of the nervous system are neurons. Gen-
erally, a neuron receives electrical signals from its dendrites and passes it to another
neuron or a muscle through its axon (Fig. 2.2) [83]. In mammals, the spinal cord
consists of thousands of linearly-oriented (rostral to caudal) axons, supporting neural
cells and capillaries that are physically protected by vertebrae. Spinal cord axons
begin from the occipital bone and end between the first and second lumbar vertebrae.
When SCI occurs, the axons are transected/injured and the information cannot be
transmitted, which causes motor and sensory functionality loss at and below the
injury. Neurons of transected spinal cord may survive the injury and minimally re-
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Figure 2.2: Image of an axon. The arrows show the direction of information flow
through a neuron: from dendrites to cell body to axons. Image is from
[51].
generate by releasing growth factors and cytoskeletal proteins [150].
2.2.2 Axon regeneration mechanism
Axon regeneration can be defined as “1) the growth of a cut axon and 2) extension
into or beyond a lesion” [173]. To enable spinal cord repair, the long tract axons of
the motor and sensory neurons need to regenerate. It is generally believed that an
axon cannot grow or regenerate without a growth cone, which is the tip of a growing
axon and the extension of the filopodium (a cell component also important for cell
migration) (Fig. 2.3). Axons use growth cones to read signals and select a growth
direction [63, 101]. One hypothesis for growth cone translocation and axon extension
is the myosin-based clutch theory. When actin filaments at the tip of the growth cone
are linked to a substrate and extend toward a target, they are used as “clutches” to
pull the central part of the growth cone forward and therefore extend the axons (Fig.
2.4) [164].
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Figure 2.3: The image illustrates the growth cone of an axon with some of its main
components: actin, lamellipodium and filopodium. Image is from [89].
Figure 2.4: The clutch hypothesis for growth cone translocation and axon growth.
The actin-based motor, myosin, anchored to ends of microtubules, pulls
actin filaments toward the central domain. Image is from [146].
10
2.2.3 Inhibitory environment of SCI for axon growth
A traumatic injury to the spinal cord triggers a series of secondary responses that
significantly limit the growth of axons (Fig. 2.5). The accumulation of inflammatory
molecules is one of the immediate responses that is both beneficial and detrimental
to axon regeneration [38]. After SCI, an influx of neutrophils occurs within hours
followed by macrophages within days to remove cellular debris [135]. Simultaneously,
microglia migrate and proliferate in the lesion in the first few hours of injury and
often form an inhibitory glial layer within 2 weeks [135]. In addition, since cystic
cavities form after severe SCI, meningeal cells and oligodendrocytes fill the lesion
to reduce edema, ischemia, hemorrhage, and change in electrolyte level [94, 166].
Consequently, the lesion swells with fluid, reducing tissue density below a point that
can provide a permeable matrix for axon growth [138, 166, 174]. Two weeks post-SCI,
inhibitory molecules such as oligodendrocytes, reactive astrocytes and chondroitin
sulfate proteoglycans (CSPGs) [49, 77, 144] fill the lesion and create an inhibitory
environment for axon growth. Overall, since a permeable matrix is necessary for axon
growth [174], spontaneous axon growth is limited after SCI.
2.3 Peripheral nerve injury overview
2.3.1 PNI impact
According to Christopher and Dana Reeve Foundation, about 1.4% of the US
population with an average age of 52 ± 18 years live with peripheral nerve injury
(PNI) [26]. About 20,000 procedures are performed annually to help repair peripheral
nerve injury [125]. Following a PNI, peripheral neuropathy (nerve disease or damage)
may occur which a↵ects the somatosensory system [170]. Neuropathy symptoms
include, but are not limited to, tingling or numbness, burning or stabbing pain,
muscle weakness and extreme sensitivity to touch [14]. About 66% of individuals
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Figure 2.5: The temporal (a) anatomical and functional results and (b) inflammatory
responses in SCI rodents [38].
with PNI live with pain and 50% with neuropathy pain [27]. Extreme neuropathic
pain often has a more negative impact on the life quality than the disability itself
[27]. Because of the pain as well as the loss of body movement and sensation, more
workdays are lost and financial burden is high [27, 45]. Individuals with paralysis
report a lower quality of life and higher depression rates [27, 45].
2.3.2 Axon regeneration in the peripheral vs. central nervous system
Unlike in SCI, axons can regenerate through a PNI and form functional neural
relays after a process called Wallerian degeneration (Fig. 2.6). Several factors dis-
tinguish the post-trauma lesion environment in SCI compared to PNI. First, myelin
debris is removed immediately after a PNI, but have a delayed removal in SCI, which
causes an inhibitory environment for axon regeneration [148]. Second, the axon re-
generating genes are silenced in the spinal cord but can be upregulated upon injury
in the peripheral nerves [48]. Third, a PNI lacks the inhibitory molecules that are
present in SCI. Instead, Schwann cells form a guiding structure called Bu¨nger bands
that support axon regeneration through the PNI [92, 129]. Forth, Schwann cells
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Figure 2.6: Cascade of cellular events after an injury to a peripheral nerve during Wal-
lerian degeneration. (a) Upon injury, the axon cytoskeleton and myelin
degenerates. (b) Within 1-3 days, Schwann cells and macrophages start
removing the axon and myelin debris. (c) 10-20 days later, Schwann cells
form Bu¨nger bands for axons to regenerate along. Images are from [5].
release growth factors after PNI, which induce axon regeneration.
2.3.3 Approaches to peripheral nerve repair
Peripheral nerve repair can occur if the nerve end epineuria are sutured together
to connect a severed peripheral nerve [29]. However, when the nerve gap is larger
than ⇠4 mm, suturing the nerve stretches the nerve and diminishes axon regenera-
tion [145]. Currently, autologous grafts are the most prevalent treatment [76, 120]
and are considered the“gold standard” approach for acute PNI. They, however, have
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practical limitations such as donor site morbidity and painful neuroma formation
and are not always possible [11, 95]. Therefore, synthetically engineered grafts are
under investigation as an alternative approach. The main purposes of these grafts
are to circumvent the disadvantages of autologous grafts while achieving comparable
at worst or superior at best clinical outcomes compared to autologous nerve grafts.
These grafts are discussed in section 2.5.
2.4 Biomaterials used for nerve guidance sca↵olds
2.4.1 Biomaterials selection criteria
The material choice for a nerve implant is critical for its design and performance.
Not only should the material be bioinert and degradable, it must also be compatible
with a nerve guidance sca↵old fabrication technique. Ideally, the material should
also allow for the integration of a drug delivery technology. Moreover the implant
material should have adequate mechanical properties to survive the rigors of sca↵old
fabrication process, implantation and patient motion during recovery particularly
for the highly mobile regions such as sciatic nerves. Consequently the mechanical
properties of a material play an important role in the development of e↵ective nerve
guidance sca↵old technology. Commonly used biomaterials are divided into biological
polymers, natural hydrogels and synthetic polymers and are described in more details
below.
2.4.2 Biological polymers
Biological polymers are derived from living systems and are bioresorbable. Colla-
gen, a component of the extracellular matrix [8], is a common example used in nerve
sca↵olds [39, 149] but it requires cross-linking chemicals that can be toxic [124]. Fibrin
is another biomaterial commonly used as tissue adhesives that is derived from blood
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[155]. Fibrin primarily consists of fibrinogen, which, in conjunction with platelets,
forms blood clots [13, 70]. Thrombin enzymatically breaks fibrinogen to initiate fibrin
formation [13, 70] after which a 3-dimensional network is formed [155]. Other exam-
ples include gelatin and hyaluronic acid. Biological polymers, however, generally do
not have adequate mechanical integrity to sustain a sca↵old fabrication technique or
implantation process. Overall, it is generally challenging to engineer natural polymers
into sca↵olds [21]. In addition, since they are driven from the body, they may induce
immune response [21].
2.4.3 Polysaccharide hydrogels
Natural hydrogels are polysaccharides generally isolated from sea products and are
commonly tested for nerve repair because: 1) they are typically inert, 2) have high
water contents similar to tissue, and 3) their mechanical properties can generally
be controlled. One example is agarose hydrogel previously used as nerve sca↵olds
[55, 65, 158]. However, agarose is non-degradable in the body and is generally known
to have poor cell adhesion properties. Chitosan is another natural hydrogel widely
used for nerve repair [3, 52, 132, 176, 178] and depending on its chemical structure can
degrade between a few days to more than 3 months [52, 142]. Despite the advantage of
having a tunable degradation, its elastic modulus is reported to be approximately 40
kPa [37], which may limit the fabrication of a sca↵old with the necessary mechanical
integrity to maintain linear channels. Alginate hydrogel, on the other hand, has
adjustable mechanical properties and can have a sti↵ness of 300 kPa [134], which is
su cient for maintaining linear channels as previously demonstrated [103, 158]. This
hydrogel can be ionically cross-linked with earth Alkalines such as calcium [82] and
is reported to degrade within 2 months [84] through the leaching of the cross-linking
cations. However, the degradation rate of ionically cross-linked alginate has not been
accurately characterized for its performance in the nerve tissue.
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2.4.4 Synthetic polymers
Synthetic polymers are artificially produced; therefore, their properties and func-
tionality are more controllable and predictable than natural materials. For example,
their chemical structure can be tailored to obtain a wide range of mechanical and
chemical properties [21]. The most common synthetic sca↵old polymers are saturated
aliphatic polyesters such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA) and
their copolymers [143]. Among this class of polymers, the behavior can vary signifi-
cantly, owing to their unique composition. For example, the degradation mechanism
of these polymers is based on the hydrolysis or the cleaving of ester bonds [109]. The
degradation rates depend on the ratio of PLA and PGA since PLA is more hydropho-
bic and degrades slower. Overall, the degradation rate is more or less una↵ected by
the in vivo environment [143]. However, if an inflammatory response occurs, the pH
changes and the hydrolysis rate (and therefore degradation rate) is a↵ected [21]. One
example of aliphatic polyester copolymers is PEG (poly(ethylene glycol) or polyethy-
lene oxide (PEO) which is a particularly hydrophilic substrate that results in poor
cell and/or protein attachment and can lower the inflammatory response [21]. How-
ever, if cell/protein adhesion is desired, PEG can be modified with di↵erent peptides
such as RGD, IKVAV and YIGSR [66, 186]. In addition, the mechanical properties
of PEG can be controlled by changing the PEG weight% [17, 66]. Another polyester
previously used for nerve repair applications is poly caprolactone (PCL) [23, 90, 149].
Similar to PEG, PCL does not allow cell attachment [136, 147] likely because of its hy-
drophobic structure and non-porous morphology. Moreover, PCL is a relatively slow
degrading polyester (degradation period reported from 1 year up to 3 years [34, 54]).
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2.5 Nerve grafts for axon guidance
2.5.1 The significance of linear axon guidance
Regenerating axons have limited sense of directionality; as a result, they lack
the ability to spontaneously grow toward distal targets. However, interventional
technologies such as a nerve guidance sca↵old can provide physical cues to linearly
guide axons. Since axons grow in bundles, guiding individual axons toward distal
targets is not only impractical, it is ine↵ective. Instead, nerve fascicles, integrated
with support cells and capilaries, can be linearly guided by nerve guidance sca↵olds
[46]. A nerve fascicle, in this context, is a group of axons that move toward the
distal target [175]. In principal, if the nerve fascicle is confined to a space with
a matching diameter, though there may be some misalignment between the native
proximal and distal axonal tracts, recapitulation within native nerve tracts is feasible
[72, 163, 168, 188]. Thus, nerve guidance sca↵olds consisting of linearly-arranged
microchannels are a viable approach to guide axonal regeneration.
2.5.2 Nerve grafts designs
Nerve grafts consisting of a range of architectures and designs have been widely
investigated. The role of the grafts is to provide a supporting substrate to promote
and guide regenerating axons into and beyond nerve gaps (Fig. 2.7). The idea of
nerve implants first started in the late 1800s. Later, veins and arteries [179, 180],
followed by plastics [56] and metals [40] were studied and even implanted in damaged
peripheral nerves in humans. Although some of these grafts enabled nerve growth,
they all caused neural impairment and some trigged immune system rejection. Sim-
ilarly, the use of biological nerve grafts in the PNI from the individual or a cadaver
causes damage to the donor nerve, has limited availability and can induce immune
rejection [10, 189]. Hollow conduits have been investigated for peripheral nerve re-
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pair [132, 181, 182, 185]. In addition, di↵erent types of FDA-approved conduits such
as Surgisis® [71, 157], Neurotube® [79], NeuroMatrix® [79], Neuroflex® [96] and
NeuraGen® [4, 85] are currently available for PNI. Filling the nerve gap with a gel
or a matrix is another approach to promote the penetration and growth of axons. For
example, collagen gels were transplanted in the transected rats spinal cords and some
axon growth through the matrix was observed [110]. Hashimoto et al. compared
alginate, collagen and fibrin gels for axon growth in sciatic nerve gaps [69]. To fur-
ther enhance the degree of linear guidance, electrospun fibers are under investigation
and the presence of supporting neural cells and some axonal growth were observed
[25, 74, 117]. In addition, electrospun fibers may be embedded in a conduit for im-
proved ease of handling during surgery [178]. Other designs such as seeding Schwann
cells on a collagen sheath and rolling the sheath has also been investigated [64]. Over-
all, although some axon growth is observed with myriad designs, linear guidance of
axons is generally poor and the majority of axons do not reach their distal targets. To
further improve linear axon guidance, multilumen sca↵olds are under development.
Extensive research has been conducted to develop a process for fabricating mul-
tilumen sca↵olds. For example, non-degradable agarose [55, 65, 158] and chemically
cross-linked alginate [131, 137] sca↵olds as well as degradable poly 2-hydroxyethyl
methacrylate (pHEMA) [50] and poly lactic-co-glycolic acid (PLGA) [172] sca↵olds
with linear microchannels were fabricated. These multilumen sca↵olds provided lin-
ear directionality for growing axons; however, the microchannel sca↵olds occupied
more than 55% of the lesion volume. The low lumen volume drastically limits nerve
regeneration as well as vascularization and is therefore non-ideal. Another important
criterion for a nerve sca↵old is for it to have a month-long degradation rate to allow
complete axon growth through the lesion. Overall, further modifications are needed
to improve the current multilumen sca↵old designs.
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Figure 2.7: Examples of di↵erent nerve grafts. (a) Chitosan conduit [3], (b) alginate
hydrogel [69], (c) electrospun poly-L-lactic acid fibers [74], and microchan-
nel sca↵olds from (d) agarose [158], (e) pHEMA [50] and (f) PLGA [169].
The scale bar in (c) is 50 µm. All the other scale bars are 500 µm
2.5.3 Criteria for nerve guidance sca↵olds
When designing a sca↵old, several criteria must be simultaneously satisfied. First,
the sca↵old material must be biocompatible and exhibit month-long degradation rates
(for example, one month of regeneration was required to guide axons for 2 mm in
spinal cord cavities [158]). Second, the sca↵old channel diameter should be large
enough for axon bundles (nerve fascicles) to grow into but small enough to provide
linear guidance. There is a debate on the optimum channel diameter, which is re-
ported from 20 µm by Pawar et al. [131] to 200 µm by Stokols et al. [158]. Third,
even though it has not been definitively demonstrated, sca↵old walls may require
interconnected porosity to allow nutrients, waste and oxygen to permeate laterally
between microchannels and the sca↵old periphery, but small enough to prevent axon
cross-over [20, 75]. Fourth, to maximize lumen volume and therefore regeneration,
the sca↵old channel wall thickness should be minimized. Lastly, it should be possible
to manufacture clinically relevant cm-long sca↵olds.
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2.6 Growth factor delivery
A sustained supply of growth-promoting neurotrophic factors, at a su cient dosage,
can substantially promote axon regeneration and nerve growth [9, 53, 171]. An ap-
proach to deliver these factors is to virally transfect or genetically modify cells to
produce nerve growth factors [55, 65, 158]. Though e↵ective in stimulating the re-
generation of axons, the cellular drug delivery approach can cause tumor formation,
spread outside of the injury site, and raise ethical controversies. To avoid these issues,
alternative approaches involving acellular drug delivery are under development.
One acellular drug delivery technique is to coat the implant with proteins by im-
mersion in a protein solution [133, 162]. However, this method causes initial burst
release and fast protein degradation [98, 152]. Drug delivery systems such as poly-
meric microspheres can prolong the bioactivity of proteins by encapsulating and de-
livering drugs, yet they also cause initial burst release and require a secondary carrier
to remain in the lesion site and are therefore non-ideal [19].
Protein immobilization on a nerve graft is another approach in which proteins are
covalently bonded to the sca↵old walls. However, this technique limits the sca↵old
material to substances with specific functional groups suitable for protein binding.
In addition, there are still contradicting results regarding the e cacy of a protein
for nerve regeneration when it is bound to a surface and cannot be internalized by
neurons [2, 61, 107, 108].
Another drug delivery technique is the layer-by-layer (LbL) drug delivery system.
LbL is based on the alternating assembly of materials and the sequential incorpora-
tion of drugs on a matrix through complementary interactions [31, 32]. The use of
carboxylic acid-based polyelectrolytes allows the assembly of such layers through hy-
drogen bonding at a pH below the pKa of the polymers and later releasing the layers
in a less acidic environment (Fig. 2.8) [22, 160, 161, 177]. Studies on pH sensitive LbL
assembly on agarose hydrogel have shown the release of lysozyme for at least 4 weeks
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Figure 2.8: (a) Assembly and (b) release of poly (acrylic acid) (PAA) and poly (ethy-
lene glycol) (PEG) alternating layers on a substrate. One layer acts as the
hydrogen donor and another as the hydrogen acceptor. Hydrogen bonds
are formed at a pH below the pKa of the polymers. The layers are gradu-
ally dissociated when the pH rises above the pKa. Proteins (red dots) can
be taken up in between the polymeric layers and therefore slowly released
upon pH rise.
[115] and brain-derived neurotrophic factor (BDNF) for 2 weeks [105]. Furthermore,
increasing the surface area of the material causes a higher protein uptake and release
[104, 115]. Overall, the LbL drug delivery technique has promising potential for use
with nerve implants.
Despite the progress in the fields of neuroscience, materials synthesis and pro-
cessing, sca↵old engineering and drug delivery systems, no therapy exists for SCI as
well as few cm-long PNI. An approach that combines the findings and discoveries
of all these fields may significantly propel the progress in nerve repair. Numerous
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research groups currently work on developing such combinatorial therapies. However,
there is yet to be reported a nerve guidance sca↵old with favorable biocompatibility
and degradation rate functionalized with a local and sustained drug release, which
stimulates nerve growth and linearly guides the axons through nerve gaps.
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CHAPTER III
Characterizing the Degradation of Alginate
Hydrogel for Use in Microchannel Sca↵olds for
Spinal Cord Repair
3.1 Abstract
Alginate was studied as a degradable nerve guidance sca↵old material in vitro and
in vivo. In vitro degradation rates were determined using rheology to measure the
change in shear modulus vs time. The shear modulus decreased from 155 kPa to 5
kPa within 2 days; however, alginate samples maintained their superficial geometry
for over 28 days. The degradation behavior was supported by materials characteriza-
tion data showing alginate consisted of high internal surface area (400 m2/g), which
likely facilitated the release of cross-linking cations resulting in the rapid decrease in
shear modulus. To assess the degradation rate in vivo, microchannel sca↵olds were
fabricated using a fiber templating technique. The sca↵olds were implanted in a 2
mm-long T3 full transection rodent spinal cord lesion model for 14 days. Although
there was some evidence of axon guidance, in general, alginate sca↵olds degraded
before axons could grow over the 2 mm-long lesion. Enabling alginate-based sca↵olds
for nerve repair will likely require approaches to slow its degradation.
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3.2 Introduction
Agarose hydrogel sca↵olds with linear channels were previously fabricated and
scaled to cm-long sca↵olds for spinal cord repair [55, 65, 158]. However, these implants
are non-degradable and inflammation is frequently observed at the sca↵old-host tissue
interface [65]. The ideal nerve guidance sca↵old (NGS) should have the following
characteristics: 1) be biocompatible [28, 128]; 2) have high channel volume and/or
thin walls to maximize open space for axonal growth; 3) have linear channels to guide
axons and maintain their organization in the spinal cord [1, 158]; 4) have channel
diameters between 25 µm and 200 µm [131, 158]; 5) degrade after nerve regeneration
to avoid permanently occupying the spinal cord [1] and 6) be cost-e↵ective [1].
In this work, a calcium cross-linked alginate hydrogel was investigated as a guid-
ance sca↵old material for axonal regeneration owing to its biocompatibility with
nerve tissue [91, 122, 127, 165], wide range of elastic moduli (1 kPa to 320 kPa)
[86, 113, 134], and tunable degradation rate [86, 134]. Ionically cross-linked alginate
degrades through the release of divalent cross-linking cations such as calcium, and
their exchange with monovalent cations such as sodium [91].
The in vitro degradation of alginate has been previously studied. For example,
McKay et al. studied the change in the shear modulus of 0.25 wt.% and 0.5 wt.% algi-
nate hydrogel after 2 days of in vitro degradation [113]. Other studies have performed
cell attachment studies on alginate for up to 10 weeks and suggested techniques such
as adding NaCl to preserve material integrity [111, 112]. However, to date there have
been no studies that correlate the change in the shear modulus of calcium cross-linked
alginate in week-long experiments.
Previous in vivo works on alginate such as Prang et al. and Suzuku et al. studied
the e cacy of covalently cross-linked microchannel alginate sca↵olds and calcium
cross-linked alginate hydrogel sponges for spinal cord repair, respectively [137, 165].
However, there have been no studies to evaluate the in vivo degradation of calcium
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cross-linked alginate hydrogel sca↵olds for spinal cord repair. To determine if alginate
hydrogel is a viable nerve guidance sca↵old material, it is important to understand
its degradation behavior in vitro and to test its e cacy in vivo.
This study entailed a two-pronged approach to characterize the degradation of
calcium cross-linked alginate hydrogel. First, the in vitro degradation was measured
using rheology, and by assessing the specimen for macroscopic deterioration. Second,
in vivo degradation was characterized by fabricating and implanting microchannel
alginate sca↵olds in rodent T3 full transections to determine if adequate integrity is
maintained to e↵ectively guide axons over two weeks. To achieve shear moduli similar
to that of previously reported 3 wt.% agarose hydrogel sca↵olds [55, 65, 158], a 3 wt.%
alginate hydrogel composition cross-linked with 100 mM calcium chloride (CaCl2)
was chosen, which is reported to have the same modulus as 3 wt.% agarose [134].
It was observed that the shear modulus of the alginate hydrogel decreased by 97%
within 3 days in vitro. In addition, in vivo tests demonstrated that while sca↵olds
may initially maintain channels to guide axons, the sca↵old was not visible through
optical and fluorescent imaging after two weeks of in vivo testing.
3.3 Experimental
Both high-purity (HP) alginate suitable for in vivo studies and the more commonly
used low-purity (LP) alginate were used (Provona UP MVG and Provona MVG,
respectively. FMC Nova Matrix; Philadelphia, PA). Both alginate grades had more
than 60% guluronate monomer. All other chemicals were purchased from Sigma (St.
Louis, MO) unless otherwise mentioned.
Alginate was dissolved in reverse osmosis (RO) water (3 wt.%) and cross-linked
in a 100 mM CaCl2 solution to form a hydrogel.
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3.3.1 Fabrication of alginate hydrogel
To make homogeneous alginate hydrogels, a 1-dimensional (1-D) cross-linking
technique was developed to improve uniformity Fig. 3.1. A glass microfiber filter
paper (Whatman grade GF/A) was placed between two 2024 alloy aluminum rings
(7.6 cm inner diameter, 8.9 cm outer diameter. McMaster; Aurora, OH). The tubes
and filter paper were adhered together using double-sided tape forming a reservoir
to contain the alginate precursor during the cross-linking process. Alginate solution
was poured on top of the filter paper, but was too viscous to permeate through it.
The reservoir assembly was placed in a 100 mM CaCl2 solution (Alfa Aesar; Ward
Hill, MA) to allow the calcium ions to permeate through the filter paper and into the
alginate solution. A 6.4-mm diameter hole was made in the bottom ring, approxi-
mately 3 mm below the filter paper, to release air bubbles. After 24 hr of immersion
to cross-link the alginate solution, disks were cut from the alginate hydrogel using a
custom punch consisting of 0.8 mm wall thickness, titanium 6 aluminum-4 vanadium
alloy (McMaster) tube, sharpened to a knife edge (11.4mm inner diameter). Alginate
hydrogel faces were cut with a razor blade to produce 5 mm-tall samples with flat
and parallel opposing surfaces.
To compare cross-linking techniques, the conventional radial cross-linking method
was also used to fabricate alginate disks. Briefly, plastic mesh (1 mm opening size,
McMaster) was shaped into cylindrical tubes about 25 mm in diameter. The tubes
were immersed in alginate solution, where the longitudinal axis was oriented vertically,
and immediately transferred to and kept in a 100 mM CaCl2 solution, after which
the hydrogels remained for 24 hr. The alginate hydrogels were cut perpendicular to
the longitudinal axis using a razor blade to produce disks about 5 mm tall and 11.4
mm in diameter.
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Figure 3.1: (a) Conventional radial and (b) 1-D cross-linking of alginate. Unlike radial
cross-linking, 1-D cross-linking produces uniform disks for up to 15 mm
tall samples.
3.3.2 Shear modulus measurements
Parallel 2024 aluminum plates (11.4 mm diameter) were custom-made and in-
serted in an Ares rheometer (TA instruments; Schaumburg, IL) for shear modulus
testing. Sand paper (1200 grit) was adhered to the parallel plates using double-sided
tape to avoid sample slippage during testing (as suggested by Meyvis et al. [118]).
First, the initial contact point, and thus the height of the sample, was measured upon
the initial detection of normal force. Since the shear modulus of hydrogels changes
with the frequency of the shear strain [7, 93, 100, 118], the frequency was fixed at
1 Hz for all rheology experiments. To optimize the shear strain rate, a range of
0.01% to 50% shear strain was applied and the shear modulus was recorded. Since
the shear modulus of alginate continuously decreased at dynamic shear strains higher
than 0.5%, a dynamic shear strain of 0.5% was chosen for all experiments. In gen-
eral, the procedure by Meyvis et al. was followed to measure the shear moduli [118].
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Briefly, the shear modulus was recorded after 50 s of applied dynamic shear strain
with a frequency of 1 Hz. Each disk was then compressed for a distance of 25-100 µm
(0.5-2.0% compression strain), and the modulus was measured. Subsequent compres-
sion was applied until the shear modulus did not change; full contact with the sample
was established and the shear modulus was recorded (n = 5). In addition, to confirm
1-D cross linking was uniform, the shear modulus measurements were conducted on
both faces of a cylindrical specimen to ensure the modulus was the same on each face.
3.3.3 Assessing the in vitro degradation rate of alginate disks
The HP and LP alginate disks, made using the 1-D and radial cross-linking meth-
ods (n = 5), were stored in 37 C 1xDPBS with a volume equivalent to five times
the volume of each disk. The solution was exchanged daily. Images of the alginate
disks were taken to qualitatively assess swelling and degradation. To characterize the
swelling of alginate, the diameters of the disks were measured using electronic calipers
(Mitutoyo; Aurora, IL). The heights of the HP alginate disks were measured daily
until day 6 using the initial contact point detected by the rheometer. The diameter
and height measurements were used to determine the volume and hence track the
degree of swelling. The shear modulus of the disks were measured daily until the
modulus decreased to less than 3% of the original value.
3.3.4 Pore characterization
Cross-linked HP alginate was supercritically dried to preserve the pore structure.
The procedure was the same as previously reported by Lynam et al. [104]. The hy-
drogel was immersed in 100% ethanol (Decon Labs, Inc.; King of Prussia, PA) for 3
days and the ethanol was changed every day. The samples (n = 3) were then washed
with liquid CO2 over 2 days followed by supercritical extraction. Scanning electron
microscopy (SEM) (JOEL 7500F; Peabody, MA) was used to characterize the poros-
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ity. Brunauer, Emmett, Teller (BET) (Micromeretics ASAP 2020; Norcross, GA)
was used to measure surface area and pore size distribution as described elsewhere
[104]. Briefly, water was removed under vacuum (10-6 torr) at 80 C for 12 hr before
each nitrogen sorption test. Free space and surface area were measured through the
quantification of the adsorption/desorption behavior using ultra high purity helium
and nitrogen, respectively and were correlated using Barrett-Joyner-Halenda (BJH)
desorption method.
3.3.5 Sca↵old fabrication
HP alginate sca↵olds were fabricated using a fiber templating technique [103, 158].
Briefly, multicomponent fiber bundles (MCFB) of hexagonally-packed polystyrene
(PS) fibers with 167 µm diameter separated by a poly(methyl methacrylate) (PMMA)
matrix with 67 µm spacing were used (Paradigm Optics; Vancouver, WA). After
templating, alginate sca↵olds contracted longitudinally and expanded laterally when
immersed in physiological solutions, likely caused by an osmotic e↵ect. To account
for these dimensional changes, the MCFBs were made 5% longer in the longitudinal
direction and 10% shorter in the lateral dimensions, resulting in 2 mm long and 1.8
mm by 1.8 mm wide sca↵olds. The MCFBs were bonded to PS caps, and the PMMA
matrix was removed using a 80:20 vol/vol propylene carbonate:acetonitrile solution.
Templates were then soaked in 3 wt.% HP alginate solution and centrifuged at 1000
revolutions per minute (rpm) (9 relative centrifugal force (rcf)) for 30 s to facilitate hy-
drogel permeation between the PS fibers. To ensure complete permeation, templates
were kept in an alginate solution overnight at room temperature, and centrifuged at
1000 rpm (9 rcf) for another 30 s before cross-linking in 100 mM CaCl2 for 4 hr.
Excess alginate hydrogel along the template periphery was trimmed o↵ using a razor
blade. The alginate-permeated templates were immersed in 37 C cyclohexane under
agitation for 2 days to selectively etch away the PS fibers. The alginate sca↵olds
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with linear channels were then washed with 100 mM CaCl2 to remove any remaining
residue.
Alginate sca↵olds were placed in 1 ml of 1xDPBS at 37 C and the solution was
replaced every 24 hr. Optical images of the sca↵olds were taken on days 1, 3, 7,
14, 21 and 28 to ensure the channels and the bulk geometry of the sca↵olds were
maintained in vitro. Agarose (3 wt.%) hydrogel was selected as a control sca↵old
material, because it is known to be non-degradable and its e cacy for spinal cord
repair has been studied [55, 65, 158]. Agarose sca↵olds were prepared similar to
alginate sca↵olds following the protocol first described by Stokols et al. [158]. Briefly,
fiber templates were cut to 2.0x1.8x1.8 mm, bonded to PS caps and reinforced with
PS lateral supports as explained above. Agarose (3 wt.%) was heated to 70 C to
produce a molten agarose solution. The fiber template was placed in the molten
agarose and centrifuged at 1000 rpm (9 rcf) for 45 s to remove air bubbles and
promote fiber wetting. Upon cooling to room temperature and gelling, the fiber
templates were extracted from agarose and any extra agarose was trimmed from the
template using a razor blade. The fiber template permeated with agarose construct
was placed in tetrahydrofuran (Alfa Aesar, Ward Hill, MA), at 37 C for 3 days under
agitation while exchanging the solution every day. The sca↵olds were then washed in
RO water.
3.3.6 Surgical procedures and in vivo characterization
Details regarding the animal handling and surgeries are described elsewhere [81].
Briefly, adult female Fischer 344 rats (150-200 g) were used in this study according to
the NIH guidelines for laboratory animal care and safety. A combination (2 ml/kg)
of ketamine (25 mg/ml), xylazine (1.3 g/ml), and acepromazine (0.25 mg/ml) was
used to anesthetize the animals. T2-T4 laminectomies were performed. Micro scissors
were used to create 2 mm-long lesion cavities in the T3 spinal cord segments. The
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lesions were cleared using micro aspiration. Animals were divided into three experi-
mental groups (n = 3 per group): Group 1 received no treatment; Group 2 received
non-degradable agarose hydrogel sca↵olds; and Group 3 received alginate hydrogel
sca↵olds (alginate hydrogel sca↵olds were soaked in 1 ml of phosphate bu↵er (pH
7.4) for 20 min prior to implantation).
To examine sca↵old degradation in vivo, animals were sacrificed 2 weeks post-
implantation and perfused with 4% paraformaldehyde (PFA) in 100 mM phosphate
bu↵er at 4 C. Segments (2 cm-long) centered above the lesion sites were separated
and post-fixed in 4% PFA overnight at 4 C, and then in 30% sucrose (w/v) in 100
mM phosphate bu↵er at 4 C for another 48 hr prior to cryosectioning. Longitudinal
sections at a thickness of 30 µm were collected on a cryostat. For immunolabeling,
slides were suspended in proteinase K (1:20, antigen retrieval) (Millipore; Darmstadt,
Germany) for 20 min followed by postfix with methanol for 5 min at room temper-
ature. Slides were blocked using 5% goat serum in Tris-bu↵ered saline (TBS) con-
taining 0.25% Triton X-100 for 1 hr. The slides were then incubated overnight with
mouse-anti-Neurofillament 200 for axons staining (Millipore) with a 1:500 dilution.
The sections were washed with TBS and labeled with secondary antibody: goat-
anti-chicken 647 (1:250, for 2.5 hr in dark at room temperature) (Life Technologies,
Carlsbad, CA). The slides were then washed with TBS, labeled with Fluoromount G
(Southern Biotechnology Associates, Inc.; Birmingham, Alabama) and imaged using
a fluorescent microscope (Olympus BX53; Center Valley, PA).
3.4 Results
3.4.1 In vitro degradation testing
Images of the conventional and 1D cross-linked gels after immersion ion 1xDPBS
are shown in Fig. 3.2. The radially cross-linked alginate hydrogel disks fragmented
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Figure 3.2: Visual changes of 11.4 mm-diameter (a) radially cross-linked low-purity
alginate and 1D cross-linked (b) low-purity and (c) high-purity alginate
during in vitro degradation. Unlike radially cross-linked hydrogels, 1D
cross-linked alginate does not fragment and exhibits uniform degradation.
Scale bars are 5 mm.
within 3 days, thus it was not possible to make dimensional measurements as a func-
tion of time (Fig. 3.2). Conversely, the alginate hydrogel disks fabricated by the 1-D
cross-linking technique maintained their geometry making it possible to quantitatively
assess the change in physical properties as a function of time (Fig. 3.1). Thus, only 1-
D cross-linked samples were considered for quantitative degradation characterization.
Since only the HP alginate would be implanted, only HP swelling was characterized.
Negligible changes in the diameters of the samples were measured. The majority of
the changes in height (and therefore swelling) occurred between days two and three,
after which the volume increase subsided, e.g. between days three and six (Fig. 3.3).
To accurately characterize and quantify the degradation of alginate hydrogel disks,
changes in shear moduli were measured using rheology. The shear moduli of HP and
LP alginate hydrogel were 155 ± 21 kPa and 186 ± 20 kPa, respectively. The
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Figure 3.3: The change in the volume of HP alginate disks during degradation. The
data are normalized to the volume of the samples from day 0. The disks
swell to about 40% by day 6.
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Figure 3.4: Rheology measurements for low-purity (⇤) and high-purity (4) alginate,
including optical images of the high-purity samples (with a diameter of
11.4 mm) on days 0 and 7. While the shear modulus drops by 97% within
3 days, the superficial geometry is maintained.
di↵erent moduli may have resulted from the di↵erent purities; regardless, the shear
moduli of both HP and LP alginate hydrogel disks decreased by approximately 97%
by day three (Fig. 3.4).
3.4.2 Pore characterization
SEM images showed 3 wt.% alginate hydrogel consisted of cross-links in the 10-20
nm range and interconnected pores in the tens of nanometer range (Fig. 3.5). The
BJH method on nitrogen desorption data on supercritically dried 3 wt.% alginate
hydrogel corroborates the SEM analysis, indicating that most pores fell within the
25-35 nm diameter range with a total surface area of 415.7 ± 12.0 m2/g (n = 3)
(Fig. 3.6). These data are consistent with similar studies on supercritically dried 3
wt.% agarose and 2 wt.% alginate hydrogels [104, 139].
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Figure 3.5: SEM image of supercritically dried 3 wt.% alginate showing intercon-
nected pores, which are in the tens of nanometer range. Scale bar is 200
nm.
Figure 3.6: Nitrogen desorption data of supercritically dried alginate showing that
the majority of nanopores are 25-35 nm in diameter.
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3.4.3 Sca↵old characterization and in vivo testing
Images of a template and an alginate sca↵old are shown in Fig. 3.7. The aver-
age template fiber diameter and the spacing between fibers were 219.7 ± 16.0 µm
and 95.7 ± 9.1 µm, respectively. The alginate hydrogel sca↵old matched the tem-
plate pattern and had an average channel diameter and sca↵old wall thickness of
197.5 ± 25.4 µm and 83.5 ± 35.6 µm, respectively. Contraction during cross-linking
may explain the slight reduction in dimensions compared to the templates. Di↵er-
ences between template-to-sca↵old channel diameter and wall thickness was 10.1%
and 14.6%, respectively. This was comparable to fiber templated agarose hydrogel
sca↵olds exhibiting 14.2% and 22.0% channel diameter and wall thickness template-
to-sca↵old shrinkage, respectively. Optical images (not shown) demonstrated that
alginate sca↵olds generally maintained their channels for at least 28 days.
Histology sectioning 2 weeks post-implantation showed that non-degradable agarose
hydrogel sca↵olds were intact and the channels were distinguishable (Fig. 3.8a). Some
linear axonal growth was observed throughout the agarose hydrogel sca↵olds. How-
ever, the channels and the alginate hydrogel sca↵olds were not, in general, distin-
guishable in the histology (Fig. 3.8b). Nevertheless, there was some evidence of linear
axonal regeneration in Fig. 3.8b and Fig. 3.8c, suggesting that some microchannels
could maintain integrity long enough to guide axons up to approximately 0.5 mm
(Fig. 3.8c).
3.5 Discussion
Alginate hydrogel was investigated as a degradable nerve sca↵old for spinal cord
repair owing to its reported biocompatibility and tunable degradation rate [86, 91,
122, 127, 134]. After developing a technique to fabricate uniform disks, the degra-
dation of alginate hydrogel was quantified in vitro by monitoring the change in its
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Figure 3.7: (a) Cross-section and (b) longitudinal view of a multicomponent fiber
bundle template consisting of a PMMA matrix and PS fibers. The PS
components (b) maintain PS fiber linearity after the PMMA matrix is
etched. Templated alginate sca↵old cross-section and side view (c) and
(d), respectively. Scale bars in (a) and (c) are 400 µm and in (b) and (d)
are 500 µm.
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Figure 3.8: Representative images of neurofilament (green) labeling of a completely
transected rat spinal cord 2 weeks post-implantation: (a) agarose sca↵old
and (b) alginate sca↵old. The agarose hydrogel sca↵old remained intact
while the alginate sca↵old mainly degraded. Some axonal growth into
the agarose sca↵old is observed. A higher magnification image (c) shows
some axonal growth at the rostral end of the alginate sca↵old. The Scale
bars in (a) and (b) are 200 µm and the scale bar in (c) is 50 µm.
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shear modulus over time. Sca↵olds with linear channels were then fabricated and
implanted in rodent spinal cords to test their e cacy for axonal guidance in vivo.
To measure the change in the shear modulus during degradation, first a technique
for fabricating homogeneous alginate hydrogel disks was developed. Conventional
radial cross-linking was initially attempted, but samples fragmented within 3 days
likely due to the non-uniform permeation of calcium ions. To achieve uniform cross-
linking, a novel 1-D cross-linking technique was developed. The uniformity of samples
with a height less than 15 mm was confirmed since the same modulus was obtained
when performing rheometry on the top and on the bottom of the disks (with the
bottom of the disk being the side against the filter paper).
Once a technique was established to fabricate homogenous alginate hydrogel disks,
rheometry was used to characterize their degradation in vitro. Rheometry was se-
lected because, unlike techniques such as uniaxial compression testing, swelling dur-
ing loading (the “barreling e↵ect”) is minimized [119]. The barreling e↵ect can cause
deformation and sometimes rupture, which prevents the re-testing of the same sam-
ple as it degrades. In this study, rheology was used to measure the shear modulus
to characterize the degradation rate in vitro. Applying a dynamic sinusoidal shear
stress minimizes the barreling e↵ect and yields information about both the shear
and the viscous behavior by providing shear and loss moduli, respectively. The ini-
tial shear modulus on day zero was in agreement with the previously reported value
[134], but had relatively lower standard deviations (generally below 10%) compared
to previous work [93, 100, 126, 134]. The 1-D cross-linked samples maintained their
integrity to allow for mechanical testing beyond day 1, unlike samples obtained by
radial cross-linking. These results confirmed the e↵ectiveness of rheology for quan-
tifying the degradation of hydrogels, which was previously suggested by Meyvis and
co-workers [118].
Rheological analysis showed that the shear modulus of HP alginate hydrogel dra-
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matically decreased from 155 kPa to 5 kPa in 2 days, while no change in the super-
ficial geometry was observed for over 28 days. The exchange of cross-linking calcium
cations with monovalent sodium cations is the main cause of degradation of calcium
cross-linked alginate hydrogel [80, 91, 139]. The combination of high internal surface
area (415.7 ± 12.0 m2/g) and nano scale interconnected porosity (Fig. 3.2), likely
facilitated calcium ion loss and swelling (Fig. 3.2 and Fig. 3.3), which decreased the
shear modulus and later caused fragmentation.
The observed degradation behavior suggested that alginate hydrogel undergoes
bulk degradation. Since alginate hydrogel maintained its superficial geometry in
vitro for over 1 month, alginate was considered a promising candidate for degradable
nerve guidance sca↵olds. To test this hypothesis, microchannel alginate hydrogel and
non-degradable agarose hydrogel (control) nerve guidance sca↵olds were fabricated
using a fiber templating technique [158]. The fiber template construction resulted in
alginate permeation from two opposing faces (Fig. 3.7b shows one of only two open
template faces that the alginate solution could permeate). Thus, upon immersion in
the CaCl2 solution, the cross-linking direction was one-dimensional. The degradation
of alginate sca↵olds was first studied in vitro and it was confirmed that the sca↵olds
generally maintained their channels and bulk geometry for at least 28 days. In light
of the promising in vitro data both on alginate disks and sca↵olds, the sca↵olds were
implanted in a T3 full transection rodent model to test their e cacy in vivo. The
approach used to characterize degradation was based on a qualitative assessment of
the lesion cavity two weeks post implantation (Fig. 3.8). In agreement with previous
work [55, 65, 158], linear walls and channels are clearly discernable in the lesion
containing the agarose sca↵old. However, compared to the agarose sca↵olds, there
was no clear evidence of linear walls or channels in the lesion containing the alginate
sca↵old, aside from a few linear axons on the proximal and distal ends of the cavity;
perhaps evidence that initially the alginate sca↵old guided axons before it degraded
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away. Though the details of the degradation mechanism are di cult to determine,
it is believed that the images in Fig. 3.8 indicate that the alginate sca↵old was not
present/functional after two weeks post implantation.
3.6 Conclusions
Alginate hydrogel was evaluated as a nerve guidance sca↵old material. The degra-
dation rate of alginate was measured in vitro using rheology. A methodology was
developed to fabricate uniformly cross-linked alginate hydrogel disks to measure the
shear modulus as a function of time. It was determined that the shear modulus
of alginate hydrogel decreased by 97 % in 2 days, but no change in the superficial
geometry of the hydrogel was observed in 28 days. In vivo studies demonstrated,
qualitatively, that calcium cross-linked alginate hydrogel did not maintain adequate
mechanical integrity to guide axons toward distal targets over a 2 mm T3 full tran-
section spinal cord injury model. It is possible that if alginate hydrogel sca↵old walls
degraded slower, linear guidance to the distal targets may have occurred. In future
work, approaches to decrease the degradation rate of alginate should be pursued to
make it a viable sca↵old material for nerve regeneration sca↵olds.
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CHAPTER IV
Dense Alginate Films Fabricated into
Microchannel Sca↵olds and Functionalized for a
Gradient Protein Release
4.1 Abstract
This work investigates the synthesis of an alginate-based material with lower
degradation rate compared to alginate hydrogel. Alginate solution was dried to dense
films and cross-linked with calcium chloride (CaCl2). Possibly due to the increase in
surface roughness, the NIH 3T3 fibroblast cells adhered to alginate in its dense form
but not in its hydrogel form. It was shown that the tensile elastic modulus of the
films increased from 76.1 MPa to 552.2 MPa as the concentration of CaCl2 changed
from 100 mM to 1000 mM . In addition, to obtain continuous drug release from dense
alginate films, proteins (lysozyme or brain-derived neurotrophic factor (BDNF)) were
incorporated with the hydrogel solution prior to dehydration and cross-linking. A
sustained protein release was obtained in vitro for at least 50 days and the BDNF
bioactivity released from the films was confirmed. Next, two novel techniques were
introduced to fabricatemm-long disks. The disks were microdrilled into microchannel
sca↵olds and implanted in 2 mm-long transected rats spinal cords. It was observed
that the dense alginate sca↵olds degraded within 4 weeks in vivo. Overall, further
42
modifications are necessary for alginate to be used as a viable nerve guidance sca↵old
for spinal cord repair.
4.2 Introduction
To linearly guide axons through the lesions of spinal cord, microchannel sca↵olds
were investigated [55, 65, 131, 158]. These sca↵olds, however, were not degradable.
Alginate hydrogel microchannel sca↵olds were investigated as an alternative degrad-
able material (Chapter III). However, alginate hydrogel degraded before complete
axon regeneration occurred in the spinal cord cavity. The hydrogel had high surface
area and interconnected porosity, which likely facilitated degradation. In this study,
it was hypothesized that a significant reduction in the alginate porosity may decrease
the leaching of cross-linking calcium ions and consequently prolong the degradation
of alginate. Overall, the goal of this study was to produce non-porous dense alginate
that can be fabricated into microchannel sca↵olds. The sca↵olds were aimed to 1)
allow cell attachment, 2) can be functionalized for month-long drug release, and 3)
linearly guide axons through spinal cord lesion sites.
Alginate was fabricated into dense films. Tensile testing was performed to quantify
the e↵ect of cross-linker concentration (CaCl2) on the elastic modulus of the films.
Similar to a previous report by Leroux et al. [93], the modulus increased by increasing
the CaCl2 concentration. In addition, upon significantly reducing the porosity, the
cell adhesion properties of the films were increased compared to alginate hydrogels,
which is likely due to the increase in surface roughness of dense alginate.
In addition to providing linear guidance for growing axons in a lesion cavity, it is
necessary to stimulate axonal growth. Therefore, providing a sustained drug release
is necessary [12, 174]. In addition, a gradient protein release can further facilitate cell
growth and guidance [33, 78, 121]. Proteins were therefore incorporated with alginate
films to obtain a sustained gradient release. In addition to obtaining a 50-day release
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profile, the bioactivity of the released protein was confirmed.
Lastly, the films were fabricated into microchannel sca↵olds and implanted in the
transected T3 spinal cords of rats. Sectioning and immunolabeling were performed
after 4 weeks. Inflammatory response was observed and the sca↵olds had fragmented
into debris within 4 weeks. Therefore, similar to alginate hydrogel, dense alginate
microchannels did not have the adequate degradation rate. It is possible that the
degradation rate of dense alginate was slower than alginate in its hydrogel form;
nevertheless, the degradation rate was not long enough to allow nerve growth through
the 2 mm-long spinal cord lesion cavity in rats.
4.3 Experimental
4.3.1 Alginate film fabrication
Alginate (Provona UP MVG) was purchased from FMC Nova Matrix (Philadel-
phia, PA). To fabricate films, 16 g of 3 wt.% alginate/RO water was poured on a
130 mm-diameter polystyrene petri dish (VWR; Radnor, PA) and air-dried for 18
hr (Fig. 4.1). All alginate films were cross-linked with CaCl2 solution at 100 mM
concentrations for 4 hr unless specified otherwise.
4.3.2 Material characterization
The cross-linked alginate films were fractured in liquid N2. The surface fracture of
the films were coated with 3 nm-thick gold (SPI Supplies; West Chester, PA) and im-
aged under scanning electron microscopy (SEM) (ZEISS AURIGA FIB; Thornwood,
NY).
To characterize the change in the elastic modulus of alginate films versus cross-
linking concentration, alginate films were cross-linked with CaCl2 at 100, 200, 300
to 1000 mM . Alginate films were cut to 30 x 8 mm rectangular pieces and tensile
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Figure 4.1: Fabricating dense alginate films. (a) The top picture on the left shows al-
ginate hydrogel and (b) the bottom left shows alginate collapsed film after
dehydration. The gray schematics on the right correspond to predicted
macroscopic structure of alginate in either form. The black dots repre-
sent the optional addition of protein molecules temporarily immobilized
by the alginate.
testing was performed at 1.5 N/min load rate (n = 5) (Instron; Norwood, MA).
To study the change in cell attachment based on porosity, NIH 3T3 fibroblasts
were cultured on both alginate hydrogel (Chapter III) and the dense alginate films
(n = 3). Cells were imaged after 48 hr using a contrast microscope.
4.3.3 Protein incorporation and bioactivity measurements
Alginate powder (1 wt.%) was added to 1 mg/ml lysozyme/RO water solution.
The solution (5 ml) was poured in a 6 well-plate (VWR) and air-dried for 18 hr
(n = 3) to produce films. The films were cross-linked with 100 mM of CaCl2 for 4
hr. Excess CaCl2 was removed in 1xDPBS for 15 min and films were stored in 1 ml
of 1xDPBS at 37 C. The solution was collected and exchanged daily for 50 days. To
measure the protein concentration of the collected solutions, a Micro BCATM protein
assay kit (Thermo Fisher Scientific; Wayne, MI) was used and the protocol by the
manufacturer was followed.
To obtain a gradient release profile, a barrier was placed at the center of a
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Figure 4.2: Fabricating dense alginate films with gradient protein release. (a) Using a
barrier, two reservoirs were created in a rectangular-shape container and
filled with alginate solution- one with and one without protein. (b) The
barrier was removed and the solution was air-dried. Three pieces of the
film as shown with the dashed circles in (b) were extracted for protein
release measurements.
rectangular-shape reservoir (60 x 20 mm). Each reservoir was filled with 5 ml of
1 wt.% alginate solution with or without lysozyme (1 mg/ml) (Fig. 4.2(a)). The
barrier was then removed and the solutions were air-dried for 18 hr. Three 10 mm-
diameter circles as shown in Fig. 4.2(b) were extracted from the film and cross-linked
with 100 mM CaCl2 solution for 4 hr. Each film was rinsed with 1xDPBS for 15
min and stored in 1 ml of 1xDPBS with the solution collected and refreshed daily.
Micro BCATM assay was used to measure the protein concentrations (n = 3).
BDNF-incorporated films were fabricated to characterize the bioactivity of the
released protein. 6 ml of a 1.2 wt.% alginate solution with 29 µg of human BDNF
(ProSpec; Rehovot, Israel) was poured in a 6 well-plate (n = 3). To reduce the
adhesion of BDNF to well-plate walls, an ultra low-adhesion well-plate (Corning;
Corning, NY) was used. The alginate/BDNF solutions were dried for 18 hr to produce
films. Films were cross-linked with 100 mM CaCl2 for 4 hr. 1xDPBS was used
for 15 min to wash the films. The films were stored in a defined culture medium
prepared according to the protocol described by Lynam et al. [105]. The solutions
were exchanged daily and stored at 4 C. The bioactivity of the released BDNF for the
first 6 days was tested by applying the solution on transfected NIH 3T3 cell line that
expressed BDNF-recognition tropomyosin receptor kinase B (TrKB). The cells were
seeded at a concentration of 5 x 104 cells/ml. Contrast imaging and cell counting
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was performed after five days and normalized to the cell count obtained from control
group treated with 50 ng/ml of fresh BDNF.
4.3.4 Dense alginate disk and sca↵old fabrication
Two techniques were used to fabricate alginate disks. In the first technique, algi-
nate films were rolled and cross-linked to fabricate a solid dense disk. Alginate films
were prepared as explained in 4.3.1. The films were then rolled around a 1 mm-
diameter steel rod for a final diameter of 1.8 mm. The alginate roll was then inserted
in a 2 mm inner diameter plastic tube. The steel rod was gently removed from the
film and the assembly was placed inside a 100 mM CaCl2 solution for 4 hr for the
alginate to cross-link and fully fill the tube. The alginate disk was cut to 2 mm-long
pieces. In the second technique, incremental amounts of alginate solution was poured
on top of alginate films to produce disks. Specifically, 17 g of 6 wt% alginate was
poured in a well of a 12 well-plate and air-dried for 4 hr. The process was repeated
until a 2 mm-long disk was fabricated.
Alginate disks were microdrilled in a hexagonal pattern using a computer numer-
ical control (CNC) machine (US Digital, Vancouver, WA) and a patterning program
(Artsoft Software Inc.; Livermore Falls, ME). A microdrill bit of size 0.30 mm was
used to microdrill channels with a spacing of 0.20mm at a feed-rate of 0.020mm/min.
The sca↵olds were sterilized in 50:50 vol ratio of ethanol (Decon Labs, Inc.; King of
Prussia, PA) and RO water for 15 min; rinsed with autoclaved RO water and stored
dry.
4.3.5 Surgical procedure and in vivo characterization
The NIH guidelines for laboratory animal care and safety was followed. The
implantation protocol and characterization are described elsewhere [81]. Briefly, 150-
200 g adult female Fischer 344 rats were deeply anesthetized using a combination
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of ketamine (25 mg/ml), xylazine (1.3 mg/ml), and acepromazine (0.25 mg/ml).
Laminectomy on T2-T4 sections were performed and 2 mm-long lesion cavities in the
T3 sections of spinal cords were performed. Sca↵olds from section 4.3.4 were inserted
into lesions upon micro-aspiration and cleaning (n = 4).
Animals were perfused with 4% paraformaldehyde (PFA) 4 weeks post-implantation.
Segments (2 cm-long) were post-fixed in 4% PFA overnight at 4 C followed by 48
hr storage in 30% sucrose (w/v) in 100 mM phosphate bu↵er at 4 C. Longitudi-
nal sections (0.03 mm-thick) were cryosectioned. Slides were stored in proteinase K
(1:20, antigen retrieval) for 20min and methanol for 5min. Goat serum (5%) in Tris-
bu↵ered saline (TBS) was used to block the slides for 1 hr. Mouse-anti-Neurofillament
200 with a 1:500 dilution for axons staining was used overnight. Slides were washed
with TBS and stored in secondary antibody: goat-anti-chicken 647 for 2.5 hr in dark
and washed with TBS. Slides were then labeled with Fluoromount G and imaged
(Olympus BX53; Center Valley, PA).
4.4 Results and Discussion
4.4.1 Material properties
To compare the di↵erence between the porosity of alginate hydrogel and alginate
dense films, the SEM image of supercritically dried alginate hydrogel from Chapter
III was compared to the cross-sectional image of a dense alginate film (Fig. 4.3). The
images confirm the loss of pores in the dense alginate film. In addition, the change
in porosity was hypothesized to reduce solution exchange in dense alginate film and
prolong its degradation.
Since CaCl2 is the cross-linking solution, it was expected that the elastic mod-
ulus of the films increases with the increase in the cross-linkers concentration [93].
To confirm and quantify the change, alginate films with varying concentrations were
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Figure 4.3: SEM images of (a) highly porous supercritically dried alginate hydrogel
versus (b) collapsed alginate film. Scale bar in (a) is 0.15 µm and in (b)
is 1 µm.
prepared and tensile testing was performed. As shown in Fig. 4.4, the elastic mod-
ulus of films increases from 76.1 MP to 552.2 MPa by changing the cross-linkers
concentration from 100 mM to 1000 mM . To better match the elastic modulus of a
nerve tissue ( 1-3 kPa), 100 mM concentration was chosen through this study. It was
noted that robust films were not successfully produced with a CaCl2 concentration
below 100 mM .
It was predicted that cell adhesion may improve on dense alginate compared to
its hydrogel form due to the change in its morphology. Previous reports on peptide-
modified dense alginate films confirmed cell attachment [36, 57]. In this study, the
cell attachment of NIH 3T3 fibroblasts was tested on alginate hydrogel versus dense
alginate films. The results confirm the enhancement in cell adhesion on alginate films
versus alginate hydrogel (Fig. 4.5).
4.4.2 Protein release measurements and bioactivity characterization
To obtain a sustained protein release from alginate films, proteins were incorpo-
rated with alginate solution prior to drying and cross-linking. Lysozyme was initially
used due to its similarity in size to BDNF as well as its low-cost. The lysozyme
release profile showed a sustained release for 50 days with a total amount of 277 µg
released protein per cm2 of alginate film (Fig. 4.6). In addition, unlike conventional
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Figure 4.4: The elastic modulus of dense alginate films increased by raising the con-
centration of the cross-linking solution (CaCl2).
Figure 4.5: NIH 3T3 fibroblasts do not attach on (a) hydrogel form of alginate but
attach on (b) dense alginate films. Scale bars are 30µm.
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Figure 4.6: The graph shows a 50-day sustained release from a lysozyme-loaded dense
alginate film. The schematics represent a dense alginate film (gray) with
protein molecules (black) incorporated. The schematic on the left demon-
strate that, due to the dense alginate structure, the protein is initially
primarily released from the outer layers of alginate. As the film degrades
(schematic on the right), protein can be released from inner layers.
drug delivery techniques, no burst release was observed. As the schematics in Fig. 4.6
show, the non-porous structure of alginate might have aided in the controlled release
of protein by the gradual release of protein molecules as the film degrades.
Next, attempts were made to produce alginate films with a gradient protein re-
lease. Alginate solutions with and without lysozyme were used to fabricate a con-
tinuous film (Fig. 4.2). Fig. 4.7 shows release profiles from both ends of the film as
well as the center. Protein was not detected from the portion of the film that did not
initially have protein incorporated. This observation indicated that the di↵usion of
proteins through the alginate solution minimally occurred. In addition, there was a
clear di↵erence between the release profiles from the center and the segment of the
film with the initial high amount of protein, which indicated a gradient release profile
was obtained. Overall, it was concluded that a continuous film could be fabricated
using the reservoir-fabrication system with molecules minimally di↵using through al-
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Figure 4.7: The graph shows the cumulative release profile of a lysozyme-gradient
alginate film described in Fig. 4.2. (⇤) is the release profile of the section
with lysozyme while (x) is from the section without lysozyme. ( ) is the
release profile from the center of the film. The comparison between the
profiles shows a gradient release profile can be achieved.
ginate solution. Thus, separate alginate solutions containing increasing amounts of
protein can be used on a mulit-reservoir system to potentially produce a film with a
robust gradient release.
Upon obtaining promising lysozyme release data, BDNF release was tested. How-
ever, one of the concerns of protein release from dense alginate films was that the
protein may become inactive during dehydration and/or cross-linking in CaCl2 so-
lution. To test the bioactivity of protein released from dense alginate, BDNF was
incorporated with alginate films for a targeted daily release of 50 ng/ml (a concen-
tration optimum for axon growth). A proliferation assay using TrKB-expressing cells
was used to assess the bioactivity of released BDNF. As Fig. 4.8 shows, cells prolifer-
ated when treated with the solution released from the dense alginate/BDNF film on
day 1. To quantify the bioactivity of BDNF and confirm its bioactivity for the fol-
lowing days, the number of cells present after 5 days of proliferation were normalized
to the positive control treated with 50 ng/ml of fresh BDNF (Fig. 4.9). The prolif-
eration of the cells responding to the released BDNF was between 10-70% compared
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Figure 4.8: The cell proliferation images after 5 days of culturing with cells treated
with (a) 50 ng/ml fresh BDNF as positive control, (b) no BDNF as
negative control, and (c) solution released from dense alginate/BDNF film
on day 1. Positive control confirms the proliferation of cells while only few
cells were present on the negative control. Cells had proliferated when
treated with solution released from dense alginate/BDNF film confirming
the bioactivity of released BDNF. The scale bars are 50 µm.
to 50 ng/ml of fresh BDNF for the first 6 days of release suggesting that the BDNF
bioactivity was at least partially preserved. The lower proliferation rate of the exper-
imental group could be because the bioactivity of BDNF was partially lost and/or
the release concentration was below the optimum value of 50 ng/ml. In future work,
the released BDNF concentration is measured to better understand this phenomena.
The presented drug delivery technique can be used for the delivery of one or
multiple molecules/proteins as long as the bioactivity of the drug is maintained. In
addition, the released concentration can be controlled by simply changing the initial
amount of drug incorporated in the dense film. The gradient release profile is yet
another advantage of this novel technique since it is known that a gradient release of
drugs can act as a chemoattractant and further stimulate cell growth [33, 78, 121]. To
the knowledge of the author, this is the first report of a drug delivery technique that
provides sustained month-long drug release with control over the release concentration
and capability to have a gradient release.
4.4.3 Sca↵old characterization
As shown in Fig. 4.10(a) and Fig. 4.10(b), rolled alginate films can form a disk.
The disks were successfully microdrilled into microchannel sca↵olds (Fig. 4.10(c)). It
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Figure 4.9: The graph shows the bioactivity results of a BDNF-incorporated alginate
film using cellular assay on transfected TrkB 3T3 cells. Proliferation re-
sults are normalized to the cell count from 50 ng/ml fresh BDNF-treated
cells. Data show that the released BDNF is at least partially active.
was, however, observed that the sca↵olds dissociated into pieces when stored in RO
water for 2 days. A di↵erent technique was, therefore, developed to fabricate more
robust alginate disks and sca↵olds. Careful subsequent drying of alginate solution
on previously dried alginate films led to the fabrication of alginate disks with desired
lengths. The disks were then microdrilled (Fig. 4.10(d)) into sca↵olds with 0.30 mm
diameter channels and a spacing of 0.20 mm.
4.4.4 In vivo results
While valuable information can be obtained about cell attachment and degra-
dation of dense alginate films in vitro, in vivo studies are necessary to assess the
biocompatibility and degradation of dense alginate in the nerve tissue. Sca↵olds
were, therefore, implanted in the transected T3 section of rats spinal cords. Fig. 4.11
shows alginate sca↵old immunolabeled for neurofilaments 4 weeks post-implantation.
Massive inflammatory response and necrosis (cell death) of the host spinal cord oc-
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Figure 4.10: Dense alginate sca↵olds fabricated via two di↵erent techniques. 1) (a)
Alginate films were rolled, (b) cross-linked with CaCl2 into a disk and (c)
microdrilled to obtain microchannel sca↵olds. 2) Subsequent amounts of
alginate solution was dehydrated on top of alginate films until the disk
reached a targeted hight. (d) The alginate disks were then microdrilled
into sca↵olds with channel diameters of 300 µm. The scale bars are 300
µm.
curred indicating that the biocompatibility of dense alginate microchannel sca↵olds
ought to be optimized for future in vivo applications. In addition, the sca↵old had
fragmented and debris were observed (Fig. 4.11). Thus, this study demonstrated
that the fabricated dense alginate sca↵old did not have adequate degradation rate for
nerve repair. Overall, further modifications are necessary for alginate to be used for
nerve repair.
4.5 Conclusions
Dense non-porous alginate was fabricated which, unlike alginate hydrogel, allowed
cell attachment. To functionalize the films for drug release, lysozyme was incorpo-
rated and a sustained protein release for at least 50 days was observed. When BNDF
was used, the released BDNF was at least 10-70% bioactive for 6 days. Furthermore,
the films could be fabricated to have a gradient protein release. The introduced
drug delivery technique is, therefore, a simple yet promising technique for a sus-
tained month-long gradient release of proteins and/or molecules with the capability
to control the released concentration. In addition, by developing a novel technique,
mm-long disks and microchannel sca↵olds were produced. However, the dense al-
ginate sca↵olds caused inflammatory response in the spinal cord and degraded too
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Figure 4.11: Dense alginate sca↵old implanted in a transected T3 rat spinal cord and
immunostained for neurofilaments (green) after 4 weeks. The box with
dashed lines shows the transected spinal cord. The box with solid lines
demonstrate a 250 µm-thick layer of scar tissue formed at the rostral end.
Scar tissue is also formed at the distal end of the sca↵old. Necrosis of
the host spinal cord was also observed (an example is shown by the solid
arrow on the left). In addition, the dashed arrows point to the sca↵old
debris indicating that the sca↵old fragmented in less than 4 weeks. The
scale bar is 250 µm.
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quickly before complete axon growth could occur. Further modifications are necessary
to improve the biocompatibility of dense alginate and reduce its degradation rate.
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CHAPTER V
Poly(ethylene glycol) diacrylate (PEGDA)
Microchannel Sca↵olds for Spinal Cord Repair
Functionalized with Layer-by-Layer Controlled
Protein Release
5.1 Abstract
The goal of this work was to fabricate month-long degradable nerve guidance scaf-
folds that are functionalized with an acellular drug release technique. Poly(ethylene
glycol) diacrylate (PEGDA) hydrogels modified with RGD peptides were selected as
the sca↵old material owing to their reported biocompatibility to the nerve tissue as
well as month-long degradation rates. By increasing the weight% (wt.%) of PEGDA
from 5 wt.% to 20 wt.%, the elastic modulus increased from 2.6 kPa to 130.1 kPa.
Next, PEGDA/RGD microchannel sca↵olds were fabricated by modifications to a
previously reported fiber optic templating technique. The sca↵olds provided linear
axon growth after 28 days when implanted in 2 mm-long transected T3 rat spinal
cords. However, the material swelled by over 50% and had reduced open volume.
To further improve the sca↵olds and promote higher density axon growth, the scaf-
folds were functionalized with a layer-by-layer drug delivery technique. The release
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of brain-derived neurotrophic factors (BDNF) was confirmed in vitro for 8 days with
a concentration above 50 ng/ml of a microchannel volume. While further work is
needed to increase the open volume of the sca↵olds, PEGDA/RGD sca↵olds are a
promising approach as a degradable microchannel sca↵old functionalized with an
acellular drug release.
5.2 Introduction
Spontaneous spinal cord repair scarcely occurs in adult humans because of the
random and limited axon regeneration [18]. Thus, providing spinal cord repair re-
quires 1) guiding growing axons through the lesion and 2) increasing the density of
axons [12]. Microchannel sca↵olds have linearly guided axons through transected
spinal cords in rats [55, 65, 137, 158, 169]. In addition, non-degradable microchan-
nel agarose sca↵olds filled with genetically engineered or transfected cells to release
brain-derived neurotrophic factor (BDNF) [55, 158] or NT-3 [65], respectively, showed
a high density of axons linearly growing in lesions of rats spinal cords. However, cellu-
lar drug delivery has possible disadvantages such as ethical issues, immune response,
and tumor formation. To eliminate the drawbacks of cellular approach, acellular drug
delivery systems are being developed. One example is a layer-by-layer (LbL) drug
delivery technique, which involves the bonding of alternating layers of polyelectrolytes
and proteins on a material [31, 32]. When carboxylic acid-based electrolytes are used,
hydrogen bonds are formed between the layers at a pH below the pKa of the layers
[160, 161]. All the layers including the protein are slowly disassembled at a pH above
the pKa resulting in a continues pH-controlled drug release. Agarose microchannel
sca↵olds have previously been functionalized with LbL system to release BDNF for
at least 2 weeks and the bioactivity of the released BDNF was confirmed [105].
Leveraging the e cacy of nerve guidance sca↵olds (NGS) in linearly guiding ax-
ons, this work aims to produce degradable microchannel sca↵olds functionalized with
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the LbL system. uv crosslinkable poly(ethylene glycol) diacrylate (PEGDA) was se-
lected as the sca↵old material since it is FDA-approved for applications such as drug
delivery, has tunable mechanical properties [17, 66] and has a favorable degradation
rate [16, 140]. In addition, the inflammatory response of PEGDA can be reduced by
incorporating RGD peptides [106].
In this work, the mechanical properties of PEGDA was characterized and opti-
mized based on its wt.% and uv crosslinking time. A fiber optic templating technique
[103, 158] was modified to fabricate PEGDA-containing RGD sca↵olds with linear
microchannels. The in vivo performance of the sca↵olds was tested in transected
T3 spinal cords in rats. In addition, the PEGDA sca↵olds were functionalized with
the pH-responsive LbL drug delivery system to obtain over a week release of brain-
derived neurotrophic factor in vitro. This work, therefore, introduces a combinatorial
approach to both guide and promote the growth of axons for spinal cord repair.
5.3 Experimental
5.3.1 Mechanical testing
The mechanical properties of PEGDA with wt.% of 5, 10, 15 and 20 crosslinked
for 20, 35 and 50 min under uv light (365 nm) were characterized using compres-
sion testing. All samples were prepared by dissolving 0.75 wt.% photo initiator (2-
Hydroxy-4‘-(2-hydroxyethoxy)-2-methylpropiophenone. Sigma; St. Lois, MO) and
the corresponding amount of PEGDA (MW 8,000. Alfa Aesar; MW ) in deionized
water (DI water). The cylinders were formed by crosslinking 15 ml of PEGDA/photo
initiator solution in the wells of a 12-well plate (Corning; Corning, NY). Cylinders
with parallel surfaces were obtained by sanding the top surfaces with an 800 grit-sand
paper (McMaster; Aurora, OH). Compression testing was performed using an Instron
(Instron; Norwood, MA) at 1.5 mm/min compression rate (n = 5).
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5.3.2 Sca↵old fabrication
PEGDA/RGD sca↵olds were fabricated by modifications to a templating tech-
nique [158]. Hexagonally packed multicomponent fiber bundle (MCFB) templates
composed of 0.167 mm-thick polystyrene (PS) fibers with claddings of poly methyl
methacrylate (PMMA) (0.067 mm-thick) were used. Since PEGDA swells in water
after crosslinking, the sca↵olds templates were undersized and cut to 1.6 mm-high
and 1.45 x 1.45 mm cross-sections to produce 2.0 mm-high and 1.8 x 1.8 mm wide
sca↵olds. The PS fibers of the cut MCFBs were chemically bonded to PS pieces
matching the cross-section of the template using 40 C cyclohexane (Alfa Aesar).
Two opposing sides of the MCFBs were also bonded to PS caps to further support
the PS fibers. The PMMA claddings were removed in 80:20 volume ratio of propylene
carbonate:acetonitrile mixture at 60 C in 3 days under agitation. The templates were
washed in ethanol for 2 hr followed by a wash in deionized (DI) water for 1 hr, and
then air-dried. Following the protocol by Browning et al. [16] RGD peptides with
a sequence of Cys-Arg-Gly-Asp-Ser were prepared by American Peptide Company
(Sunnyvale, CA) and dissolved in DI water for a 1.5 mM concentration. PEGDA (5,
10 and 15 wt.%) and the photo initiator (0.75 wt.%) were dissolved in the 1.5 mM
RGD/DI water solution. The templates were immersed in the PEGDA mixture and
centrifuged for 45 s at 1000 revolutions per minute (rpm). The PEGDA-containing
templates were crosslinked under 365 nm uv light for 35 min. For sca↵olds used in
animal studies, sterile conditions were maintained from this point. Upon crosslinking,
the hydrogel surrounding the template was carefully removed by passing a razor blade
parallel to the template on each side. The templates were then placed in cyclohexane
for 2 days at 37 C to remove the PS fibers and produce PEGDA sca↵olds with empty
channels. Autoclaved reverse osmosis (RO) water was used to rinse and store the
sca↵olds with.
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5.3.3 Surgical procedure, sectioning and immunolabeling
All animal procedures were handled according to the NIH laboratory protocol for
animal care and safety. The in vivo work and characterization was followed by a
previously reported protocol [158]. Adult female Fischer 344 rats (150-200 g) went
under anesthetics using a solution of ketamine (25 mg/ml), xylazine (1.3 mg/ml)
and acepromazine (0.25 mg/ml). Laminectomy on the T2-T4 section of the spinal
cord of rats was performed. T3 segment of the spinal cord (2 mm) was removed
and micro-aspirated. RGD-containing PEGDA (10 wt.%) sca↵olds were inserted in
the transected spinal cords (n = 7). Using 4% paraformaldehyde (PFA) at 4 C,
animals were perfused and the implantation site was cut and placed in 30:70 wt. ratio
sucrose:1xDPBS for 48 hr. Longitudinal sections (30 µm thick) were cryosectioned for
n = 5 of the animals and stored in proteinase K:antigen retrieval (1:20) (Millipore;
Darmstadt, Germany) for 20 min. Slides were then placed in methanol for 5 min
and placed in 5% of goat serum in Tris-bu↵ered saline (TBS) with 0.25% Triton
X-100 for 60 min. Mouse-anti-Neurofillament 200 (1:500) (Millipore) was used to
stain neurofilaments overnight. Slides were then placed in the secondary antibody,
goat-anti-chicken 647 (1:250) (Life Technologies; Carlsbad, CA), for 2.5 hr followed by
labeling with Fluoromount G (Southern Biotechnology Associates, Inc.; Birmingham,
Alabama). For n = 2 of the animals, toluidine blue staining was performed on 1
µm-thick cross-sections and gold-sputtered prior to electron microscopy.
5.3.4 LbL deposition and release
The protocol by Lynam et al. [105] was used for LbL assembly on PEGDA/RGD
sca↵olds fabricated from 10 wt.%PEGDA described in section 6.3.2. Briefly, poly(acrylic
acid) (PAA) (MW 15,000. Sigma) and poly(ethylene glycol) (PEG) (MW 10,000.
Sigma,) were dissolved in DI water for a concentration of 1 mg/ml. DI water was
used as wash baths. The pH of all the solutions was adjusted to 3.5 using acetic
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acid (Sigma). Human BDNF (ProSpec; Rehovot, Israel) was dissolved in 1xDPBS
solution (Invitrogen; Carlsbad, CA) (1 µg/ml). The pH of the 1xDPBS solution was
adjusted to 3.5 using acetic acid and contained 1% bovine serum albumin (BSA).
BSA was added with the recommendation of the BDNF manufacture’s protocol to
enhance the stability of BDNF and to act as a blocking agent to reduce the adhesion
of BDNF to the walls of the container. Layers of PAA, PEG and BDNF were as-
sembled by dipping PEGDA sca↵olds in polymer or protein bath for 30 min followed
by one or two 10 min dips with agitation in wash baths (pH 3.5 of DI water). 30.5
bilayers were coated by assembling five bilayers of PAA/PEG followed by five bilayers
of PEG/BDNF, repeating this cycle three times and ending LbL deposition with one
final PAA layer. These steps were done automatically using Thermo Scientific Varis-
tain 24-4 Automatic Slide Stainer (Waltham, MA). After LbL assembly, the sca↵olds
were rinsed with neutral pH DI water for 2 minutes. To obtain BDNF release profile,
samples were then stored at 37 C in 1 ml of 1xDPBS solution. The 1xDPBS solution
was collected and refreshed daily for a total of 14 days. The BDNF concentration
from each day was measured using an ELISA assay (Boster Immunoleader; Pleasan-
ton, CA). BDNF release from 2 sca↵olds was studied and the protein release from
each day was measured twice using ELISA. To relate the BDNF release measurements
to the BDNF concentration released inside the lumen of a sca↵old, the ELISA mea-
surements were normalized to the sca↵old lumen volume (3.5 mm3). The normalized
values with a unit of ng/mlmllumen allow a better estimate of how much protein may
be available for axon growth in the microchannels of the sca↵old in vivo.
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5.4 Results and Discussion
5.4.1 Mechanical properties of PEGDA
The elastic modulus of 5, 10, 15 and 20 wt.% PEGDA samples crosslinked for
20, 35 and 50 min are shown in Fig. 5.1(a). The graph shows that changing the
crosslinking time from 20 min to 50 min minimally a↵ected the elastic moduli. How-
ever, increasing the wt.% of PEGDA increases the elastic modulus. Fig. 5.1(b).
shows the linear increase of the elastic modulus of samples crosslinked for 35 min
as their wt.% is increased. Since the PEGDA concentration is 50 times more than
the RGD peptides concentration, the a↵ect of RGD on the mechanical properties of
PEGDA was considered insignificant. Therefore, no RGD was added to the PEGDA
samples used for compression testing.
To our knowledge, there is no study that characterizes the e↵ect of uv crosslinking
time on the mechanical properties of PEGDA. Measuring the change in the elastic
modulus of PEGDA with changing uv crosslinking time may help understand the
penetration of uv light. On the other hand, PEG and PEGDA mechanical properties
based on their wt.% were quantified in previous works [16, 17, 66]. However, the
mechanical properties of a hydrogel may change based on its MW . Therefore, in
addition to understanding the e↵ect of uv crosslinking time on the elastic modulus of
PEGDA, the change in the modulus based on wt.% was quantified.
5.4.2 Sca↵old fabrication
Studies such as Gunn et al. [66] have shown PC12 cells neurite extension increases
on softer PEGDA surfaces. Therefore, the sca↵olds were aimed to have the lowest elas-
tic modulus to improve nerve growth. However, while 5 wt.% PEGDA demonstrated
the lowest elastic modulus among all the studied wt.%, 5 wt.% PEGDA sca↵olds did
not have adequate mechanical properties to maintain linear channels. Thus, 10 wt.%
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Figure 5.1: The change in the elastic modulus of PEGDA based on its wt.% and uv
crosslinking time. (a) shows the modulus of 5 wt.% ( ), 10 wt.% (⇧) and
15 wt.% (-) did not significantly change when the uv crosslinking time
was increased, while the modulus of 20 wt.% (x) PEGDA increases when
crosslinked for 50 min. Increasing wt.% increased the elastic modulus as
more closely shown in (b) in which a 35 min uv-crosslinking time was
used while varying the wt.% of the PEGDA.
PEGDA sca↵olds were used to fabricate sca↵old. In addition, it was noted that al-
though the change in the uv crosslinking time did not significantly change the elastic
modulus (Fig. 5.1(b)) or the strain to failure (data not shown) of PEGDA cylinders,
sca↵olds crosslinked at 20 min uv crosslinking did not have linear channels while 50
min crosslinking made the sca↵olds brittle. These results suggest limitations for the
penetration of uv light into cm-long disks. Therefore, 35 min uv crosslinking time
was used through the rest of the study. Overall, the data suggests that the mechanical
properties of sca↵olds may be di↵erent than PEGDA cylinders possibly due to the
geometrical and dimensional di↵erences.
When sca↵olds were removed from cyclohexane upon PS matrix etching, the scaf-
folds had the same dimensions as the templates (1.6 x 1.45 x 1.45 mm). However,
within an hr of placement in RO water, the sca↵olds were 2.0 x 1.8 x 1.8 mm while
still mimicking the linear structure of the templates (Fig. 5.2). The sca↵olds also
maintained the same hexagonal pattern of the templates and had 44% channel vol-
ume with an average channel diameter of 160 µm. It was noted that the dimensions
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Figure 5.2: The longitudinal view of the template (a) and PEGDA sca↵old (b) shows
the sca↵old matches the structure of the template with microchannels.
The scale bars are 0.5 mm.
of the sca↵olds did not change in RO water within 1 week after the initial swelling in
vitro.
5.4.3 In vivo performance
Since no growth factors were introduced in the lesion site, a low axon growth
density was expected. Nevertheless, all the sca↵olds (n = 5) provided linear axon
growth through some of their channels (Fig. 5.3). In addition, serotonergic (5HT)
axons were observed in the sca↵old channels (Fig. 5.4). When 5HT axons are present
in a damaged spinal cord, it is di cult to verify if transected serotonergic axons
regenerated or the surrounding undamaged axon terminals sprouted into the sca↵old
[173]. However, since a full spinal cord transection was performed, it is highly likely
that all axons were cut during the injury and that the increase in the serotonergic
axons is because of regeneration and not sprouting.
To further characterize the in vivo behavior of PEGDA sca↵olds, the cross-sections
of the sca↵olds were stained with toluidine blue (Fig. 5.5). The open volume of
the sca↵olds were ⇠13.8% which translates to over 50% swelling after 4 weeks of
implantation in the spinal cord. Similarly, Browning et al. [16] shows that 10 wt.%
PEGDA subcutaneously swells for 45% within 12 weeks. Swelling of PEGDA is likely
because of the crosslink cleavage and the reduction in the crosslink density [12, 16].
Finally, it was also noted that PEGDA sca↵olds did not degrade in vivo 1 month
post-implantation. Previous work on templated hydrogel sca↵olds focused on non-
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Figure 5.3: Linear axon growth is observed through some of the PEGDA sca↵old
channels. Neurofilaments are stained in green. Figure (a) shows a repre-
sentative image of a PEGDA sca↵old 4 weeks post-implantation in the T3
transected rat spinal cord. The boxed region in (a) is the nerve gap where
the sca↵old was inserted. Figures (b), (c), (d) and (e) are the most axon-
dense channels of 4 di↵erent implants and highlight the reproducibility
and e cacy of PEGDA microchannel sca↵olds in linearly guiding axons
along the nerve gap. The scale bar in (a) is 0.25 mm and the scale bars
in (b), (c) and (d) are 0.04 mm.
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Figure 5.4: Serotonergic axon presence and regeneration in the nerve gap. The boxed
region shows the transected T3 spinal cord in a rat with the sca↵old
implanted for 4 weeks. 5HT serotonergic axons grew linearly along some
of sca↵old channels. The scale bar is 0.25 mm.
Figure 5.5: PEGDA continues swelling in the spinal cord after initial in vitro swelling.
A cross-sectional image of PEGDA sca↵old 4 weeks post-implantation in
the T3 spinal cord of a rat stained with toluidine blue is shown. The
lumen volume of the sca↵old is 13.8%. Solids arrows point to the open
channels and dashed arrow point to the sca↵old wall. The scale bar is 0.3
mm.
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degradable agarose sca↵olds [55, 65, 158]. Thus, the PEGDA in vivo results provide
encouraging data for a degradable sca↵old that maintains its linear channels for a
month-long period and can linearly guide axons through the transected spinal cords
in rats.
5.4.4 LbL BDNF release
To functionalize the PEGDA/RGD sca↵olds with a local sustained protein release,
a HLbL drug delivery system was used. BDNF was chosen as the growth factor
since it was previously shown that its presence significantly increased axon density in
transected spinal cords in rats [55, 158]. As shown in Fig. 5.6, a high dosage of BDNF
was released on day 1 (6000 ng/ml of microchannel volume) and reduced by more
than a factor on day 2. The BDNF concentration remained above the required value
of 50 ng/ml of microchannel volume for nerve regeneration for 6 more days. Studies
on the pH-controlled LbL assembly on agarose hydrogel have shown the release of
lysozyme (a BDNF analog for the LbL system) for at least 30 days [116]. In addition,
BDNF was released from templated agarose sca↵olds for at least 14 days and its
bioactivity was confirmed [105]. Hence, LbL drug release shows significant potential
for integration with nerve implants. This work confirms the compatibility of the
HLbL drug delivery system to PEGDA hydrogels.
Providing linear guidance for growing axons and promoting their growth are two
important criteria for nerve repair [12]. Previous works confirmed the e cacy of
linear microchannel sca↵olds in guiding axons in the gaps of spinal cord in rats [55,
65, 158]. However, the degradation rate of the sca↵olds needed to be optimized. In
addition, it was ideal to functionalize the microchannel sca↵olds with an acellular drug
delivery system that continuously releases a nerve growth factor to promote nerve
regeneration. Leveraging the experience in 1) microchannel sca↵olds [55, 65, 158]
and 2) LbL drug delivery systems [104, 105, 115, 116], a new generation of dual-
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Figure 5.6: BDNF LbL release profile from PEGDA sca↵olds. The concentration of
BDNF released from a BDNF/LbL-coated PEGDA sca↵old shows BDNF
release for 8 days. The dashed line indicated the minimum BDNF required
for nerve regeneration (50 ng/ml). Relatively high dosages of BDNF is
released on days 1 and 2, while the release plateaus thereafter.
purpose sca↵olds is introduced. First, degradable PEGDA microchannel sca↵olds
were tested for their e cacy in linearly guiding axons in the transected rat spinal
cord. Second, the sca↵olds were functionalized with the acellular LbL drug delivery
system to continuously release BDNF above the required dosage for nerve regeneration
for 8 days. Future work will involve increasing the lumen volume of the PEGDA
sca↵old and implanting BDNF/LbL-incorporated PEGDA sca↵olds in the transected
rat spinal cord to assess the performance of the functionalized sca↵olds in linearly
guiding high density of axons through the nerve gap.
5.5 Conclusion
The elastic modulus of PEGDA increased from 2.6 kPa to 130.1 kPa as the
hydrogel wt.% increased from 5 wt.% to 20 wt.%. However, the uv crosslinking time
minimally a↵ected the sti↵ness of the material. Next, PEGDA was modified with
RGD peptides to improve its biocompatibility. PEGDA/RGD microchannel sca↵olds
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were fabricated using a fiber templating technique. The sca↵olds were inserted in 2
mm-long transected spinal cords of rats and linear axon growth through the channels
was observed 28 days post-implantation. Moreover, PEGDA sca↵olds swelled by over
50% in 28 days in vivo. PEGDA was also modified with an HLbL drug delivery system
and the release of BDNF in vitro was confirmed for 8 days. Overall, PEGDA/RGD
sca↵olds are e↵ective in linearly guiding axons but modifications are necessary to
increase their open volume.
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CHAPTER VI
Hydrogel Peripheral Nerve Microchannel Sca↵olds
Mechanically Supported by poly caprolactone
(PCL) Conduits
6.1 Abstract
Nerve repair in cm-long nerve gaps often requires interventional technology. Mi-
crochannel sca↵olds have proven e↵ective for bridging nerve gaps and guiding axons in
the peripheral nervous system (PNS). Nonetheless, fabricating cm-long microchannel
sca↵olds remains a challenge. In this work, a computer aided microdrilling technique
was used to fabricate cm-scale agarose sca↵olds consisting of 0.3 mm diameter mi-
crochannels and 0.085 mm thick walls. The agarose sca↵olds alone, however, did not
exhibit adequate sti↵ness and integrity to withstand the mechanical stresses during
implantation and suturing. To provide mechanical support and enable suturing, poly
caprolactone (PCL) conduits were developed. A modified salt-leaching technique was
developed to introduce interconnected porosity in PCL to allow for tuning of the me-
chanical properties such as elastic modulus and strain to failure. Over 10 mm long
kink resistant conduits were fabricated. In in vivo testing, it was shown that the PCL
conduits were e↵ective in stabilizing the agarose sca↵olds in sciatic nerve gaps in rats
for at least 8 weeks. Robust axon ingress and Schwann cell integration with axons
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were observed within the microchannel sca↵olds without the use of growth factors.
6.2 Introduction
Peripheral nerve injury (PNI) occurs in 3% of all trauma cases and 30% of combat
injuries [4, 11, 85]. This results in approximately 600,000 surgical procedures for PNI
annually [15]. Although spontaneous nerve regeneration can occur, functional restora-
tion is often limited and depends on the severity of the injury. Interventional technol-
ogy may be required to repair cm-long injuries after acute nerve trauma. Autologous
grafts are the current “gold standard” approach to treat PNI, but have practical lim-
itations such as donor site morbidity and can result in painful neuromas [11, 95, 175].
Bioengineered grafts are under development as an alternative therapy. The goal of
this approach was to circumvent issues related to donor availability while guiding
axons in cm-long peripheral nerve gaps. Several types of bioengineered conduits such
as Neurotube®[79], Surgisis®[68, 71, 157], NeuroMatrix®[79], Neuroflex®[96] and
NeuraGen®[4, 85] are currently approved by the USA FDA for PNI repair. All of
these devices, consist of single-lumen or open channel tubes. An alternative implant
design entails the use of linear, multi-lumen microchannels that can organize or group
axons into fascicles [175] and guide them toward distal targets. Examples involve the
design, fabrication, and testing of multi-lumen microchannel sca↵olds consisting of <
0.3 mm inner diameter channels [55, 65, 130, 151, 159]. Compared to single-lumen
conduits, multi-lumen microchannels confine axons into discrete bundles, thus provid-
ing physical guidance toward distal targets. For example, multi-lumen agarose scaf-
folds were e↵ective in linearly guiding axons in transected spinal cords [55, 65, 159].
The agarose sca↵olds were fabricated using ordered arrays of polystyrene fibers as a
template to pattern 2 mm long, hexagonally-packed linear channels.
In this work, a subtractive mechanical technique (microdrilling) was used as an
alternative approach to make 10 mm-long microchannels in agarose hydrogel. The
73
drilling process was controlled by a computer numerical control (CNC) machine to
pattern hexagonally-arranged microchannels to achieve ⇠ 40% lumen volume, which
is comparable to that of the fiber templating process previously used. For use in a
rat sciatic nerve model, 10 mm-long, 1.4 mm-outer diameter agarose sca↵olds were
prepared consisting of 0.3 mm-diameter microchannels separated by 0.085 mm-thick
walls. However, agarose hydrogel does not have adequate mechanical integrity to
allow its suturing to nerve stumps.
To mechanically stabilize the agarose sca↵old, a novel outer nerve guidance conduit
was fabricated to secure the agarose microchannel sca↵olds to the nerve stumps. The
conduits consisted of poly caprolactone (PCL). PCL was selected as the conduit
material because: 1) it is FDA-approved for applications such as sutures, 2) it is
known to be biocompatible with nerve tissue [24, 34], and 3) it can be made porous
[87, 97, 141] to control its mechanical properties [183]. Porosity was introduced into
the PCL using a salt-leaching technique to enable suturing to the nerve stumps by
reducing the elastic modulus (sti↵ness) and increasing its strain to failure. In addition,
a casting process was used to prepare relatively thin-wall PCL conduits (0.06 mm)
to minimize the conduit/sca↵old construct volume.
The purpose of this work was to fabricate and test the in vivo e cacy of an
agarose microchannel sca↵old that is mechanically supported by a porous PCL nerve
guidance conduit. In this study, agarose sca↵olds were fabricated using micromachin-
ing, consisting of 0.3 mm-diameter 10 mm-long microchannels with 0.085 mm-thick
spacing. PCL conduits enabled suturing of the microchannel agarose sca↵olds to the
nerve stump. By introducing porosity into the PCL using a modified salt-leaching
technique, strain to failure was increased from 17% to over 100%. Moreover, the
porous PCL conduit was kink-free for up to 58  of bending; an important criterion to
consider when implanted in regions where muscle tissue undergoes significant displace-
ment [30, 79, 96, 114]. When sutured to a rat sciatic nerve stump, the sca↵old/conduit
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construct remained mechanically stable with negligible inflammation after 8 weeks in
vivo and some axon and Schwann cell penetration into the proximal site of the sca↵old
was observed. This work demonstrates the e cacy of a hybrid nerve guidance sca↵old
approach whereby a hydrogel microchannel sca↵old (agarose) physically guides axons
toward distal targets while a robust outer conduit provides mechanical integrity and
enables suturing to nerve stumps. It is thought that the hybrid design can allow for
the integration of myriad sca↵old material types and configurations to produce viable
alternatives to autologous nerve implants.
6.3 Experimental
6.3.1 Agarose sca↵old fabrication
Agarose hydrogel was prepared by heating agarose powder (3 wt.%, Sigma Aldrich;
St. Louis, MO) in reverse osmosis (RO) water at ⇠ 100 C to form a monomer
solution. To eliminate air bubbles, the agarose solution was centrifuged at 1500
rotations per minute (rpm) for 30 s. The solution was poured into a 12 well-plate
(VWR; Radnor, PA) and cooled to room temperature to form a hydrogel. After
gelation, the cylindrically-shaped hydrogel cylinders were extracted from the well
plate and machined to produce 10.0 mm-tall cylinders. A computer numerical control
(CNC) machine (US Digital, Vancouver, WA) was used to machine the hydrogel
cylinder height using a 3.0 mm drill bit (McMaster, Aurora, IL) and create cylinders
with parallel faces.
The sca↵old microdrilling process is illustrated in Fig. 6.1. A 3 x 8 mm piece of
polystyrene (PS) (VWR) was attached to the top corner of a well of a 12-well plate.
To ensure the channels extended through the 10 mm-tall cylinder, a sacrificial layer
(7 mm-thick) of agarose hydrogel was prepared similar to the 10 mm-tall cylinder
and was placed at the bottom of the well plate. The 10 mm-tall agarose cylinder
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Figure 6.1: Steps in microdrilling agarose sca↵olds. (a) A sacrificial agarose disk
is placed at the bottom of the well of a well-plate. An agarose disk
with a height equivalent to the desired height of the sca↵old (10 mm in
the present study) was placed over the sacrificial layer with a PS piece
anchoring the disk in place. (b) A CNC-controlled microdrill patterned
linear channels in the agarose disk. (c) A titanium tube was sharpened to
a knife-edge and was used to cut sca↵olds. (d) The sca↵olds are extracted
from the sharpened punch.
was placed over the sacrificial agarose with the PS piece anchoring the cylinder and
preventing it from spinning/moving during microdrilling. A 0.300 mm (McMaster)
microdrill bit was used to drill the agarose cylinder in a hexagonal arrangement with
spacing of 0.1 mm using the CNC and a patterning program (Artsoft Software Inc.;
Livermore Falls, ME). A feed rate of 25.4 mm/min was used to microdrill channels.
After each 0.25 mm of drilling, the bit was extracted from the agarose hydrogel disk
to remove swarf (also known as peck drilling). Feed rates and peck drilling depths
above and below the mentioned values did not result in linear channels or symmetric
hexagonal patterning. A total depth of 11.6 mm was drilled (thus drilling into the
sacrificial cylinder) to ensure the channels extended the entire length of the sca↵old.
A few ml of water was maintained above the hydrogel cylinder during drilling to
prevent dehydration and help remove swarf from the channels and microdrill bit.
The agarose cylinder was drilled for at least 1.4 x 1.4 mm-wide surface to fabricate a
sca↵old with a diameter of 1.4 mm.
A customized sharpened punch with an inner diameter of 1.4 mm was used to
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extract agarose sca↵old from the drilled cylinder. The punch was inserted perpendic-
ular to the surface of the cylinder at a speed of 25.4 mm/min for a depth of 14 mm
and retracted above the surface. The agarose sca↵old was pushed out of the punch
by inserting a 1 mm-wide metal rod inside the punch. Air was gently blown into the
sca↵old to remove any residual agarose and clear the channels. The channel linearity
and agarose sca↵old dimensions were characterized using optical microscopy (Leica
EZ4D; Bu↵alo Grove, IL). The sca↵olds were stored in RO water with 5% ethanol
(Alfa Aesar; Ward Hill, MA) until implantation.
6.3.2 Nerve guidance conduit fabrication and sca↵old assembly
Porosity was introduced using sodium chloride (NaCl) particles as a porogen.
NaCl (Columbus Chemical Industries, INC.; Columbus, WI) was ground using a
planetary ball-mill (Retsch PM 100; Haan, Germany) in a 250 ml agate jar with 12
agate balls for 1 hr at 400 rpm with 5 min rest every 5 min. ✏-caprolactone (MW :
114.14) (Sigma; St. Lois, MO) was dissolved in chloroform (Sigma) (3 wt.%) and
added to the ball-milled NaCl to produce a 30:70 vol % of PCL:NaCl mixture. The
mixture was ball-milled for 20 min at 400 rpm with 5 min rest every 5 min. The
rest period prevented over-heating of the jar. To fabricate porous PCL conduits, a
steel rod with an outer diameter of 1.4 mm was placed in the PCL/NaCl mixture
and air-dried. After the chloroform evaporated (⇠2 min), the PCL-coated rod was
immersed in methanol (Sigma) for ⇠1 min. The PCL tubes were removed from the
rod and cut into 12 mm-long tubes using a razor. The tubes were then placed in RO
water to leach out NaCl. The PCL conduit was bent around fingertips and optical
images were taken (iPhone 5, Apple Inc.; Cupertino, CA).
Assembling the sca↵olds entailed the insertion of the agarose sca↵olds into the
tubes. Agarose sca↵olds (fabricated in section 6.3.1) were partially dehydrated to
temporarily cause radial contraction and facilitate insertion into the tubes. Dehy-
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drated sca↵olds were inserted and centered in the 12 mm-long PCL tubes with 1 mm
overhangs at each end. Agarose sca↵olds returned to the original dimensions after
rehydration in RO water. By dehydrating, inserting, and re-hydrating, the outer di-
ameter of the agarose sca↵olds matched the inner diameter of the PCL tube, which
immobilized the sca↵old inside the PCL tubes. The sca↵olds were sterilized and
stored in 10 vol% ethanol in RO water.
6.3.3 Characterizing the mechanical properties and porosity of PCL
Non-porous and porous PCL films were fabricated to characterize the mechanical
properties of PCL. The 3 wt.% PCL dissolved in chloroform and the PCL/NaCl
mixture (described in section 6.3.2) were poured on copper foil (McMaster) secured
to an automated tape casting coater using vacuum (MTI Corporation; Richmond,
CA). A doctorblade (Tape Casting Warehouse, Inc.; Morrisville, PA) with a height
of 0.050 mm was used to evenly spread the solutions. The PCL films were air-dried.
To delaminate the films from the copper foil, methanol (Sigma) was poured on top of
the films. The film with NaCl was then placed in water for at least 12 hr to remove
NaCl. PCL rectangular pieces (25 x 6 mm) were cut using a razor, and tensile testing
was performed with a 1.5 N/min loading rate (n = 5) (Instron; Norwood, MA). To
characterize porosity, the salt-leached PCL tubes described in 6.3.2. were fractured
after immersion in liquid N2 followed by sputter coating with gold for 120 s (3 nm-
thick coating) (SPI Supplies; West Chester, PA). The fracture surfaces were imaged
using scanning electron microscopy (SEM) (FEI Nova NanoLabTM 600 DualBeam;
Columbus, OH). A needle was passed through a salt-leached PCL tube in vitro to
evaluate suture-ability. The punctured PCL was gold-coated similar to the PCL tube
and characterized in the SEM.
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6.3.4 In vivo testing
Animals were housed 2-3 per cage with free access to food and water in a vivarium
approved by the American Association for the Accreditation of Laboratory Animal
Care. All animal studies were carried out according to protocols approved by the
Institutional Animal Care and Use Committee of the VA Healthcare System, San
Diego and following the IASP Guidelines for Use of Animals in Research. Adult male
Sprague-Dawley rats (150-200 g) underwent surgery under anesthesia using ketamine
(25 mg/ml), xylazine (1300 mg/ml) and acepromazine (0.25 mg/ml). A total of 7
animals were used. The hindquarters were shaved and sterilized with ethanol (Sigma).
Skin was incised parallel to the femur, and the sciatic nerve was exposed via a gluteal
muscle-splitting approach. A 5-mm segment of sciatic nerve, 5 mm proximal to the
sciatic trifurcation, was cut. A sterilized 10 mm-long agarose sca↵old inside a 12
mm-long PCL conduit (described in sections 6.3.1 and 6.3.2) was inserted in each rat
nerve gap and the PCL conduit was sutured to the ends of nerve stumps with two
interrupted 9-0 nylon microsutures. Muscle was sutured with 5-0 polyglactin (Vicryl
Ethicon Suture; Somerville, NJ), and the skin was stapled. Following surgery, rats
received banamine (1mg/kg) and ampicillin (0.2mg/kg) in lactated Ringers for three
days.
Paraformaldehyde (PFA) (4%) was used to perfuse the animals eight weeks after
implantation. The site of surgery was cut and the sca↵old and the nerve were trans-
ferred to sucrose:1xDPBS solution (30:70 wt. ratio) prior to dissection and sectioning.
For evaluation of the sca↵old site, 0.020 mm-thick longitudinal tissue sections were
cryosectioned. The slides were treated with proteinase K:antigen retrieval (1:20) (Mil-
lipore; Darmstadt, Germany) for 20 min. Subsequent washes were followed by using
50% methanol for 10 min, 100% methanol for 20 min and 50% methanol for 5 min.
Later the slides were placed in 5% of goat serum and Tris-bu↵ered saline (TBS) for
20 min. Mouse-anti-Neurofilament 200 (1:500) (Millipore) and rabbit-anti-S100 pro-
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tein (1:500) (Dako; Carpinteria, CA) were used to label neurofilaments and Schwann
cells, respectively. Slides were washed with TBS and labeled with Goat-anti-mouse
Alexa-Fluor 488 and Goat-anti-rabbit 594 (Life Technologies, Carlsbad, CA). Slides
are visualized using an Olympus BX 53 microscope. Fluorescent images were taken
with a mounted camera (Q imaging Retina 2000R) and CellSens Digital Imaging
computer software.
6.4 Results and Discussion
6.4.1 Agarose sca↵old and PCL conduit characterization
The agarose sca↵old PCL nerve guidance conduits constructs were characterized
using optical microscopy (Fig. 6.2). The agarose sca↵olds were 10.0 mm in length
and 1.4 mm in outer diameter. Each microchannel diameter was 0.3 ± 0.01 mm with
spacing of 0.085 ± 0.005 mm (Fig. 6.2(a)). The spacing between the channels (speci-
fied as 0.1 mm on the CNC) was the smallest spacing that resulted in linear channels
when microdrilling the agarose and was therefore used to maximize the lumen volume
of the sca↵old. Attempts in reducing the wall thickness to increase the lumen volume
resulted in sca↵olds with inadequate mechanical integrity to withstand implantation
and suturing. To ensure microchannel linearity, longitudinal images were analyzed
(Fig. 6.2(b)). The linear features in Fig. 6.2(b) represent the microchannels, which
appear continuous and regular along the entire sca↵old length. The optical analy-
sis confirms that the microdrilling process was successful in fabricating microchannel
agarose sca↵olds with relatively thin walls (0.085 ± 0.005 mm) and high aspect ratio
channels (33:1), but using a mechanical rather than a chemical removal process.
The agarose microchannel sca↵olds did not have su cient mechanical properties
to allow for their suturing to nerve stumps. Thus, PCL conduits were developed
to mechanically reinforce the agarose sca↵olds (Fig. 6.2(c)). The PCL mechanical
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Figure 6.2: Agarose microchannel sca↵old with PCL nerve guidance conduit. (a)
Cross-section showing an array of 0.3 mm inner diameter channels and
0.085 mm thick walls, (b) longitudinal view shows 10 mm long linear
channels, and agarose sca↵old is inserted in (c) a PCL conduit with an
overhang of 1 mm from each end. The solid arrow points to the PCL
conduit around the agarose sca↵old and the dashed arrow highlights the
additional channels created by the conduit around the sca↵old. The scale
bar in (a) is 0.3 mm and the scale bars in (b) and (c) are 10 mm.
property characterization is separated into two separate sections below.
6.4.2 Correlating PCL mechanical properties with porosity
A dramatic reduction in elastic modulus was observed by introducing porosity.
PCL films without porosity had an elastic modulus of 182MPa while 70 vol% porous
PCL films had an elastic modulus of 2.1 MPa (Fig. 6.3). To assess handle-ability
and suture-ability, the degree of deformation was measured by obtaining the strain to
failure. Strain to failure is the strain% ((lengthfinal - lengthinitial)/lengthinitial))x100
before rupture. Strain to failure increased with increasing porosity from 17% in non-
porous films to 100% in 70 vol% porous films (Fig. 6.3). By increasing the strain to
failure by introducing porosity, the PCL conduits could withstand puncturing with
a suturing needle without rupture (Fig. 6.4). Without the porosity, dense PCL of
comparable thickness cracks rather than punctures, thus demonstrating the need to
increase the strain to failure to allow for suturing. Representative SEM cross-sectional
images of the salt-leached porous PCL (70 vol%) conduit consisted of interconnected
porosity with a diameter of 17 µm (Fig. 6.5). In addition to reducing the elastic
modulus and increasing the strain to failure, the interconnected porosity may also
facilitate wetting and transport of nutrients, oxygen, and waste products within the
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Figure 6.3: Stress-strain curves of non-porous and porous PCL. (a) Dashed line
demonstrates 100% non-porous PCL and solid line indicates 70 vol%
porosity PCL. The elastic modulus of PCL reduces from 182 MPa to
2.1 MPa while the strain to failure increases from 17% to 100% when
70 vol% porosity is introduced. (b) is the stress-strain curve of 70 vol%
porosity PCL and highlights the elastic behavior to about 17% strain and
plastic behavior thereafter
implant.
6.4.3 PCL conduit flexibility
The PCL conduits were fabricated in lengths > 100 mm and exhibited flexibility
comparable to state-of-the-art nerve guidance conduits [30, 79, 96, 114]. PCL conduit
flexibility was demonstrated by measuring the maximum bend angle before a kink
occurred. As demonstrated in Fig. 6.6, the tubes were kink-resistant up to a bend
angle of 58 . Based on their flexibility and kink-resistance, the PCL conduit properties
are comparable to state-of-the-art, FDA-approved conduits.
6.4.4 Sca↵old nerve stump integration
Microchannel agarose sca↵olds integrated into PCL conduits were implanted in
10 mm long rat sciatic nerve gaps. The agarose sca↵olds were 10 mm long and
inserted into 12 mm long PCL conduits. The additional PCL conduit length created
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Figure 6.4: An SEM image of a PCL conduit after a simulated suturing test. The
scale bar is 0.1 mm.
Figure 6.5: Interconnected pores are observed in the salt-leached PCL nerve guidance
conduit. (b) is a higher magnification of the box in (a). The scale bars
in (a) and (b) are 50 µm and 20 µm, respectively.
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Figure 6.6: PCL conduit is kink-resistant up to 58 . No kink is present when the
conduit is bent around fingertips. (b) is a magnified image of the box in
(a) and demonstrates no kink is present for at least 58  of bending. The
scale bar in (a) is 10 mm and in (b) is 0.5 mm.
1 mm overhangs (cu↵) on each end of the implant. The overhangs enabled suturing
of the sca↵olds to the ends of the nerve stump. After 8 weeks of in vivo, the sca↵old
remained integrated with the nerve, demonstrating the e cacy of the PCL tube in
stabilizing a sca↵old in the highly mobile region of sciatic nerve (Fig. 6.7(a),(b)). In
addition, the PCL tubes and agarose sca↵olds maintained their mechanical integrity
and no signs of degradation were observed. The overhangs allowed for suturing of the
nerve stumps to the sca↵old, which was also previously demonstrated; for example,
PGA NeurotubeTM conduits with 3 mm long overhangs were sutured to the nerve
stumps of 10 mm-long rat sciatic nerve gaps using 4 sutures on each side [73]. The
conduits remained stable for at least 16 weeks confirming the advantages of overhangs
in stabilizing sca↵olds to nerve stumps.
6.4.5 In vivo characterization
Agarose microchannel sca↵olds integrated into PCL conduits were implanted in
10 mm-long sciatic nerve gaps. Animals were perfused 8 weeks post implantation and
the sca↵olds were sectioned at the proximal, middle, and distal ends. The longitudinal
view of the proximal end confirmed a high density of axons and Schwann cells were
present in the sca↵old channels (Fig. 6.8). In addition, the neural orientation was
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Figure 6.7: The PCL nerve guidance conduit stabilized the agarose sca↵old in the
nerve gap. The agarose sca↵old with PCL conduit 8 weeks post-
implantation (a) in the nerve tissue in vivo and (b) dissected from the
nerve tissue shows the sca↵old remains intact and integrated with the
nerve. The conduit was sutured to the host nerve using two sutures at
each end as shown with solid arrows. Some capillary formation was ob-
served at the distal end as indicated by the dashed arrow. The scale bars
are 10 mm.
linear and parallel to the sca↵old channels. To further assess the stability of the
sca↵olds and the presence of axons/Schwann cells, cross-sectional images in the middle
of the sca↵old were taken (Fig. 6.9). The microchannels of the sca↵old remained
intact and in the original hexagonal pattern. Some of the channels contained axons
and Schwann cells, but were mostly observed around the periphery of the sca↵old in
close proximity to inner walls of the PCL conduit. Nevertheless, Fig. 6.9 demonstrates
the partial channels that occupy the space between the periphery of the agarose
sca↵old and the inner wall of the PCL conduit can also linearly guide axons toward
distal targets. This observation may also suggest that since axons and Schwann cells
recruitment were most pronounced along the inner wall of the PCL conduit, that
PCL may be a more favorable surface for cell attachment compared to agarose.
A microchannel construct provides a structure that, compared to hollow conduits,
is more e↵ective in linearly guiding axons through the nerve gap and maintaining their
organization. The present agarose microchannel sca↵old/PCL constructs provided
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Figure 6.8: Axon and Schwann cell penetration into sca↵old channels. (a) The proxi-
mal side of an agarose sca↵old in a PCL conduit in a 10mm long rat sciatic
nerve gap 8 weeks post-implantation. Neurofilament (red) immunoreac-
tivity highlights axon penetration into the agarose sca↵old channels. The
boxed region in (a) is magnified in (b), (c), and (d). (b) Axon immunore-
activity with NF200 (red) and (b) Schwann cells (SC) immunoreactivity
with S100 (green) inside sca↵old channels. The axon (red) and SC (green)
labeling is superimposed in (c), which indicates their integration. The
scale bar in (a) is 400 µm; all the other scale bars are 100 µm.
Figure 6.9: Axons and Schwann cells are located inside some channels and around
the periphery of the sca↵old. Cross-section of an agarose sca↵old inside
a PCL conduit stained with (a) NF200 for axons (red) and (b) S100 for
Schwann cells (green). Axons and Schwann cells grew through some of
the channels and in the interstitial space between the sca↵old periphery
and the inner wall of the PCL conduit. Scale bars are 400 µm.
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linear ingress of axons and peneteration of Schwann cells into the sca↵olds after 8
weeks of implantation. It is believed that the axon and Schwann cell density and
degree of axon growth could be significantly augmented if growth factors for axons
and Schwann cells were present. Future work will involve filling sca↵olds with growth
factors in e↵orts to improve nerve regeneration and recapitulation.
6.5 Conclusions
A computer-controlled microdrill was used to fabricate agarose hydrogel sca↵olds
consisting of 10 mm-long microchannels. To provide mechanical support, robust PCL
outer conduit technology reinforced the agarose microchannel sca↵olds and enabled
suturing of the PCL conduits to peripheral nerve stumps. In vivo testing in the
sciatic nerve model demonstrated that the agarose microchannel sca↵old/PCL nerve
guidance implants were e↵ective in linearly guiding and organizing axons and Schwann
cells. Overall, this investigation demonstrated that the combination of synthetic
microchannel sca↵olds and outer protective conduits could be a viable alternative to
autologous nerve implants.
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CHAPTER VII
A Novel Technique to Synthesize and Fabricate
High Lumen Volume poly caprolactone (PCL)
Microchannel Sca↵olds for Spinal Cord Repair
7.1 Abstract
Microchannel sca↵olds can linearly guide growing axons in the lesion of the spinal
cord. However, the volume occupied by the sca↵old walls must be reduced to max-
imize the volume available for regeneration. In this work, nerve guidance sca↵olds
with significantly higher open volume were developed by reducing the thickness of
the walls of the sca↵olds. Poly caprolactone (PCL) was selected as the sca↵old ma-
terial based on its biocompatibility and month-long degradation. However, dense
PCL does not exhibit suitable properties such as porosity, sti↵ness, strength and cell
adhesion for nerve regeneration. To address these issues, PCL was processed using
a modified salt-leaching technique whereby sodium chloride (NaCl) particles were
planetary ball-milling (PBM) to reduce the average particle size (⇠0.017 mm). By
controlling porosity, the tensile elastic modulus was controlled between 182.1-2.09
MPa. The porosity also enhanced cell attachment and proliferation. Salt-leached
PCL microtubes were fabricated and translated into sca↵olds with 60 lumen vol%.
The sca↵olds were tested in a rat spinal cord injury model and linear axon growth
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into the sca↵old was observed. Overall, a new materials processing and sca↵old fabri-
cation technique is presented that generates sca↵olds with significantly higher lumen
volume than state-of-the-art sca↵olds for spinal cord repair.
7.2 Introduction
One approach to regenerate axons is to provide physical cues to guide regenerating
tissue across the lesion site. Examples include electrospun fibers [25, 74, 117, 178],
conduits [181, 182, 185] and multilumen sca↵olds [50, 55, 67, 116, 130, 137, 158, 172,
176]. While linear guidance of axons toward distal targets was demonstrated using
several of these approaches, the ability to achieve native axon densities compara-
ble to native nerve tracts requires further technological refinement. Specifically, in
approaches employing synthetic nerve regeneration sca↵olds, the volume fraction of
sca↵old occupying the lesion site must be reduced to maximize the open volume avail-
able for guidance and nerve tissue regeneration. For example, sca↵olds consisting of
close packed arrays of microchannels (honeycomb structure), can achieve over 40%
lumen volume using a fiber templating process to pattern hydrogels [158]. In practice,
fiber templating can achieve > 60% lumen volume [103]; however, the strength and
strain to failure of typical hydrogels is not likely to be su cient to fabricate high
lumen volume, thin-wall sca↵olds that can survive the rigors of fabrication and/or
surgical implantation [103]. Hence, there is a need to develop new materials and
materials processing technology to enable the fabrication of nerve guidance sca↵olds
comprised of microchannels with relatively high lumen volume.
In this study, an approach was developed to create sca↵olds consisting of micro-
tubes with walls < 0.060 mm-thick that are porous to 1) reduce sti↵ness and 2)
enhance cell attachment. Poly caprolactone (PCL) was selected as a representative
synthetic polymer based on its known biocompatibility with the nerve tissue [24, 34],
month-long degradation rate [24, 34] and strength. However, some properties of PCL
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need to be modified. First, interconnected porosity is required for the transport of
nutrition, oxygen and waste in the nerve tissue. Second, the elastic modulus and
strain to failure of PCL needs to be optimized to be suitable as a nerve guidance scaf-
fold. Third, PCL does not allow cell attachment [136, 147] and it may be beneficial
to improve its cell adhesion properties to improve nerve growth. Several techniques
have been previously studied to introduce porosity to tune the mechanical proper-
ties of PCL. For example, techniques such as photo cross-linking of a modified PCL
[42] and a customized patterning technique [153] were developed to pattern porous
PCL nerve guidance sca↵olds. However, in these studies, the porosity was > 0.450
mm in diameter, which can allow the axons to cross between sca↵old walls and lose
directionality along the lesion cavity. Selective laser sintering is also a patterning
technology used to create pores in PCL [44, 183, 184, 187]. Although the pore size
distribution was precisely controlled, the pores were > 0.030 mm, which may again
allow axonal growth between sca↵old walls. Solvent casting is another technique to
fabricate porous PCL by mixing a porogen with the monomer solution or melted
polymer, forming a solid polymer and selectively etching the porogen with a solvent.
Porogens such as poly propylene glycol [24], poly ethylene glycol (PEG) [97], sodium
chloride (NaCl) [87] and a mixture of PEG and NaCl [141] were used to create pores
within PCL. Although there are examples that demonstrate the ability to create in-
terconnected porosity [97, 141], control of pore size can be di cult. Moreover, the
NaCl porogen particles that have been reported are generally > 0.150 mm in diam-
eter [87]. When the porogen size was reduced using a vortex, the distribution of the
particle size was relatively large (from 0.020 to 0.50 mm) [141]. Because the goal of
this work is to reduce the sca↵old wall thickness to < 0.060 mm, the state-of-the-art
porogen size would create line-of-site voids that axons could penetrate. In addition,
these relatively large discontinuities compared to the targeted sca↵old wall thickness
compromise the mechanical integrity of the sca↵old. By reducing the porogen dimen-
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sions, synthetic polymer sca↵old walls consisting of numerous interconnected pores
can be created. The reduction in pore size can also prevent axons from growing
between microchannels.
A modified salt-leaching process was developed to introduce and control porosity
in the PCL sca↵old walls. A technique commonly used in ceramic material processing
(high energy planetary ball-milling) was used to reduce the porogen (NaCl) particle
size, thus reducing the porogen size to unprecedented length scales. Using the salt-
leaching technique, the volume fraction of porogen in PCL monomer solution was
varied between 0 and 70% to control the porosity and therefore the elastic modulus.
An optimum volume fraction of resulting porosity was determined to obtain intercon-
nected porosity and reduced sti↵ness. The porogen size was reduced from 0.350 mm
(as received) to ⇠ 0.017 mm while producing a more uniform size distribution. The
formation of pores in PCL was characterized by changing the porogen size and con-
centration. It is also demonstrated that by increasing porosity in PCL, the strain to
failure is improved from 17% to 100% and the sti↵ness of the films was reduced from
182.1 MPa to 2.09 MPa. In addition, porous PCL improved cell attachment, which
may promote axon survival and growth. The modified PCL salt-leaching process
was integrated into a modified fabrication process [67] to produce microtubes (0.060
mm wall thickness and 0.260 mm inner diameter). The microtubes were assembled
into packed arrays to achieve 60 vol % lumen sca↵olds and implanted into rats with
complete transections of the spinal cord at thoracic level 3 (T3). The primary pur-
pose of this study was to determine if the high lumen volume sca↵olds had adequate
strength to withstand fabrication, implantation, and were durable enough to maintain
integrity and provide linear axon growth for four weeks in vivo. In addition, because
no growth factor or cells were integrated in this study, high-density axon growth and
functional recovery were not predicted. Nonetheless, favorable integration with host
tissue and linear axonal growth were observed.
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7.3 Experimental
7.3.1 Porogen size reduction
Sodium Chloride (NaCl) was purchased from Columbus Chemical Industries, INC.
(Columbus, WI). NaCl (5 g) was placed in a 250 ml agate vial with twelve 9.1 mm-
diameter agate balls. A planetary ball-mill (Retsch PM 100; Haan, Germany) was
used to reduce NaCl particle size (Fig. 7.1, step (1a)). To study the e↵ects of ball-
milling time and vial rotational speeds on particle size distribution, 100 and 400
revolutions per minute (rpm) and ball-milling times of 1, 5, 10, 30, 60 and 90 min
were used. An alternating sequence of 5min of ball-milling followed by 5min rest was
used to minimize media heating. In addition, the ball-milling direction was reversed
after each 5 min rest to reduce NaCl particle agglomeration. The ball-milled NaCl
particle morphology and size were characterized and measured using scanning electron
microscopy (SEM) images (FEI Nova NanoLabTM 600 DualBeam; Columbus, OH).
Owing to favorable particle size distributions, the NaCl ball-milled at 400 rpm for 60
min was used for all the polymer fabrication processes unless otherwise is mentioned.
7.3.2 PCL/NaCl mixture preparation
✏-caprolactone (MW : 114.14) (Sigma; St. Lois, MO) was dissolved in chloroform
(3 wt.%) and mixed with 0-80 volume % (vol%) of the NaCl ball-milled at 400 rpm
for 60 min. The mixture (20-30 g) was ball-milled for 20 min at 400 rpm with 5 min
rests every 5 min to enhance the dispersion of the NaCl (Fig. 7.1, step (1b)). The
vol% of the NaCl in the PCL mixture corresponds to the intended vol% of porosity
after solvent evaporation and salt-leaching. To characterize the e↵ect of porogen size
on pore formation in PCL, 70 vol% of NaCl ball-milled at 400 rpm for 1 min was
vortexed (Mini vortexer- VWR; Radnor, PA) with the PCL solution for 1min. Mixing
with a vortex was chosen over ball-milling to prevent altering the NaCl particle size.
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Figure 7.1: Porogen preparation and film fabrication. (1) Synthesizing a uniform
solution of PCL and NaCl and (2) fabricating porous PCL films. (1):
(a) NaCl is ball-milled to the desired diameter and (b) the NaCl from
(1a) is ball-milled with a PCL:chloroform solution to uniformly disperse
the NaCl. The slurry from (1b) is used on an automated tape casting
apparatus as shown in (2) to produce porous films for tensile testing.
7.3.3 PCL film fabrication and characterization
PCL films consisting of 0-70 vol% porosity were fabricated for mechanical test-
ing and SEM imaging. To fabricate films, the ball-milled PCL/NaCl mixtures were
cast using an automated tape casting coater (Fig. 7.1, step (2)) (MTI Corporation;
Richmond, CA). Copper foil (McMaster; Aurora, OH) was placed on the tape casting
coater and the slurry was poured on the foil. A doctor blade (set at 0.050 mm clear-
ance between the copper foil and bottom of the blade) was passed over the slurry,
spreading it uniformly at 0.05 s/mm. The film was air-dried after casting. To de-
laminate the PCL films from the copper foil, the films were moistened with methanol
(Sigma). The NaCl was removed from the PCL films by placing the films in 2 l of
tap water for 18 hr.
To perform uniaxial tensile testing, films were cut to rectangular pieces of about
30 x 8 mm using a razor blade. A uniaxial tension test was performed on the films
(Instron; Norwood, MA) under a constant extension rate of 0.2 mm/min and the
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elastic moduli were measured. To characterize the porosity of the films, PCL films
were fractured in liquid N2 before and after salt-leaching, gold-sputtered for 120 s and
their cross-sectional images were taken using SEM. Films with 100% PCL remained
ductile in liquid nitrogen and could not be fractured for SEM cross-sectional imaging.
Therefore, the 100% PCL films were mounted in epoxy (Leco Corporation; St. Joseph,
MI) and polished using 600, 1200 and 1500 grit sand paper (McMaster). The cross-
section was further polished with 0.012 mm and 0.006 mm diamond paste (Leco
Corporation). The 100% PCL film was then coated with gold for SEM analysis.
7.3.4 Cell attachment characterization
PCL films (100% and 30 vol% porosity) were fabricated as explained in section
7.3.3 and were cut to the diameter of the wells of a tissue culture-treated 24 well-
plate (Fisher Scientific; Pittsburg, PA). The films were sterilized in ethanol (Decon
Labs, Inc.; King of Prussia, PA) for 10 min, washed 3 times with sterile 1xDPBS
(ThermoFisher Scientific; Grand Island, NY) and placed under uv (280 nm) for 30
min. PCL films were then placed in the wells of a 24 well-plate. Three di↵erent
surfaces were studied: 1) control well-plate surface, 2) 100% PCL film and 3) 30
vol% porous PCl film (n = 3 for each group) with and without fibronectin (Sigma)
pre-coated (1 mg/ml) for 18 hr and then washed with 1xDPBS. NIH 3T3 fibroblast
cells were plated at a seeding density of 5 x 104 cells/well. After 72 hr of incu-
bation, the cells were washed with warm 1xDPBS and fixed with 4% formaldehyde
(ThermoFisher) for 10 min followed by 3 washes with 1xDPBS. To stain for actin,
Alexa Fluor 488 Phalloidin (ThermoFisher) was used. Briefly, the fixed cells were
incubated with 1% bovine serum albumin (BSA) (Sigma) in 1xDPBS solution for 20
min at room temperature, washed with 1xDPBS and stained with Phalloidin for 20
min at room temperature and washed with 1xDPBS. The nuclei of the cells were
stained with DAPI and subsequently washed with 1xDPBS. Fluorescent images were
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taken (fluorescent microscope- Olympus BX53; Center Valley, PA).
7.3.5 Sca↵old fabrication
The tube and sca↵old fabrication process is illustrated in Fig. 7.2(a) and 7.2(b).
A copper wire (99% purity) (McMaster) with a diameter of 0.200 mm and a stainless
steel rod (grade 304) (McMaster) with a diameter of 1.60 mm were used to fabricate
inner and outer tubes, respectively. The metal wires and rods (referred here as fibers)
were placed in a PCL:NaCl mixture with 30:70 vol% and were removed after 5 s of
immersion and spun manually while holding horizontally to uniformly evaporate the
solvent. To facilitate delamination, the PCL coated metal rods, were immersed in
methanol for about 30 s. The tubes were removed, dried in a fume hood and cut into
2 mm-long tubes using a razor blade.
To fabricate sca↵olds, eleven inner tubes (0.260 mm inner diameter, 2 mm long)
were inserted into an outer tube (1.6 mm inner diameter, 2 mm long). Optical
microscope (Leica EZ4D; Bu↵alo Grove, IL) was used to image the sca↵olds. The
sca↵old lumen volume percentage was calculated according to the following equation:
Lumen V olume = Outer Tube Open V olume   V olume of Inner tube wallsOuter Tube Open V olume x 100
The sca↵olds were placed in water for at least 18 hr to remove the NaCl. Ster-
ilization was done in ethanol for 1 hr following sca↵old-coating with 1 mg/ml of
fibronectin (Sigma) for 1 hr prior to implantation.
7.3.6 Surgical procedures and in vivo characterization
Adult female Fischer 344 rats (150-200 g) were handled according to the NIH labo-
ratory protocol for animal care and safety. Animal preparation, sca↵old implantation
and tissue fixation was performed as described previously [81, 158]. Briefly, animals
were anesthetized using a mixture of ketamine (25 mg/ml), xylazine (1.3 mg/ml)
and acepromazine (0.25 mg/ml). Laminectomy was performed at spinal level T3 and
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Figure 7.2: Steps in fabricating (1) PCL tubes and (2) PCL sca↵olds.
2 mm of the spinal cord was removed by scissors, cut and micro-aspirated.
Sterilized PCL sca↵olds (described in section 7.3.5) were surgically placed in the
transected spinal cord (n = 8). Four weeks after implantation, animals were per-
fused with 4% paraformaldehyde (PFA) (4 C) and spinal cords were stored in su-
crose:1xDPBS solution (30:70 weight ratio) for 48 shr. Longitudinal sections (0.030
mm-thick) were obtained through cryosectioning. Slides were placed in proteinase
K:antigen retrieval (1:20) (Millipore; Darmstadt, Germany) for 20 min, washed in
methanol for 5 min, and were blocked with 5% of goat serum and Tris-bu↵ered saline
(TBS) for 1 hr. Axons were identified by a mouse-anti-neurofilament 200 (1:500) (Mil-
lipore). Sections were washed with TBS. Slides were labeled with Goat-anti-mouse
647 (1:250) (Life Technologies; Carlsbad, CA) as a secondary antibody for 1 hr and
washed with TBS. Prior to fluorescent imaging (Olympus BX53; Center Valley, PA),
slides were labeled with Fluoromount G (Southern Biotechnology Associates, Inc.;
Birmingham, Alabama).
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7.4 Results and Discussion
7.4.1 NaCl porogen size reduction via planetary ball-milling
Planetary ball-milling was used to reduce the NaCl porogen particle size. After
PBM at 100 rpm, regardless of time ranging from 1 min to 90 min, a negligible
reduction in NaCl particle size was observed. It was likely the kinetic energy was not
su cient to fracture particles [59]. To improve the kinetic energy, a rotation speed
of 400 rpm was used to correlate PBM time with NaCl particle size. To determine
the particle size and characterize the surface morphology, SEM was conducted (Fig.
7.3). The as-received NaCl consisted of particles with relatively smooth surfaces and
an average diameter of 0.360 ± 0.115 mm (Fig. 7.3(a)). The NaCl particle size was
reduced to 0.191 ± 0.070 mm with 1 min of PMB at 400 rpm (Fig. 7.3(b)). After 5
and 30min of PMB at 400 rpm, the particle size was reduced to 0.043± 0.012mm and
0.017 ± 0.010 mm, respectively (Fig. 7.3(c),(d)). Compared to the as-received NaCl,
the PBM particle surfaces and geometries were irregular, which is common when
using a mechanical comminution process [59]. No significant change in particle size
was observed after PMB at 400 rpm for more than 30 min, indicating that increasing
time would not further significantly reduce particle size. In mechanical comminution,
it is common for the particle size to approach an asymptotic limit governed by the
kinetic energy of a particular process [59]. Assuming the kinetic energy of each ball
collision is fixed (by the rotational speed of the PBM in this case), it is known that
the impact energy required to fracture particles is inversely proportional to the square
root of the diameter of the particles. Thus, when the NaCl particles reached ⇠0.017
mm (at 400 rpm), increasing the PBM time did not further reduce the particle size.
Nevertheless, the goal of this activity was to produce NaCl particles that were smaller
(2-4X) than the sca↵old walls (aimed to be 0.03-0.06 mm) to prevent line-of site gaps
between microchannels that would allow axons to lose directionality as they extend
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Figure 7.3: Increasing the planetary ball-milling time reduces the particle size and
size distribution. SEM images of NaCl (a) as-received, and NaCl ball-
milled at 400 rpm for: (b) 1 min, (c) 5 min, (d) 30 min, (e) 60 min and
(f) 90 min. The inset scale bars are 0.025 mm; all other scale bars are
0.20 mm.
toward distal targets. Thus, 0.017 mm diameter NaCl particles were su ciently small
to produce PCL tubes for sca↵old fabrication.
7.4.2 Salt-leached PCL microstructural analysis
As described in the previous section, 0.017 mm NaCl was selected as the porogen
size to introduce porosity in PCL. The volume fraction of 0.017mm NaCl porogen was
varied between 0 and 70 vol% to form PCL films. Above 70 vol% NaCl, the samples
were fragile and di cult to handle and therefore not characterized. SEM was used to
assess the pore morphology and to determine if the NaCl was uniformly distributed.
The fracture surface of a 100% solvent cast PCL exhibited no porosity (Fig. 7.4),
which was in agreement with previous reports [97, 147]. Though it may be assumed
that the absence of NaCl porogen would produce dense films, bubbles, voids, or other
defects may have formed; however, image in Fig. 7.4 confirms that the PCL was 100%
dense. Because one of the goals of this work was to reduce the PCL elastic modulus,
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the highest vol% porosity (70%) was the focus and therefore this composition is used
hereafter unless otherwise specified. SEM analysis was conducted on PCL before and
after removal of the 0.017 mm NaCl porogen (NaCl ball-milled at 400 rpm for 60
min) (Fig. 7.5). Prior to salt-leaching, the NaCl particles (Fig. 7.5(a),(c)) consisted
of cuboidal or faceted NaCl particles embedded in PCL. After salt-leaching and re-
moval of NaCl, pores with sizes and geometries similar to the NaCl particles were
generated (Fig. 7.5(b),(d)). Additional observations were made. First, the cuboidal
or faceted NaCl particles in Figs. 7.5(a) and 7.5(c) did not resemble the irregular
NaCl particle surfaces observed after 60 min of PBM at 400 rpm (Fig. 7.3(e)). It
is possible that the NaCl/PCL monomer solution partially etched the NaCl particles
resulting in a change in morphology from irregular before casting to cuboidal after
casting. To investigate this, NaCl particles were exposed to chloroform and methanol
with no PCL monomer present. The NaCl particles maintained their irregular shape
in both cases (data not shown); thus, the presence of PCL monomer is believed to
cause partial etching resulting in smooth and faceted surfaces. Further work is re-
quired to better understand this phenomenon. Second, in addition to the porosity
created by the NaCl particles, a second smaller scale of porosity was apparent (Fig.
7.5). Because the smaller pores were apparent before salt-leaching (Fig. 7.5(a),(c)),
they are considered intrinsic; to be distinguished from salt-leached porosity. Lin et al.
[97] also observed similar intrinsic porosity when PEG was used as a porogen. The
intrinsic porosity increases the vol% porosity and likely reduces the elastic modulus
and perhaps enhances cell attachment as discussed below. We believe the intrinsic
porosity is a combination of both the volume fraction of porogen (70%) and relatively
small porogen particles (0.017 mm) that modulates the PCL polymerization process.
To support the latter aspect, PCL salt-leached with 0.191 mm NaCl was prepared
and observed using SEM (Fig. 7.6). The only porosity observed when using 0.191
mm NaCl was the porosity introduced using the salt-leaching process. Overall, hi-
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Figure 7.4: SEM analysis of 100% PCL (no porosity). The scale bar is 3 µm.
erarchical porosity was generated; relatively large ⇠0.017 mm pores were created by
salt-leaching while relatively small intrinsic pores were formed as a byproduct of the
modified salt-leaching process described in this work.
7.4.3 Correlating porosity with mechanical properties
Tensile testing was used to measure the elastic modulus and strain to failure. Since
the goal was to reduce the elastic modulus of PCL and improve the strain to failure,
porosity was introduced using NaCl as a porogen. To characterize the change in the
elastic modulus as a function of porosity, PCL films with di↵erent densities were used
for tensile testing. The elastic moduli of PCL films decreased from 182.1 to 2.09
MPa when the porosity was increased from 0 to 70 vol% (Fig. 7.7) demonstrating
the ability to control the sti↵ness of PCL by introducing porosity. Eshraghi et al.
reported an average elastic modulus of 354.1 MPa for 100% solvent cast PCL [44].
However, the study used a higher PCL MW , which likely explains the higher elastic
modulus exhibited by the 100% PCL. Another study [141] used a porogen (0.02-0.5
mm porogen sizes) and correlated the compressive modulus of PCL to porosity. The
reported modulus of 80 vol% porous PCL is comparable to the present study. Because
one of the goals of this work was to reduce the PCL elastic modulus, the modified salt-
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Figure 7.5: SEM analysis before and after salt leaching. A 70 vol% porosity PCL film
fabricated using 17 µm (avg. diameter) NaCl particles (a) prior to and
(b) after salt-leaching. (c) and (d) are higher magnification images of the
dashed-boxes shown in (a) and (b), respectively. The solid arrow in (c)
points to a NaCl particle and the dashed arrows point to PCL. Scale bars
in (a) and (b) are 10 µm and in (c) and (d) are 5 µm.
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Figure 7.6: SEM analysis of PCL salt leached with 0.191 mm NaCl. Cross-sectional
SEM image of a 70 vol% porosity PCL film fabricated using 0.191 mm
(avg. diameter) NaCl particles. The black arrow points to a salt-leached
pore. The scale bar is 0.1 mm.
Figure 7.7: The elastic modulus PCL vs. porosity% created by 0.017 mm NaCl par-
ticles.
leaching process described herein introduces su cient porosity to reduce the elastic
modulus by nearly two orders of magnitude.
7.4.4 Cell attachment
NIH 3T3 fibroblast cells did not attach or survive well on non-porous PCL, but
attached to and proliferated on porous PCL (Fig. 7.8). The observed di↵erences
are believed to be a result of the increase in surface roughness (as shown in Fig.
7.8(c),(f)) as well as improved wettability. The presence of interconnected porosity
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improved the water permeability of the films and likely translated to improved cell
attachment and survival. To our knowledge, this is the first report that enhances
cell attachment on PCL by optimizing its physical properties. Previous reports have
used chemical modifications to enhance cell attachment. For example, a composition
of PCL and proteins such as collagen and hyaluronic acid (HA) improved cell at-
tachment [149, 184]. Similarly, when PCL was coated with fibronectin, regardless of
its porosity and physical properties, cell attachment and proliferation was observed
(Fig. 7.8(e),(h)). However, the improved cell attachment with fibronectin-coating is
predicted to be temporary due to the lack of a nity of fibronectin for PCL, while the
physical modification of PCL is only e↵ected through its degradation. Overall, it is
demonstrated that enhancing surface roughness provided robust cell attachment and
proliferation on PCL.
7.4.5 Sca↵old characterization
The sca↵olds consisted of close-packed arrays of microtubes in which inner chan-
nels were separately fabricated and inserted into a larger outer tube as illustrated in
Fig. 7.2. Both the inner and outer tubes consisted of 70 vol% porous salt-leached
PCL. This composition was chosen because it had interconnected porosity and the
lowest elastic modulus while maintaining mechanical integrity for sca↵old fabrication.
A representative cross-sectional image of a 2 mm-long PCL sca↵old is shown in Fig.
7.9. The inner tubes of the sca↵old had a wall thickness of 0.060 ± 0.015 mm and
an average inner diameter (ID) of 0.260 mm. The outer tube ID was 1.62 mm with
a wall thickness of 0.090 mm occupying an outer diameter (OD) of 1.80 mm. The
ID of the inner tubes was selected as 0.20-0.30 mm since linear axon growth was
previously demonstrated in micro-channel sca↵olds with 0.20 mm-diameter channels
[55, 65, 158]. In addition, the PCL sca↵old was designed to have an OD of 1.8 mm
to fit in the T3 rat spinal column. The sca↵olds had 60% open volume as compared
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Figure 7.8: Cell attachment and proliferation on PCL is improved by introducing
porosity and by fibronectin-coating. NIH 3T3 fibroblasts were cultured
on (a) uncoated and (b) coated tissue-culture treated flask as controls, (d)
uncoated non-porous PCL film, (e) fibronectin coated non-porous PCL
film, (g) uncoated 30 vol% porous PCL film, and (h) fibronectin-coated
70 vol% porosity PCL film. Cells were fixed after 72 hr and stained for
actin (green) and nuclei (blue). Unlike non-porous PCL, 70 vol% porosity
PCL films provided cell attachment and proliferation comparable to the
positive control. Both groups exhibited cell attachment and proliferation
after fibronectin coating. SEM images of the top surface of (c) non-porous
PCL film and (f) 70 vol% porosity PCL with corresponding magnified
images demonstrate an increased surface roughness in porous PCL. Scale
bars in the magnified boxes in (c) and (f) are 0.01 mm. All other scale
bars are 0.1 mm.
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Figure 7.9: Optical image of a PCL sca↵old. Microtube inner diameter is 0.260 mm,
salt-leached (0.017 mm NaCl), 70 vol% porosity PCL walls were 0.060
mm thick. Scale bar is 0.2 mm..
to < 45% open volume provided by state-of-the-art sca↵olds.
To characterize the porosity of the tubes and to confirm interconnected porosity,
SEM images of the inner surface, cross-section and outer surface of the inner PCL
tubes were taken (Fig. 7.10). Interconnected porosity with average pore size of
0.017 mm was observed. The interconnected porosity could allow the transport of
nutrients, oxygen and waste in the nerve tissue and may be important for nerve
growth. In addition, the scale of the porosity is believed to be su ciently small
to prevent axonal growth orthogonal to the microtubes. Few studies successfully
fabricated micro-channel sca↵olds with ideal wall porosity; nevertheless, the sca↵olds
had less than 45% open volume [55, 116, 130, 137, 158, 172]. The sca↵olds described
in this work have more than 60% open volume and do not allow the axons to cross
through the sca↵old walls of the sca↵old. In addition, since the NaCl particles used
during sca↵old fabrication were 0.017 mm in diameter, tubes with a wall thickness
of about 0.020 mm were fabricated. Therefore, using the microtubes with a wall
thickness of 0.020 mm can produce sca↵olds with 85% open volume, which is a
significant improvement compared to previously described nerve guidance sca↵olds.
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Figure 7.10: Interconnected porosity is maintained through the wall of the tubes. (a)
shows the inner surface (b) the cross-section and (c) the outer surface of
a PCL tube. Images in (d), (e) and (f) are the x2 magnifications of (a),
(b) and (c), respectively. Scale bars in (a), (b), (c) are 5 µm and in (d),
(e) and (f) are 2.5 µm.
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Figure 7.11: Axons grow into PCL sca↵olds after implantation in T3 complete tran-
section. PCL sca↵old is shown 4 weeks post-implantation by immuno-
labeling neurofilaments (green). (a) Sca↵old interfaces with host are
indicated by dashed lines. (b) Higher magnification of boxed region in
(a) demonstrate axonal growth into sca↵old and linear growth pattern.
Solid arrows in (b) demonstrate the axons grow linearly inside the mi-
crotubes while the dashed arrow indicate some axons grow linearly in
between the microtubes. The scale bar in (a) is 0.3 mm and in (b) is
0.1 mm.
7.4.6 In vivo characterization
PCL sca↵olds (2 mm long) were implanted in the T3 rat transected spinal cords
for 4 weeks and analyzed by histology. Sections parallel to the longitudinal axis of
the spinal cord were sliced and immunostained for neurofilaments. Since no growth
factor was introduced in the lesion, high density axon growth was not expected [158].
Nonetheless, neurofilament-labeled axons grew into the sca↵old and extended linearly
through the sca↵old for distances up to 0.7 mm (Fig. 7.11). In addition, axons grew
both inside and between the inner tubes (Fig. 7.11(b)) demonstrating that the entire
open volume of the sca↵old (including the space between the inner tubes) is e↵ectively
available for nerve growth. The sca↵old was present after 4 weeks of in vivo and had
not yet degraded.
Microchannel sca↵olds are a promising approach to treat spinal cord injuries.
However, existing sca↵old technologies require further refinement to establish clini-
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cal relevance. In this study, novel materials processing and sca↵old fabrication ap-
proaches were investigated to develop nerve guidance sca↵olds exhibiting an unprece-
dented combination of features. First, this study leverages previous e↵orts to develop
microchannel sca↵olds, but with an emphasis on increasing lumen volume compared
to state-of-the-art technology. Herein, a process was developed to fabricate sca↵olds
with a unique architecture to enable high lumen volume. Rather than fabricate ar-
rays of microchannels in one step, this process entails the fabrication of individual
thin wall tubes that were assembled into close-packed arrays (Fig. 7.2). This fabri-
cation approach created additional interstitial volume between the microtubes that
is equally capable of linearly guiding axons toward distal targets. Second, the novel
sca↵old manufacturing process provided the impetus to develop alternative materi-
als to enable the fabrication of individual, thin-wall tubes. Hydrogels in general, do
not exhibit adequate mechanical properties and are not compatible with this pro-
cess. Hence, PCL was selected owing to its higher sti↵ness and strength. In annealed
(melting and cooling) form, however, PCL was too brittle during implantation. To
improve the handling of PCL and increase its strain to failure, PCL was solvent-cast.
Porosity was also introduced via a modified salt-leaching process to allow the trans-
port of nutrition, waste and oxygen through the walls. By controlling the mechanical
properties, individual 0.060 mm thick PCL microtubes with few centimeter lengths
could be fabricated, cut to desired lengths and integrated into 60% open volume
sca↵olds (Fig. 7.9). Third, the porosity that was introduced in PCL enhanced cell
attachment. Achieving cell attachment demonstrates another significant benefit of
salt-leached PCL over most hydrogel-based sca↵olds that do not inherently allow cell
attachment.
When characterized in vivo for 4 weeks, the microtube PCL sca↵olds maintained
integrity and demonstrated the ability to linearly guide axons. It is expected that,
in the presence of growth factors, the axon growth rate and density will be much
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higher. Overall, this work presents a degradable biocompatible sca↵old with 60%
lumen volume that linearly guides axons in the transected rat spinal cords. Future
work will focus on incorporating growth factors and characterizing biocompatibility
and degradation.
7.5 Conclusion
The pore size and pore size distribution of PCL is controlled by using a modified
salt-leaching technique and optimizing the porogen size and distribution using plane-
tary ball-milling. By increasing the volume fraction of porosity, the elastic modulus of
PCL was reduced from 182.1 to 2.09MPa and the strain to failure was improved from
17% to 100%. In addition, porous PCL exhibited a significant improvement in cell
attachment and cell proliferation compared to non-porous PCL, perhaps due to en-
hanced surface roughness and wettability. To create nerve guidance sca↵olds, porous
PCL microchannel sca↵olds were fabricated consisting of 0.06 mm wall thickness,
0.260 mm inner diameter microtubes and 60% open volume. In addition, the sca↵old
length could be increased from the mm-scale to clinically-relevant cm-long sca↵olds.
The sca↵old in vivo performance was studied in a rat T3 full-transection spinal cord
model. Linear growth of axons was observed through both the microtubes interior
as well as in the interstitial space in between the microtubes, demonstrating that
the entire 60% open volume of the sca↵old can be e↵ectively used for nerve growth
and linear guidance. Also the sca↵old was not degraded after 4 weeks, which can be
beneficial for clinically relevant cm-long nerve gaps that require slower degradation
rates. Overall, this work presents a modified salt-leaching process combined with a
novel sca↵old preparation technique to fabricate high open volume nerve regeneration
sca↵olds for linear axon growth.
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CHAPTER VIII
Further Research and Outlook
8.1 Advancing the sca↵old fabrication technology
8.1.1 Translating PCL synthesis and sca↵old fabrication technology to
other polymers
The purpose of this work was to test and confirm the viability of translating the
materials synthesis and sca↵old fabrication technique introduced in Chapter VII to
other FDA-approved synthetic polymers. Poly lactic-co-glycolic acid (PLGA) is se-
lected as the experimental material owing to 1) its common use in tissue engineering
[62, 121, 167, 169, 172], and 2) its higher degradation rate compared to poly caprolac-
tone (PCL) [21, 143]. With modifications to the methods described in Chapter VII,
PLGA films with porosity% between 0-90% were fabricated. Scanning electron mi-
croscopy (SEM) images of the PLGA fracture surfaces showed the consistent increase
in the porosity as the PLGA porosity vol% was increased. Interconnected porosity
was observed at and below 30 vol% porosity. In addition, similar to PCL films, the
elastic modulus of PLGA films decreased by increasing porosity. Cell attachment
studies using primary rat Schwann cells indicated that PLGA provided cell attach-
ment when porous and fibronectin-coated. Finally PLGA tubes with inner diameters
of 300 ± 10 µm were produced and fabricated into microchannel sca↵olds.
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The SEM images of PLGA films fractured in liquidN2 with di↵erent porosity vol%
are shown in Fig. 8.1. As expected, a consistent increase with porosity was observed
by decreasing PLGA vol%. In addition, interconnected porosity is observed when the
porosity vol% is less than or equal to 30%. Consequently, increasing porosity vol%
was expected to reduce the elastic modulus of the films. Indeed, the PLGA elastic
modulus decreased from 465.7 MPa to 14.8 MPa when the porosity increased from
0% to 70 vol% (Fig. 8.2).
To understand the cell adhesion properties of PLGA, primary rat Schwann cells
were cultured on 1) tissue culture-treated well-plate coated with poly-D-lysine (PDL)
as positive control (a surface that allows Schwann cell attachment), 2) 70 vol% poros-
ity PLGA and 3) non-porous PLGA (Fig. 8.3). The a↵ect of laminin or fibronectin
coating was also studied by coating the substrates with 1 mg/ml of the protein for 18
hr. It was observed that fibronectin coating provided more cell attachment compared
to laminin-coating for both control and porous PLGA. Non-porous PLGA, regardless
of coating, exhibited no cell survival or attachment. It was concluded that PLGA
allowed Schwann cell attachment when both porous and fibronectin-coated.
PLGA inner tubes (70 vol% porosity) with inner diameters of 300 ± 10 µm were
used to fabricate tubes. The PLGA tubes were inserted into a 70 vol% PCL outer
tube (described in Chapter VII) with an inner diameter of 1.60 mm (Fig. 8.4). PCL
was used as the outer tube instead of PLGA owing to its slower degradation rate
relative to PLGA [21, 143]. A slower degrading outer tube was desired since the
outer tube stabilizes the structure of the sca↵old. Therefore, the PCL outer tube is
predicted to degrade after PLGA inner tubes in vivo thus securing the PLGA tubes
in the tissue until they degrade.
PLGA sca↵olds were implanted in the transected spinal cords of rats for 1 month.
Preliminary data confirmed the biocompatibility of the sca↵olds and some axon pene-
tration into the sca↵old. However, the sca↵old design should be optimized to increase
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Figure 8.1: SEM images of PLGA fracture surface with porosity% of 0%, 10%, 20%
to 90% are shown in (a), (b), (c) through (j), respectively. By reducing
the PLGA vol% (thus increasing porosity vol%), the morphology changes
from a non-porous structure (0% porosity shown in (a)) to porous struc-
tures. Scale bars are 5 µm.
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Figure 8.2: The elastic modulus of PLGA decreases by increasing porosity.
the number of inner tubes and avoid their movement in vivo. In addition, further in
vivo characterization is necessary before conclusions can be drawn. For example, the
degradation of the sca↵olds can be assessed by implanting the sca↵olds for a longer
time period such as 4 months.
8.1.2 Microchannel sca↵old technology for clinical translation
To translate the microchannel sca↵old technology to clinical translation, it is es-
sential to develop sca↵olds with clinically-relevant dimensions. More specifically, few
mm-wide sca↵olds are desired since a human spinal cord diameter varies from 15 mm
to 6.2 mm while continuously decreasing from cervical to lumbar region [41], and the
length of the injury is 1-2 vertebra (> 10 mm). In addition, prior to human clinical
trials, it is advantageous to test the nerve guidance sca↵olds (NGS) in a large animal
model (relative to rodents) such as a minipig. The goal of this study, therefore, was
to confirm that few mm-long and wide PCL microchannel sca↵olds can be manu-
factured. The PCL technology introduced in Chapter VII was advanced to sca↵olds
with sizes matching the sciatic nerve of a minipig and tested in vivo.
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Figure 8.3: Cell attachment and proliferation on PLGA is improved when 1) porous
and 2) fibronectin-coated. Primary rat Schwann cells were cultured on
(a) uncoated, (b) laminin-coated and (c) fibronectin-coated PDL-coated
surfaces as controls. Cells were also cultured on (d) uncoated, (e) laminin-
coated and (f) fibronectin-coated 70 vol% porous PLGA, and also on
non-porous PLGA (data not shown). Cells were fixed after 48 hr and
stained for actin (green) and nuclei (blue). Porous PLGA film provided
cell attachment and proliferation comparable to the positive control when
coated with fibronectin while non-porous PLGA exhibited no cell survival
or attachment regardless of the coating substance. Scale bars 50 µm.
Figure 8.4: A cross-sectional image of a PLGA sca↵old with PLGA inner tubes in-
serted inside a PCL outer tube. The scale bar is 300 µm.
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Figure 8.5: PCL microchannel sca↵old. The boxed region in (a) is magnified in (b),
and shows the sca↵old microchannel architecture. (b) is the longitudinal
view of the sca↵old. The scale bar in (a) is 2 mm and in (b) is 0.5 mm.
A total of 79 PCL inner tubes with an average inner diameter of 0.47 mm were
inserted inside a PCL conduit with an inner diameter of 7.6mm and an outer diameter
of 8.0mm (Fig. 8.5). The inner tubes were 10mm in length and the outer conduit had
1 mm-long overhangs on each end to allow suturing to the nerve stumps. The sca↵old
was implanted in the sciatic nerve gap of a minipig for 4 months and preliminary
sensory functional recovery was observed. The developed PCL microchannel sca↵old
is therefore a promising approach for advancing nerve guidance sca↵old technology
to human translation.
8.2 Criteria for a microchannel sca↵old
The goal of this doctoral work was to select and synthesize a material and fabricate
it into a sca↵old that could linearly guide axons through nerve gaps. Throughout the
work, several criteria and materials/sca↵old properties proved to be of particular
significance when developing a sca↵old and are divided into three tasks: 1) materials
processing and optimization, 2) sca↵old design and fabrication, and 3) in vivo e cacy.
Each task is discussed below.
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8.2.1 Material selection and synthesis
When selecting and synthesizing a material for nerve regeneration, the main prop-
erties that needed to be characterized and optimized are thought to be biocompatibil-
ity, degradation, porosity, sti↵ness, strength, and cell attachment properties. Most of
these properties should be first evaluated in vitro and then in vivo. First, a material
biocompatible to the nerve tissue has to be selected/synthesized. Initial experiments
include in vitro cytotoxicity assays followed by in vivo characterization explained in
section 8.2.3. Second, the sca↵old material would be selected/synthesized to degrade
after the axons have bridged the nerve gap. Moreover, depending on the degradation
mechanism, nerve repair may be more a↵ective if the implant degrades over time and
not all at once. As an example, since the byproducts of PLGA are acidic and can be
detrimental to the nerve tissue [60], a gradual degradation can reduce pH change and
lower its negative e↵ects on the tissue. Next, fabricating a porous sca↵old is impor-
tant to allow the transfer of nutrients, oxygen and waste but prohibit the penetration
of axons in between channel walls. In addition, the mechanical properties of the ma-
terial are of particular importance and interest and are discussed in length in section
8.3. Lastly, it may be beneficial for the material to provide cell attachment. Neu-
ron cell survival and proliferation may be improved upon attachment to the sca↵old;
however, the material may also become a suitable substrate for inflammatory cells
such as fibroblasts to migrate on and form scar tissues. Thus, it is ideal to control
cell attachment on the sca↵old material and understand its e↵ect on nerve repair.
8.2.2 Sca↵old design and fabrication
A nerve guidance sca↵old should consist of linear channels to e↵ectively guide
growing axons through the lesion gap while maintaining their organization. In ad-
dition, since axons generally grow in bundles, the channel diameter should be large
enough for a nerve bundle to grow into but it should be small enough to avoid the
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turning of the axons. Unpublished work has demonstrated that axons generally de-
viate from a linear path and no longer grow toward the distal end of the nerve gap
when the channel diameter of a sca↵old is more than 300 µm. Subsequently, a chan-
nel diameter of 200-300 µm was targeted in this work. Lastly, for the translational
application of the sca↵olds, clinically-relevant cm-wide and cm-long sca↵olds should
be fabricated.
8.2.3 In vivo evaluation
Although in vitro characterization provides a valuable understanding of a material
and a sca↵old, in vivo characterization can suggest the e cacy of sca↵olds for nerve
repair. For example, once cytotoxicity assays eliminate materials with high toxicity,
in vivo evaluations such as nissl staining and immunolabeling for inflammatory cells
provide a better understanding of the biocompatibility of the material. Similar to
biocompatibility, the degradation of a material can be significantly di↵erent from in
vitro to in vivo as demonstrated in Chapter III. Axon growth, supporting neural cell
presence and capillary formation are important steps in evaluating the in vivo e cacy
of the material. More in vivo characterization methods are suggested in section 8.5.
8.3 The dogma of “softer is better”
In tissue engineering, it is often believed that an ideal implant should match the
sti↵ness of the tissue. However, there is no concrete evidence to support that softer
substrates are more e↵ective for spinal cord repair. This work is the first study that
compared the in vivo performance of microchannel sca↵olds fabricated from multiple
soft hydrogels versus rigid polymers in transected spinal cords. It was observed that
the growth of axons toward and in close proximity to a nerve guidance sca↵old was
significantly enhanced in rats transected spinal cords when the sca↵old substrate
changed from soft hydrogels to rigid polymers. This doctoral work is, therefore, the
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first report that suggests against the dogma of “softer is better”, in the context of
spinal cord repair.
Previous studies have focused on the in vitro understanding of axon growth with
the change in substrate sti↵ness. For example, multiple reports studied the change
in the rate of neurite extension of soft hydrogels with elastic moduli varying from
0.5-2.1 kPa and discovered that the softest gel provided a higher rate of neurite
extension while negligable attachment was observed on sti↵er materials [6, 58, 88, 99].
In addition, when substrates with elastic modulus of 0.1-40 kPa were tested, only
substrates with 0.1-1 kPa elastic modulus provided the di↵erentiation of stem cells to
neurons [43]. Lastly, when the adhesion of cortical neuronal cells did not significantly
di↵er on substrates with sti↵nesses of 0.25-2.1 kPa, the observation was reported as
a “surprise” [58]. Overall, in vitro works on understanding the relationship between
substrate sti↵ness and axon growth reinforce the belief that “softer is better” while
in vivo evidence is missing from the literature.
In this work, the e↵ect of substrate sti↵ness on axon growth in vivo was tested by
comparing axon penetration and growth on materials with di↵erent sti↵ness in spinal
cords of rats. Nerve guidance sca↵olds were fabricated from multiple soft hydrogels
and rigid polymers. Experimented hydrogels included agarose, alginate, chitosan and
PEGDA and rigid polymers were PCL and PLGA. The elastic moduli varied from
30.6 kPa to 14800 kPa as summarized in Table 8.1. The materials were fabricated
into microchannel sca↵olds and implanted in rats transected spinal cords. Fig. 8.6
shows the comparison of axon behavior with each sca↵old. A reactive cell layer
generally separated axons from soft hydrogels and axons did not grow toward or in
close proximity to the material (Fig. 8.6(a)-(d)). However, no scar tissue was detected
between axons and rigid polymers and, unlike what has been observed in vitro, axons
grew on the these rigid substrates in vivo (Fig. 8.6(e),(f)). These results suggest that
the formation of a reactive cell layer is significantly reduced from hydrogels to rigid
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polymers while axon attachment occurs on rigid materials in vivo.
Substrate Elastic modulus (kPa)
Agarose hydrogel (3 wt.%) 310
Alginate hydrogel (3 wt.%) ⇤388
Dense chitosan ⇤603
PEGDA hydrogel (10 wt.%) 30.6
PCL (70 vol% porosity) 2,100
PLGA (70 vol% porosity) 14,800
Table 8.1: The table summarizes the elastic modulus of the sca↵old materials used
through the dissertation. The elastic modulus of alginate is calculated
from its shear modulus of 155.3 kPa obtained in Chapter III assuming a
poisson’s value of 0.25. ⇤Alginate and chitosan degrade within weeks in the
spinal cord, which e↵ectively results in lower sti↵ness than what is shown.
It is acknowledged that the present study is not a side-by-side comparison of the
a↵ect of sti↵ness on in vivo axon behavior since the modulus is not the only variable
that changes between each material. Indeed, it may be challenging to synthesize sub-
strates with all properties, except for the sti↵ness, the same. For example, when the
sti↵ness changes, properties such as chemical structure, morphology, pH, degradation,
strain to failure and/or swelling may change. The purpose of this study was to test
how in vivo axon growth changes from a soft hydrogel to a rigid material. Unlike the
common belief, however, it was discovered that rigid materials were more e↵ective for
axon growth and induced less reactive cell layer formation.
Much research solely focuses on natural biomaterials for the prime reason of using
soft substrates to better match the sti↵ness of the tissue. The results of this disserta-
tion suggest that a softer substrate may not necessarily provide more e↵ective spinal
cord repair. It is therefore encouraged to expand the pool of materials choice to all
level of sti↵ness to not miss on valuable opportunities for better understanding axon
behavior and ultimately finding a cure for spinal cord and peripheral nerve injuries.
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Figure 8.6: In vivo evidence averse to the dogma of “softer is better” for spinal cord
repair. Microchannel sca↵olds fabricated from (a) agarose, (b) alginate,
(c) chitosan, (d) PEGDA, (e) PCL and (f) PLGA implanted in transected
spinal cords of rats and stained for neurofilaments after 2 weeks for al-
ginate and 4 weeks for all the other sca↵olds. Axons are shown in green
from (a)-(e) and red in (f) pointed to by solid arrows. The dashed lines
indicate the boundary of the sca↵old walls. Since alginate sca↵old had
degraded when sectioning was performed, it was di cult to point to its
original location; thus, a dashed line is not shown. As images (a)-(d)
demonstrate, the axons do not grow in close proximity to the foreign sub-
strate and a reactive cell layer (pointed to by dashed arrows) often forms
between the axons and the hydrogel sca↵olds walls. However, axons grew
toward and in close proximity to PCL and PLGA. The scale bars in (a)
and (b) are 100 µm, in (c) 120 µm, in (d) and (e) are 80 µm and in (f)
is 100 µm.
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8.4 Conclusions
An interventional approach to linearly guide axons through lesion gaps can sig-
nificantly help develop a cure for traumatic large-lesion nerve injuries. In this work,
materials with di↵erent sti↵ness ranging from 30 kPa to 14800 kPa were synthe-
sized, characterized and developed into microchannel sca↵olds and their in vivo e -
cacy was investigated in transected central and peripheral nerves of animals. Among
these materials, rigid polymers such as PCL appeared to be the most e↵ective for
axon guidance, penetration and integration. A novel technique was investigated to
synthesize PCL with optimized porosity, sti↵ness and cell adhesion properties. Next,
using the synthesized PCL as the sca↵old material, a unique microchannel sca↵old
design and fabrication technique was introduced which increased the open volume
available by the sca↵old by 3 fold compared to state-of-the-art sca↵olds. In addition,
PCL tubes were kink-resistant and could be sutured to the nerve stumps, which is
beneficial for peripheral nerve repair. This dissertation, therefore, introduces a viable
nerve guidance sca↵old for central and peripheral nerve repair.
8.5 Future work
The microtube sca↵old fabrication technique can be optimized to maximize the
sca↵olds open volume. PCL tubes as thin as 20 µm were produced, which would
result in over 85% open volume sca↵olds. However, the tube fabrication process was
cumbersome, which makes manufacturing sca↵olds impractical. Methods to autom-
atize tube fabrication and sca↵old assembly can significantly develop the introduced
technology. In addition, functionalizing the sca↵olds with a drug delivery technique
can further stimulate axonal growth. Techniques such as incorporating drug-eluting
nanofibers into the sca↵old channels may be considered.
Further in vivo characterization studies can provide a better understanding of
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biocompatibility, degradation and axon regeneration. Immunolabeling for inflamma-
tory cells and/or implanting sca↵olds for a longer period can help understand the
long-term biocompatibility of the material as well as its degradation behavior. In
addition, to confirm axon regeneration (as opposed to the sprouting of intact axons),
the source, pathway and termination point of an axon can be confirmed by label-
ing it with genetically-modified fluorescent markers [173]. Double retrograde tracing
can also be used by for example injecting a retrograde tracer into a section of the
spinal cord, injuring the section and introducing a di↵erent retrograde tracer into the
original injection site after su cient time is given for axon regeneration [102]. Any
axon inside or passed the lesion site that exhibits both tracers is a regenerated axon.
Finally, studies such as electrophysiology can verify the synapse formation between
newly-grown axons and host axons and confirm the e cacy of the sca↵olds for axon
regeneration and recapitulation. Motor and sensory functional recovery can provide
valuable information assuming encouraging immunolabeling and electrophysiology re-
sults are observed.
Finally, in this study, a full-transection nerve model was tested, which is considered
the most severe case of traumatic nerve injury. Though, a clinically-relevant SCI
is generally less severe than a full transection model. Indeed, most human nerve
injuries involve the contusion and/or the crush of the nerve in which, unlike in a full
transection model, the sprouting of undamaged axons through the lesion is possible
[173]. In addition, a fully transected nerve retracts, which enlarges the size of the
nerve gap and exacerbates the injury. Therefore, providing axon regeneration in a full
transection model is a promising step for clinical translation. It is, however, noted
before microchannel sca↵olds can be used in partially damaged nerves, the sca↵old
outer dimension has to match the lesion cavity. A combination of imaging techniques
to measure the shape and the dimensions of the injury as well as modifications to the
sca↵old fabrication technique such as using 3-D printing to fabricate sca↵olds with
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precise dimensions to mimic the shape of the injury may be necessary.
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APPENDIX A
Chitosan Microchannel Sca↵olds for Nerve Repair
A.1 Dense chitosan microchannel sca↵olds teste in the rat
spinal cords
A.1.1 Overview
In this work, the e cacy of chitosan microchannels for spinal cord repair is as-
sessed. Chitosan was investigated as the sca↵old material owing to reported nerve
growth in vivo [3, 52, 132, 176, 178]. Herein, to reduce the degradation rate of
chitosan hydrogel, its porosity was significantly reduced. Dense chitosan films and
later sca↵olds were produced by expanding the technique introduced in Chapter IV.
Briefly, chitosan disks were fabricated by the subsequent drying of chitosan/sodium
chloride (NaOH) solution until chitosan disk with a desired height was obtained. The
disk was then cross-linked with acetic acid and microdrilled to form microchannel
sca↵olds. The in vivo e cacy of chitosan sca↵olds was tested in T3 transected rats
spinal cords. The sca↵olds fragmented into debris and caused an inflammatory re-
sponse within 4 weeks of implantation. An alternative technique was therefore needed
to improve the biocompatibility of chitosan and reduce its degradation rate.
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Figure A.1: Image of a dense chitosan microchannel sca↵old. The scale bar is 0.5
mm.
A.1.2 Experimental and results
Dense chitosan disks (2 mm-long) were fabricated and microdrilled to produce
1.8 mm-diameter sca↵olds with linear channels (Fig. A.1). The channel diameter
was 0.20 mm and channel spacing was 0.30 mm. The sca↵olds were implanted in
the transected T3 rat spinal cords (2 mm-long) and immunolabeled after 4 weeks.
Neurofilament staining of the longitudinal section showed the sca↵old had fragmented
into debris (Fig. A.2). In addition, axons did not penetrate into the lesion possibly
due to reactive cell layer (RCL) formation around the sca↵old. Moreover, necrosis
(unnatural cell death) was observed in the host spinal cord. Overall, 1) the sca↵olds
degraded too quickly, 2) did not provide appreciable amount of axon growth, and 3)
caused inflammatory response. The introduced chitosan sca↵olds are therefore not
e↵ective for nerve regeneration and modification are needed to address the unfavorable
in vivo observations.
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Figure A.2: The longitudinal view of a dense chitosan microchannel sca↵old im-
planted in a T3 transected rat spinal cord stained for neurofilaments
(green) 4 weeks post-implantation. The dashed box demonstrates the
transected section of the spinal cord. Debris from the sca↵old were ob-
served (shown with dashed white arrows). In addition, reactive cell layer
is formed around the lesion cavity as pointed by solid white arrows. The
necrosis of host spinal cord shown by a solid black arrow was also ob-
served. The scale bar is 0.25 mm.
A.2 Microdrilled agarose sca↵olds with chitosan supporting
conduits implanted in a pig sciatic nerve
A.2.1 Overview
The goal of this work was to study the e cacy of using supporting conduits around
microchannel sca↵olds for peripheral nerve repair. Agarose was investigated as the
sca↵old material since previous reports have demonstrated the e cacy of agarose
microchannels in linearly guiding axons [55, 65, 158]. Because the sca↵old had to be
stabilized in the highly mobile region of sciatic nerve, a supporting conduit was used
around the sca↵old to be sutured to the nerve stump. Chitosan was selected as the
conduit material owing to its common use in tissue engineering [3, 52, 132, 176, 178],
flexibility and suture-ability. The sca↵olds were tested in a 1 cm-long transected
nerve gap in a minipig. Sectioning and immunolabeling 6 weeks post-implantation
showed high degree of inflammation and limited axon growth. The agarose/chitosan
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Figure A.3: (a) Cross-section and (b) longitudinal image of a microdrilled agarose
sca↵old is demonstrated. In (b) the sca↵old (pointed to by the dashed
arrow) is inserted into a chitosan tube (indicated by a solid arrow). The
scale bars are 150 µm in (a) and 200 µm in (b).
hybrid sca↵olds were, therefore, determined to be ine↵ective for nerve repair unless
further modifications are made.
A.2.2 Experimental and results
Agarose sca↵olds were microdrilled using a technique described in Chapter VI.
The sca↵olds were 10 mm-long and 4 mm in diameter with an average channel di-
ameter of 0.30 mm and an average channel spacing of 0.085 mm (Fig. A.3). Since
agarose tears if sutured, a supporting conduit was needed to secure the sca↵old to
the nerve stump. Chitosan was investigated for its e cacy as the outer conduit.
To quantify the change in the sti↵ness of chitosan with the change in its composi-
tion, chitosan films with di↵erentmass/surface area were fabricated and their elastic
moduli were measured. Briefly, 4 wt.% chitosan (MW 140,000-220,000. Sigma; St.
Louis, MO) was dissolved in 100 mM NaOH, dehydrated into films overnight and
cross-linked with 100 mM acetic acid for 4 hr. The elastic modulus of the films
were characterized based on the change in their mass/surface area. Fig. A.4 shows
the elastic modulus increases from 508.1 kPa to 1320.6 kPa for chitosan films with
concentrations of 5 g/cm2 to 15 g/cm2 (n = 5).
Upon characterizing the mechanical properties of chitosan films, chitosan con-
duits were fabricated. A 4 mm-diameter steel rod was dipped inside the 4 wt.%
chitosan/NaOH solution and dried overnight while spinning horizontally on a rotis-
serie device. The process was repeated 3 times. The rod was then placed in 100 mM
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Figure A.4: The elastic modulus of dense chitosan film increases as its
mass/surface area increases.
acetic acid for 4 hr. Chitosan conduits were removed from the rods, soaked in 2 l
of reverse osmosis (RO) water overnight and cut in length to 12 mm using a razor
blade.
Agarose sca↵olds were inserted into the chitosan conduits (Fig. A.3(b)). Two 4
mm-diameter sca↵olds were implanted adjacent to each other in the 8 mm diameter
sciatic nerve of a minipig. Due to visible inflammation of the implantation site in the
animal and the loss of a toe, the study was pre-maturely terminated 6 weeks post-
implantation and the animal was perfused. Sectioning and immunostaining indicated
a high degree of scar tissue formation around the sca↵old (Fig. A.5). Moreover, im-
munostaining for neurofilaments did not show any axon penetration. The sca↵old
design was therefore determined ine↵ective for nerve repair unless further modifica-
tions are made.
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Figure A.5: (a) Optical image and (b) electron microscopy image of the longitudinal
view of an agarose sca↵old inside a chitosan tube in a 10 mm-long sciatic
nerve gap in a minipig. The sca↵old (pointed to by the dashed arrows)
is surrounded by a scar tissue as indicated by the solid arrows. The scale
bars are 0.3 mm.
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